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Abstract 
 
Positron Emission Tomography (PET) imaging is a powerful non-invasive imaging 
modality used to quantify biochemical processes in vivo. The work described in this thesis 
encompasses two aspects of PET radiochemistry: (1) the development of new chemical 
methodology applying the principles of green chemistry to late-stage 18F-fluorination, and 
(2) developing a PET radioligand for the dopamine D3 receptor. 
(1)  As a way to simplify FDA mandated quality control and residual solvent 
analysis prior to the release of PET radiopharmaceuticals we sought to apply the 
principles of green chemistry to 18F-radiochemistry. Green radiochemistry in late-stage 
stage 18F-fluorination with [18F]KF employs ethanol and ethanol/water mixtures as the 
only solvents used throughout the entire radiopharmaceutical production: azeotropic 
drying, nucleophilic fluorination, purification and formulation. This work developed a 
method in which using ethanol in place of acetonitrile is a viable option for azeotroptic 
drying of [18F]fluoride. Furthermore, it demonstrated that aliphatic 18F-fluorination 
reactions  can proceed in an optimized 15% water, 85% ethanol mixture. Proof of concept 
was demonstrated through the synthesis of clinically relevant PET radiopharmaceuticals. 
The new methodology described challenges the long held belief that nucleophilic 
fluorination reactions cannot proceed in protic solvents or aqueous media, and 
encourages further exploration into the utility of green fluorine chemistry. 
xxii 
 
(2) Dopamine is a monoamine neurotransmitter in the Central Nervous System 
(CNS), and its signaling is mediated by pre-synaptic and post-synaptic dopamine 
receptors. These are D1-like (D1 and D5) and D2-like (D2, D3, D4) receptors, which are G 
protein-coupled receptors (GPCRs) and are classified based on these two subfamilies 
due to sequence homology and pharmacological similarities. The D3 receptor is 
implicated in many neurological and neurodegenerative diseases and disorders, including 
substance abuse, depression and schizophrenia. Significant efforts have gone into 
developing ligands as therapeutics, and as positron emission tomography (PET) 
diagnostics at this receptor. Significant challenges to this pursuit include the high 
sequence homology between the D2 and D3 receptors, and the physicochemical 
properties associated with BBB permeability and in vivo stability, while maintaining 
selectivity at this receptor. 
 The synthesis and initial evaluation of a series of new carbon-11 and fluorine-18 
PET radioligands for the D3 receptor is described. These radioligands are based on 
known ligands with good selectivity for the D3 receptor (pramipexole and BP897). Due to 
stability issues when using pramipexole-containing scaffolds, BP897 derivatives 
containing a naphthamide moiety were developed and evaluated in vitro using rad brain 
autoradiography, and in vivo using rodent microPET imaging. A carbon-11 D3-selective 
compound was synthesized and identified as a promising candidate, owing to its high 
affinity for D3 receptors, selectivity for D3 over D2 receptors, and good blood-brain barrier 
(BBB) penetration. Further evaluation and optimization of the scaffold is merited prior to 
clinical translation in the future. 
 
1 
 
 
 
  
Introduction: Positron Emission Tomography: From Bench to Bedside 
 
Medical imaging encompasses several techniques used to diagnose and treat 
diseases and disorders within the body. These include X-rays, discovered in 1895 by 
Wilhelm Röntgen, 1 which ultimately paved the way for radiology and diagnostic imaging. 
From here, other more modern techniques emerged such as computed tomography (CT), 
magnetic resonance imaging (MRI), and ultrasound (US). All of these techniques provide 
valuable structural/anatomical information, but provide little functional information about 
the physiological and biochemical processes ongoing within a complex biological system.  
Visualizing a specific biological target or process in this context is routinely 
performed through the use of radioactive probes, otherwise known as 
radiopharmaceuticals, for use in positron (β+) emission tomography (PET) and single-
photon emission computed tomography (SPECT) – and are the pillars of diagnostic 
medical imaging in modern Nuclear Medicine (NM). Interventional nuclear medicine 
includes radiotherapy with alpha and beta emitters. Although they will be discussed 
briefly, a detailed discussion of radiotherapeutics is outside the scope of this thesis which 
is focused upon diagnostic radiopharmaceuticals, but radiotherpy has been recently 
reviewed.2 These scanning techniques can be superimposed, via hybrid cameras or 
software, on other anatomical imaging modalities such as MRI or CT to provide a more 
2 
 
complete picture about the function and anatomy of interest (SPECT/CT, PET/CT, 
PET/MR). The work described herein will focus on positron emission tomography, and 
radiopharmaceutical development: including the development of novel radiolabeling 
method(s) of small, drug-like molecules (Chapter 3), and the synthesis and (initial) pre-
clinical evaluation of PET probes for CNS diseases and disorders (Chapter 4). Multi-
disciplined, this encompasses the fields of medicinal chemistry, organic chemistry, 
radiochemistry, and chemical methodology development. 
 
a. Beginnings: Radioactivity 
 
 The diagnostic radiology story began with the discovery of x-rays by WC Röntgen 
in 1895.1 Röntgen’s experiments with an electron beam tube and photographic plate lead 
to the imaging of his wife Anna Bertha’s hand with her wedding ring, when, upon seeing 
the image, exclaimed “I have seen my death!” (Figure 1-1).3,4 This work was followed 
closely by the discovery of the electron by JJ Thomson in 18975 – both of these 
discoveries resulting in an individual Nobel Prize in Physics in 1901 and 1906, 
respectively. In 1896, Henri Becquerel discovered naturally occurring radioemissions.6 
Becquerel, after unsuccessful attempts at observing X-rays (known as Röntgen rays at 
the time) emitted from minerals post-light absorption, later observed these rays from 
uranium salts. The unusual aspect of this experiment was that these rays could be 
observed in the absence of initial light absorption (or energy input). Becquerel had just 
discovered radiation, and those rays emitted were, for a time, called “Becquerel Rays”, 
and were later identified as the result of radioactive decay from the uranium salts 
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themselves. Rumored to have little interest in the results, Becquerel passed this work on 
to his graduate student looking for a topic for her PhD dissertation, Marie Sklodowska 
(Figure 1-2).  
 
 
Figure 1-1 First Medical X-Ray of Anna Bertha’s hand by Wilhelm Röntgen (public domain)7 
 
As Sklodowska began looking at other elements, compounds or minerals, to 
observe the emission of these rays, she became intrigued by different chemicals emitting 
different radiation and decided to isolate and purify them. With this, she requested the 
assistance of her husband, Pierre Curie, whose focus would be on the physical 
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measurements. This collaboration, between Marie and Pierre Curie, would later be known 
as one of the most famous scientific partnerships in history. Together, they extracted two 
new elements, polonium (Po) and radium (Ra), and found them both to be more 
radioactive than uranium (U). Thus, with the 1896 discovery of radioactivity by Henri 
Becquerel and the inspired research by Marie and Pierre Curie, they would share the 
1903 Nobel Prize in Physics. Also, in 1903, the University of Paris awarded Marie her 
Ph.D. in physics.6  
The field of radiochemistry, or chemistry of radioactive elements, was born with M. 
Curie. It wasn’t until later that the term “radiochemistry” was introduced by Frederick 
Soddy, and much of the terminology used today coined by Ernest Rutherford. The 
radiation as a result of the decay of atoms, although assumed by M. Curie, was 
demonstrated by Rutherford and Soddy in 1902 by the discovery of D and β emissions 
(Rutherford won the Nobel Prize in Chemistry in 1908 for this work).6,8,9 It is worth noting 
that M. Curie continued her work and was later awarded the 1911 Nobel Prize in 
Chemistry for characterization of polonium and radium, as well as the isolation of pure 
metal radium. With two Nobel Prizes, Marie Sklodowska-Curie was the first person to 
win/share two Nobel’s, and is one of four people to have been awarded two Nobel Prizes 
in distinct fields. The Curie’s daughter, Irène Joliot-Curie, in collaboration with her 
husband Frédéric, later won the 1935 Nobel Prize in Chemistry for the synthesis of new 
radioactive elements.6 A testament to their impact on the field, the units of radioactivity 
are denoted as Becquerels (Bq) or Curies (Ci). 
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Figure 1-2 Brief Historical Summary of the Atom and Radioactivity 
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With this budding, new field and speculation about the applications to science and 
medicine, researchers were searching for new radioisotopes. Irène Curie and Frederic 
Joliot’s work demonstrated the production of artificially produced radioactivity through the 
bombardment of aluminum, boron and magnesium with D particles to isotopes such as 
phosphorus, nitrogen and aluminum (1930s).10 Specifically, and one of the first artificially 
made radionuclides, nitrogen-13, via  10B(D,n)13N.11 In 1934, Oliphant, Rutherford and 
Harteck produced tritium through the collision of deuterium atoms.12 Interestingly, as 3H 
(low β emitter used frequently to label proteins, nucleic acids and organic drug-like 
molecules) and 14C (labeling for use in absorption, distribution, metabolism, and 
excretion, ADME, studies in drug discovery) are the most commonly used isotopes in the 
laboratory today13,14, carbon-14 was not the first carbon isotope to be discovered. The 
positron emitting isotope (used in PET imaging), 11C was discovered by Kamen and used 
to demonstrate that the source of molecular oxygen in photosynthesis was water and not 
CO2.15 Shortly after, the existence of a long-lived carbon isotope, 14C, was predicted 
before it was discovered in 1940 by Kamen and Ruben while working with Earnest O. 
Lawrence, a Nobel Laureate for the development of the cyclotron, at the Berkeley 
Radiation Laboratory (currently known as the Lawrence Berkeley National Laboratory).16 
Other organic, or physiological, isotopes 13N and 15O were utilized for biological studies, 
but diminished in popularity due to their impractically short half-lives, 10 min and 120 sec 
respectively.11 
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b. Production of Radionuclides 
 
Particle accelerators were invented to investigate the structure of the atomic nucleus. 
Their principle job is to take a beam of particles, speed them up and increase their energy 
through an electric field (acceleration) and magnetic field (steering). It is interesting to 
note that the cyclotron was established with the goal of transmutation of elements, not 
the production of artificial radioactivity. It was not until Irène Curie and Frederic Joliot’s 
synthesis of new radioactive elements in the 1930s that the Berkeley group noted the 
extended utility of their new instrument.11  
With the incorporation of radioisotopes in biochemically significant pathways and 
molecules, the natural progression of the field spread into several branches of science. 
Indeed, the modern day nuclear medicine program requires a diverse group of specialists, 
with individuals often possessing more than one area of expertise. This ranges from 
physicists, engineers, biomathematicians, medical physicists, nuclear medicine 
physicians, kinetic modelers, organic chemists, medicinal chemists, radiochemists, and 
biochemists, etc. This exodus from traditional academic boundaries of departmental 
sciences to multidisciplinary national laboratories was launched by the father of the 
cyclotron, Ernest Lawrence – at the age of 27, as a new Professor at the University of 
California, Berkeley. Lawrence’s need for space lead to the acquisition of an entire 
building in August 1931, called the “Radiation Laboratory”, to house the research, design, 
construction, and operation of his cyclotron, as well as the increasing number of 
physicists, engineers and chemists critical to the research. The university later recognized 
his departure from traditional academic divisions, and established the Radiation 
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Laboratory as a free standing entity for the pursuit of nuclear science (broader than the 
customary “nuclear physics”, “nuclear chemistry” or “accelerator physics” terms often 
used).17 
 
 
Figure 1-3 Simple Cyclotron 
 
While the idea of the cyclotron was conceived years prior, Ernest O. Lawrence 
finalized its creation in 1932 and patented it in 1934.17–20 Lawrence was awarded the 
1939 Nobel Prize in Physics, in the field of accelerator physics and instrumentation. In 
consideration of the scope of this work, the workings of the modern cyclotron as it applies 
to the production of PET radionuclides will only be discussed. A cyclotron (Figure 1-3) is 
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composed of two D-shaped metal electrodes (often called “Dees”), between the poles of 
a large electromagnet, all contained in a vacuum chamber. In the center is either H2 or 
D2 gas, which is the source of the particles accelerated, in the form of H- or D- anions. In 
the presence of a strong magnetic field and alternating voltage of the electrodes, the 
anions are accelerated in a circular path. As they gain energy, the radius of the anion’s 
path increases until it passes through a stripping foil to remove the electrons, thus 
producing H+ or D+. These particles, now positively charged, are deflected out of the 
acceleration chamber to irradiate the target of choice. Once the high-energy particle hits 
the stable isotope target, the desired radionuclide is produced and subsequently delivered 
to appropriate containment for utilization. 
 
 
Figure 1-4 Nuclear Stability 
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Nuclear stability (Figure 1-4 Nuclear Stability) is often determined by proton to 
neutron ratio; above the stability line are the radionuclides that decay via alpha decay (D 
or He nucleus emission to decrease the mass number), below is positron (β+) emission 
or electron capture (whereby the isotope gains more neutrons to become stable). 
Elements with Z>82 have no fully stable isotopes. Radioactive decay modes of interest 
for therapy are D and β, and for imaging β+ (positron) or J (gamma) emission (Scheme 1- 
1).  
Radiation therapy utilizes ionizing radiation largely in oncology to kill cancer cells, 
shrink tumors, etc. External radiation therapy exposes a specific area of the patient’s body 
to radiation, via high-energy x-rays. On the other hand, targeted radionuclide therapy is 
systemic (like chemotherapy). This employs a drug-like molecule labeled with a 
radionuclide to deliver a (toxic) dose of radiation to a diseased site (tumor). The three 
available radionuclides are, D (alpha) emitters, β (beta) emitters, and Auger electrons, 
which offer a variety of radionuclides that can be chosen for half-life, tissue range, and 
chemistries to tailor the therapeutic (personalized medicine).21  
For targeted radiotherapy, D emitters travel a shorter distance in tissue but can 
deliver 5MeV of energy over several microns, whereas β emitters typically deliver a few 
hundred KeV over a distance magnitudes larger (millimeters).22 Alpha emitting 
radionuclides include 213Bismuth, 211Astatine, and 223Radium, and have been 
demonstrated in monoclonal antibodies, and gold nanoparticles. Beta emitting 
radionuclides FDA approved for human use include 90Yttrium, 131Iodine, 153Samarium, and 
89Strontium; other β emitters include 177Lutetium, 166Holmium, 185Rhenium, 188Rhenium, 
67Copper, 149Promethium, 199Gold, and 105Rhodium.21,22 Auger therapy, on the other hand, 
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relies on the Auger electron. The Auger electron is the result of an inner shell electron 
vacancy (as the result of radionuclide decay by electron capture, for example); the 
vacancy is filled by electron transitions from shells or subshells of higher energy, and that 
energy difference can be emitted as a photon, or transferred to other orbital electrons that 
are released (this is the Auger electron). Some Auger-emitting radionuclides include: 
111Indium, 123Iodine, and 77Bromine; this therapy relies on large quantities of these 
electrons at low energy to target and kill tumors/cancer cells in a short range.21,23 
 
Scheme 1- 1 Selected PET Radionuclides and Positron Decay 
 
With regard to for imaging β+ (positron) or J (gamma) emission as the result of 
positron PET isotopes are proton rich, typically short lived (minutes to hours), and are 
produced by proton reactions, such as (p,n) and (p,D). Most of the radionuclides utilized 
in PET are produced in a cyclotron, while others are produced as daughter products in 
generators. Common PET radionuclides include carbon-11, nitrogen-13, oxygen-15, 
fluorine-18, copper-62 (generator), gallium-68 (generator or cyclotron), rubidium-82 
(generator), iodine-122, iodine-124 and zirconium-89.24  
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Table 1-1 Common PET radionuclides 
Entry Name Half-life Nuclear 
Reaction 
Final Product Decay Product 
Z-1; N+1 
1 Carbon-11 
(11C) 
20 min 14N(p,D)11C [11C]CO2 11C Æ 11B + β++ Qe 
11C + e- Æ 11B + Qe 
2 Nitrogen-13 
(13N) 
10 min 16O(p,D)13N [13N]NH3 13N Æ 13C + β+ + Qe 
3 Fluorine-18 
(18F) 
110 min 18O(p,n) 18F [18F-] in [18O]H2O 18F Æ 18O + β+ + Qe 
4 Oxygen-15 
(15O) 
2 min 15N(p,n) 15O  15O Æ 15N + β+ + Qe 
Key: p (proton), D (alpha-particle), β+ (positron),  Qe (electron neutrino) 
 
A common list of PET radionuclides (Table 1-1 Common PET radionuclides) and 
non-conventional positron emitters for imaging (Table 1-2 Non-standard PET 
Radionuclides26) are listed as such. The choice of radionuclide depends on a number of 
factors including the ability to incorporate it into a given bioactive molecule and the 
intended application (e.g. commercial distribution). Generally, it is good practice to match 
the physical half-life of the radionuclide with the biological half-life of the labeled molecule. 
Thus, carbon-11 and fluorine-18 are most commonly used to labeling small, drug-like 
molecules, while longer lived isotopes such as zirconium-89 find utility labeling biologics, 
including antibodies.25 
While the most common F-18 fluorination method for the production of 
radiopharmaceuticals is nucleophilic fluorination, certain compounds are still optimally 
prepared by using electrophilic techniques. Fluorine gas, [18F]F2, is the most simple 
fluorination reagent to handle, but is highly reactive and end products suffer with reduced 
radiochemical yields, selectivity, and low specific activity due to carrier-added production. 
Electrophilic fluorine can be produced via 20Ne(d,D)18F to encourage F-18/F-19 exchange 
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for a carrier added production of [18F]F2; on the other hand, another method is through 
18O(p,n)18F followed by secondary irradiation in 19F (gas) to provide [18F]F2.27–30 Other 
electrophilic reagents have been derived and used extensively.31 Nucleophilic F-18 
fluorinations are the most widely used and perhaps the most classical method to 
radiolabel with fluorine-18.  
 
Table 1-2 Non-standard PET Radionuclides26 
Entry Isotope Half-life Decay Modes/% Max β+  
energy 
(MeV) 
Reaction Natural 
Abundance of 
Target Isotope 
1 76Br 16.2 h β+/58.2 
EC/41.8 
3.98 76Se(p,n) 9.1% 
2 124I 4.18 d β+/22.0 
EC/78.0 
2.15 124Te(p,n) 4.8% 
3 86Y 14.74 h β+/34.0 
EC/66.0 
3.15 86Sr(p,n) 9.9% 
4 94mTc 52 min β+/72.0 
EC/28.0 
2.47 94Mo(p,n) 9.3% 
5 68Ga 68 min β+/88 1.9 68Ge/68Ga 
generator 
n/a 
6 66Ga 9.49 h β+/56.5 
EC/43.5 
4.15 66Zn(p,n) 27.8% 
7 60Cu 23.7 min β+/93.0 
EC/7.0 
3.92 60Ni(p,n) 26.1% 
8 64Cu 12.7 h β+/17.8 
EC/43.8 
β-/38.4 
0.66 64Ni(p,n) 1.16% 
9 89Zr 78.5 h β+/22.8 
EC/77.2 
0.40 89Y(p,n) 100% 
 
c. Positron Emission Tomography 
 
PET is a non-invasive multidimensional imaging modality for investigating in vivo 
physiological and biochemical processes (in vivo defined here as imaging these 
processes in living creatures); it has applications in many different disciplines including 
neurology, psychiatry, oncology, and cardiology. PET utilizes a positron emitting (β+) 
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radionuclide such as 11C, 13N, 18F and 15O. As the radionuclides decay, a positron (β+) 
and electron neutrino (Qe) are released. Essentially a core proton is transformed into a 
neutron and a positron (basically a positively charged electron) and a neutrino.32 18F 
decays by emitting a positron with an energy (max) of 635 MeV, 11C with a (max) energy 
of 0.96 MeV(Scheme 1- 1).33,34 
The positron travels in tissue (up to 1mm) until it meets its antiparticle, the electron 
(e-) and an annihilation event occurs. This event produces two 511 KeV gamma ray 
photons (J) that project 180o from the event location to detectors on the PET scanner; 
here the photon pair is simultaneously detected as a coincident event. Localization of the 
radiopharmaceutical is then determined by reconstruction of all the annihilation events 
that occurred during a PET scan into a 2D or 3D image (Figure 1-5 General PET 
Workflow).32 
 
Figure 1-5 General PET Workflow 
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Radiopharmaceutical doses are reformulated in ≤10% EtOH/saline doses, and 
undergo stringent quality control (QC) in a timely manner before being released to a 
nuclear pharmacist and nuclear medicine physician for clinical use. These are completed 
in accordance with 21CFR212 – Current Good Manufacturing Practice for Positron 
Emission Tomography Drugs or the U.S. Pharmacopeia Chapter 823 [USP-32, NF-27, 
2009] – Standards for PET Drugs. As such, the doses are analyzed as follows: visual 
inspection (clear, colorless, free of particulate matter), pH (pH paper, typically 4.5-8), 
chemical and radiochemical purity (HPLC or TLC), radionuclidic identity (half-life), 
radionuclidic purity (multi-channel analyzer), sterile filter integrity (bubble-point or filter 
integrity), bacterial endotoxins, sterility, and residual solvent analysis (GC). Chemical 
purity if often calculated by normalizing to specific activity of 2 Ci/μmol. As mentioned 
before, radioactivity is given the SI unit Becquerel (Bq), or the non-SI, but commonly used 
unit, Curie (Ci) (1 Ci = 37 GBq). Specific activity is a measure of “hot” to “cold” in the final 
radiopharmaceutical: carbon-11 (hot) to carbon-12 (cold), or fluorine-18 (hot) to fluorine-
19 (cold); this is of more concern when the radiosynthesis involves a cold carrier and 
would yield a higher injected cold mass. Optimally, radiopharmaceuticals are prepared 
no-carrier-added (N.C.A.). 
 Strategies to quickly and efficiently radiolabel drug-like molecules have developed 
vastly over the years. Indeed, advancements in carbon-11 and fluorine-18 chemistry in 
the last decade have enabled the radiosynthesis of novel PET radiotracer otherwise 
inaccessible for PET. 
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d. Fluorine in Medicinal Chemistry 
 
Fluorine is the most electronegative element on the periodic table and has the 
smallest atomic radius of the Period 2 elements (1s22s22p5). It was discovered in 1886 by 
chemist Henri Moissan (who was later awarded the Nobel Prize for these efforts in 1906). 
In organic chemistry, the C-F bond is the strongest bond at 105.4 kcal/mol. The strength 
of this bond is largely attributed to the significant electrostatic attraction between Fδ- and 
Cδ+ as opposed to the traditional covalent bond sharing of electrons.34,35 
In medicinal chemistry, fluorine is a common bioisostere for hydrogen. Thus, a C-
H to C-F substitution is common and approximately 15% of approved pharmaceuticals 
contain at least one (or more) fluorine atoms.36 Given steric considerations (F and H share 
similar van der Waal’s radii, F =1.47 Å, H = 1.2 Å), this substitution is conservative and is 
often a substitute to hinder metabolism at a labile site. Another common bioisostere is the 
F for O substitution, which matches size for electronegative atoms (van der Waal’s radii: 
F =1.47 Å, O =1.52 Å), as well as geometry. C-F for C-OH is another common substitution, 
which can also provide excellent insight into the H-bonding properties and requirements 
in biological systems.34–38 Fluorine also improves other physicochemical property 
considerations, such as pKa (not including inductive changes to neighboring functional 
groups), solubility, logD and binding affinities (selectivity and potency), and can 
additionally improve brain penetration (for CNS drugs) by hindering susceptibility to P-
glycoprotein (Pgp)-mediated efflux.34,36–38  
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A major concern in drug discovery, oxidative metabolism by liver enzymes such as 
cytochrome P450 prior to drug elimination can be evaded by substitution of a fluorine.34,37 
Fluorine’s ability to block oxidative metabolism in saturated aliphatic systems is, in part, 
due to the high heat of formation and bond energy of the C-O and O-H bond relative to 
the F-O bond, which excludes oxidative attack on fluorine. Moreover, this is also seen in 
steric and conformation effects through the use of a -CF3 group next to a C-H, which 
retards metabolism and aids in stability.37,39 Para-fluoro substitution is a common 
substitution to block or retard oxidation in aromatic systems (e.g. to prevent oxidation to 
a phenol), in addition to aromatic/ aliphatic methyl oxidation and dealkylation.37,39 One 
such clinical example of fluorine being used to modify drug metabolism is on the 
optimization of lead SH48461 (ED50 (hamster) = 2.2 mg/kg/day) to SCH58235 (Ezetimib) 
(ED50 = 0.04 mg/kg/day), the oral cholesterol absorption inhibitor (Figure 1-6 Part of 
Ezetimib Optimization: Blocking Metabolically Labile Sites With Fluorine Substitution40). 
As is a common substitution, the para-phenyl position was blocked by inclusion of a 
fluorine, as well as complete replacement of the 4-methoxy group with an additional 
fluorine to prevent oxidation to the phenol.36–40 
 
18 
 
 
Figure 1-6 Part of Ezetimib Optimization: Blocking Metabolically Labile Sites With Fluorine Substitution40 
 
e. Late-Stage 18F Fluorination PET Radiochemistry 
 
Radiochemical limitations currently limit the potential impact of PET imaging on 
personalized medicine and drug discovery. The development of new 
radiopharmaceuticals is largely represented by the compounds that can be readily 
radiolabeled but do not necessarily represent the best compound regarding selectivity, or 
fit the desired pharmacology or pharmacokinetic profile of a PET imaging agent.41,42 The 
development of fluorine-18-labeling strategies to access any radiopharmaceutical 
scaffold remains a unique challenge to the field. Fluorinations alone are challenging 
reactions, but these challenges are exacerbated when working with fluorine-18. It is 
important to note that standard (cold) F-19 fluorinations largely proceed with excess 
fluorinating agent (e.g. fluoride), whereas this system necessitates the use of F-18 as the 
limiting reagent, thus posing a unique challenge. Consequently, these reactions need to 
have stoichiometry compatible with small amounts of radionuclide (typically nanomolar 
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quantities). Moreover, radiofluorination reaction times must be short, typically 3 to 30 
minutes due to the short half-life of 18F (110 min), and be able to produce clinically usable 
amounts (> 50 mCi) in high specific activity (>1 Ci/μmol). 
Nucleophilic [18F]fluoride is produced by the 18O(p,n)18F nuclear reaction from 
[18O]H2O. Typically the 18F- anion is delivered in a bolus of [18O]H2O from where it is 
loaded on to an ion-exchange column, typically a quaternary methyl ammonium (QMA) 
anion exchange cartridge, and eluted to a cryptand, K222 (Kryptofix), an aminopolyether, 
which also acts as a phase transfer catalyst and used in conjunction with potassium 
carbonate to activate the [18F]fluoride. While the most common way to produce 18F tracers 
in the clinic is through [18F]KF.K222, other options include [18F]cesium fluoride, 
[18F]tetrabutylammonium fluoride ([18F]TBAF), and [18F]tetraethylammonium fluoride; this 
is done via elution with cesium carbonate, tetrabutylammonium bicarbonate, and 
tetraethylammonium bicarbonate.31,43,44 From here, the fluorine-18 (complex) is 
azeotropically dried (typically in water/MeCN) to remove residual water from the target, 
leaving an activated 18F nucleophile. The 18F nucleophile is then reacted with the 
precursor in aprotic, anhydrous solvents, such as MeCN and DMF.  
 
 
Scheme 1- 2 [18F]FDG 
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Radiochemical considerations include incorporation of the fluorine label at the end 
of synthesis due to the short half-life of the radionuclide and lends itself to the recently 
coined term “late stage” fluorination. These “late-stage” fluorination reactions can be 
divided into nucleophilic aromatic substitution, SNAr, direct nucleophilic fluorinations, SN2, 
and special cases such as prosthetic groups (an auxiliary that can labeled and attached 
to a precursor otherwise unsuitable for direct nucleophilic fluorination)45 and unactivated 
arenes (this is not an exhaustive list). Direct nucleophilic fluorinations traditionally utilize 
a leaving group such as a tosylate, mesylate, or triflate, then any deprotection following 
the 18F fluorination, making this labeling strategy often a two-step procedure. 
[18F]Fludeoxyglucose, aka 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG, 3) is the most 
widely used F-18 PET radiopharmaceutical and it synthesized from the mannose-triflate 
precursor 1 and later deprotected (Scheme 1- 2 [18F]FDG). Other clinically relevant tracers 
of a direct fluorine-18 labeling strategy include [18F]FEOBV (5) 
([18F]fluoroethoxybenzovesamicol) with a tosyl precursor (4) and [18F]FLT (8) (3’deoxy-3’-
[18F]fluorothymidine) with  a nosyl precursor (6)(Scheme 1- 3). As with the [18F]FLT 
precursor, the Boc-Boc-Nosyl precursor (7) provides higher yields compared to the cyclic 
precursor.46 [18F]fluoroethyl tyrosine ([18F]FET) is accessed through direct labeling of a 
prosthetic group, and 2-nitroimidazoles such as [18F]fluoroazomycin arabinoside 
([18F]FAZA) and [18F]fluoromisonidazole ([18F]FMISO) through simple SN2 displacement 
of a tosylate.47,48 
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Scheme 1- 3 Direct F-18 fluorination of [18F]FEOBV and [18F]FLT 
 
Other non-classical reactions include palladium-catalyzed allylic 18F fluorination 
reactions. Allyl 4-nitrophenyl carbonate and cinnamyl methyl carbonate (9), with 
[18F]TBAF (tBuOH)4 and catalytic (Pd(dba)2 (dibenzylidenacetone = dba), were converted 
to the cinnamyl fluoride (10) (R = C6H4NO2 in 5-7% RCY and R = Me 10-52% RCY). 
Cinnamyl bromide under similar conditions provided (10) in 40-42 % RCY from the chloro- 
and bromo-precursors (11) (Scheme 1- 4).49 Other work to access these substrates 
included iridium-catalyzed allyl fluorination of trichloroacetimidates, and allylic 
carbonates.49–51 
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Scheme 1- 4 Palladium-catalyzed allylic [18F]fluorination reactions 
 
Nucleophilic aromatic substitution, SNAr, reactions with [18F]fluoride is another 
strategy, even though these reactions require an appropriately activated arene, and often 
requires harsh reaction conditions (such as longer reaction times and high temperatures). 
Isotopic exchange with 19F, while it is an attractive option and has been applied in 
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syntheses of [18F]flumazenil, suffers from poor specific activity and the inability to 
separate the two F-19/F-18 products.52  
 
 
Scheme 1- 5 Trimethylammonium salt precursors for [18F]Flubatine and [18F]2FA 
 
Traditionally, direct [18F]fluorination of activated arenes with electron-withdrawing 
groups, contain -NMe+, -NO2, -Cl, -SAr2+, etc, leaving groups and makes these substrates 
amenable to SNAr  conditions.31,53 One such example is with the purpose of imaging the 
D4β2 subtype of the nichotinic acetylcholine receptor (NaChR); this is accessed via SNAr 
of the the Boc-protected trimethyl ammonium salt (12) to provide [18F]Flubatine (13) (an 
epibatidine derivative) or [18F]2FA (15) (Scheme 1- 5).54–56  
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Scheme 1- 6 Direct SNAr for production of [18F]MPPF 
 
Another radiopharmaceutical that utilizes a nitro-precursor (16) is [18F]MPPF (17), 
or 4-(2’-methoxyphenyl)-1-[2’(N-2’’pyridinyl)-p-[18F]fluorobenzoamido]ethylpiperazine, 
and is used to image serotonin-1A (5HT1A) receptors. This radiolabling utilizes direct 
SNAr of the nitro- precursor (16) and [18F]fluoride with no secondary deprotection step 
(Scheme 1- 6 Direct SNAr for production of [18F]MPPF).31,46,57 
 
 
Scheme 1- 7 Radiosynthesis of [18F]Flutemetamol 
 
Accessing scaffolds with electron rich, unactivated or electron neutral arenes pose 
a unique challenge to 18F nucleophilic fluorination. Protecting group manipulation through 
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alteration of the electron donating/withdrawing characteristics is such a solution for direct 
fluorination. Such is the case of [18F]flumetamol (20), which demonstrates direct labeling 
of the ortho-nitroaniline (18) through the use of a formamide protecting group to enable 
displacement of the nitro with 18F, followed by deprotection of the phenol (19) (Scheme 
1- 7 Radiosynthesis of [18F]Flutemetamol).58  
Another ingenious method to radiolabel a phenol is fluorination of the aldehyde (21 
to 22) or ketone followed by Baeyer-Villiger oxidation (23), then saponification with NaOH 
to generate the desired phenol (24) (Scheme 1- 8 Radiolabeling phenols utilizing Baeyer-
Villiger Chemistry).59 While these approaches are a testament to the creative and rather 
resourceful steps radiochemists are willing to take to access these radiopharmaceuticals, 
these reactions are limited in that they are lengthy, often messy, and difficult to automate. 
In an attempt to simplify the ease with which one radiolabels a phenol, Gouverneur 
reported a metal-free oxidative 18F fluorination with phenyliodine diacetate (PIDA) as the 
oxidant and [18F]TBAF as the fluorine source. This proceeded in one step, with excellent 
yields and good substrate tolerance.60  
The Balz-Schiemann and Wallach reaction is another established method(s) to 
incorporate 18F into arenes. The Balz-Schiemann reaction involves an aryl diazonium salt 
(diazonium fluoroborate), followed by thermal decomposition with a fluoride source to 
produce fluoroarenes. The Wallach reaction, on the other hand, prepares fluoroarenes 
through decomposition of an aryl triazene precursor. This reaction is thought to proceed 
through a diazonium salt, via triflic acid promoted protonation of the triazene. Due to low 
RCYs and emerging techniques, however, these reactions are rarely used.61–63 
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Scheme 1- 8 Radiolabeling phenols utilizing Baeyer-Villiger Chemistry 
 
The introduction of diaryliodonium salt precursors (Scheme 1- 9 Diaryliodonium 
salt precursors for the synthesis of [18F]fluoroarenes) allowed moderately electron-rich 
arene systems to be accessed. Independently, aryl(2-thienyl)iodonium salts (25) were 
developed as suitable substrates for 18F SNAr (Scheme 1- 9a).64,65 Pike’s group used a 
similar strategy with diaryliodonium tosylates (27) to synthesize PET ligands selective for 
the metabotropic glutamate receptor 5 (mGluR5) (Scheme 1- 9b).66 A challenge to this 
chemistry, however, is extreme reaction conditions (high temperatures, over 150oC), 
limited functional group tolerance, and less than optimum radiochemical yields. To 
improve upon this chemistry, iodonium ylides, later expanded to spirocyclic iodonium 
ylides to improve precursor stability, were demonstrated to be suitable precursors for 
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labeling arenes with electron donating, neutral, and withdrawing characteristics and was 
applied to existing PET radiopharmaceuticals in good radiochemical yield (29, 31) 
(Scheme 1- 9c, d).67,68 
 
 
Scheme 1- 9 Diaryliodonium salt precursors for the synthesis of [18F]fluoroarenes 
 
Another approach reported by Ametamey et al. utilizes triarylsulfonium salts (33, 
34) for fluorine-18 labeling via SNAr, utilizing [18F]KF and [18F]CsF as the nucleophilic 18F 
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source on a variety of model substrates (Scheme 1- 10 Triarylsulfonium salt precursors 
for the synthesis of [18F]fluoroarenes).69,70  
 
 
Scheme 1- 10 Triarylsulfonium salt precursors for the synthesis of [18F]fluoroarenes 
 
Diarylsulfoxide precursors were also described by Pike and coworkers, and 
proceeded in moderate to good yields, within only a few minutes, with symmetrical and 
asymmetrical substrates (Scheme 1- 11 Diarylsulfoxide precursors for the preparation of 
p-[18F]fluoroarenes).71,72 
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Scheme 1- 11 Diarylsulfoxide precursors for the preparation of p-[18F]fluoroarenes 
 
A recent advancement from the Murphy group that doesn’t require the use of 
transition metal catalysts, or special handling includes the nucleophilic 18F fluorination of 
aniline-derived N-arylsydnones (35) (Scheme 1- 12). This uses simple air stable reagents 
for direct radiofluorination, but is unusable for electron rich or unactivated arenes (no F-
18 fluorinated product was detected). The group produced 18 examples of this chemistry 
(36), fully automatable, and one labeled peptide to demonstrate utility in PET.73 
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Scheme 1- 12 F-18 Nucleophilic Radiofluorination of N -Arylsydnones 
 
A more recent development in 18F fluorination of electron-rich arenes is with 
transition metal catalysts. Radiofluorination of arenes using palladium complexes (37/38) 
was demonstrated by Hooker and Ritter as a two-step labeling procedure (37 to 40) with 
reasonable yields, and on a variety of substrates (41, 42, 43) (Scheme 1- 13).74–76 Though 
useful, air and water sensitivity (including azeotropic drying of the 18F fluoride) hindered 
the translation of this approach to automated synthesis modules. A nickel-mediated 
oxidative fluorination method was subsequently developed to address some of these 
limitations. 
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Scheme 1- 13 Palladium catalyzed F-18 Fluorination 
 
 Hooker and Ritter demonstrated utility of a nickel-mediated oxidative fluorination 
(44, 45) over their previously mentioned palladium complexes, this time utilizing aqueous 
F-18 fluoride and an oxidant (Scheme 1- 14a).77,78 While this helped counter the water 
sensitivity of the palladium complexes, this method is limited in degradation of the Ni 
complex and oxidant due to the volume of aq. 18F fluoride volume ratio, and azeotropic 
drying resulting in solutions too alkaline, and causing low radiochemical yields. Moreover, 
the application of this method to the 5HT2A receptor, [18F]MDL100907 (46), showed 
moderate yields, but was too complicated and difficult to reproduce to merit this an ideal 
labeling strategy (Scheme 1- 14b).78  
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Scheme 1- 14 Nickel-mediated oxidative F-18 Fluorination 
 
 Hooker and Ritter also demonstrated C-F bond formation through 
deoxyfluorination of phenols and alcohols. This was shown in 18F and 19F with their 
PhenoFluor and AlkylFluor reagents. PhenoFluor and AlkylFluor were later made 
commercially available through Sigma Aldrich and Strem Chemicals Inc.79–85 
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Another foray into the fluorination space was by the Sanford group demonstrating 
that copper salts catalyzed the nucleophilic fluorination of mesityl-substituted 
diaryliodonium salts (47) with high chemoselectivity and with good functional group 
tolerance.86 This work with copper(II) catalysts and KF, in collaboration with the Scott 
group, was later translated to K18F, even though catalysts were rescreened and copper(I) 
catalysts were found to provide higher yields of the desired 18F labeled arenes. This mild 
method was demonstrated on electron rich, neutral and deficient arenes, as well as 
clinically relevant PET tracers (4-[18F]fluorophenylalanine (48) and 6-[18F]fluorodopa (49)) 
in promising yields. However, the diaryliodonium precursors are challenging to prepare, 
and automated synthesis requires optimization to improve yields (Scheme 1- 15).87 
 
Scheme 1- 15 Copper-catalyzed F-18 Fluorination of (mesityl)(aryl)iodonium salts 
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The Sanford group also showed that aryl fluorides can be produced from aryl boron 
reagents, such as potassium aryl- and heteroaryltrifluoroborates, aryl boronic acids, and 
aryl pinacol boronate esters, in the presence of copper catalysts.88 This work was 
extended to 18F radiochemistry by Gouverneur as well as Sanford and Scott (Scheme 1- 
16a).89,90 Gouverneur showed that pinacol-derived aryl (50a) and heteroacyl-boronic 
ester (50b), using [Cu(OTf)2(py)4], could be fluorinated in good yield. This work also 
included successful labeling of PET tracers, 6-[18F]fluorodopa (51) and [18F]DAA1106 
(52).89 Scott and Sanford reported a mild synthetic procedure compatible with aryl, 
heteroaryl, and vinyl boronic acids utilizing Cu(OTf)2 and [18F]KF. This procedure was 
also automated and demonstrated in the production of [18F]FPEB (53) (Scheme 1- 16b).90 
Another attractive precursor for copper-mediated late-stage nucleophilic 
radiofluorination are aryl and vinyl stannanes. An 19F method for oxidative fluorination of 
aryl stannanes via tetrabutylammonium triphenyldifluorosilcate (TBAT) and copper (II) 
triflate was described, under mild conditions and good functional group tolerance by the 
Murphy group in 2016.91 Scott and Sanford reported a Cu-mediated 18F fluorination of 
aryl stannanes. The latter provided high specific activity, good radiochemical yields, and 
was also compatible with electron-deficient and electron-rich substrates, as well as 
clinically relevant PET tracers (54-58) (Scheme 1- 17).92 While Cu-mediated fluorination 
reactions are desired due to commercial availability and air stable catalysts, the iodonium, 
boronic ester, and stannane precursors can be synthetically challenging to prepare and 
not necessarily accessible to chemists often staffing PET Centers around the world. 
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Scheme 1- 16 Copper-mediated F-18 Fluorination of aryl boronic acids 
 
These transition-metal mediated radiofluorination methods are expanding the 
range of scaffolds available for PET imaging and the way in which chemists view 18F 
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fluorination (reactivity of the 18F- nucleophile). The methods are also beginning to be used 
for production of clinical PET radiotracers,93 demonstrated through the synthesis of 
Hooker and Ritter’s Ni-mediated synthesis of T [18F]5-FU to provide a cGMP compliant 
human-injectable dose free of residual metals.94  
 
 
Scheme 1- 17 Copper-mediated F-18 Fluorination of aryl stannanes 
 
Another straightforward radiolabeling strategy is to prepare a radiolabeled 
alkylating agent (or prosthetic group). This is used in the preparation of [18F]fluoroethyl 
tosylate (64), [18F]SFB, and can be found in 18F-click chemistry; moreover, it is routine in 
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carbon-11 chemistry (such is O-, S-, or N-alkylation at a heteroatom via [11C]methyl iodide 
or [11C]methyl triflate). Starting from dibromomethane (58), or 2-bromoethyl 
trifluoromethanesulfonate (61), 18F fluorination via standard procedure, then subsequent 
SN2 reactions for the production of the desired tracer. This is a common strategy for the 
production of several PET tracers, including [18F]fluorocholine ([18F]FCH) (60) and O-(2-
[18F]fluoroethyl)-L-tyrosine ([18F]FET) (64) (Scheme 1- 18).31,47,48 
 
Scheme 1- 18 Radiolabeled Alkylating Agents 
 
C-H radiofluorination is another labeling strategy for quick incorporation of the F-
18 label, bypassing the oftentimes lengthy synthetic steps to prepare sophisticated 
precursors. This was first reported by Hooker and Groves, utilizing Mn(salen)OTs as a 
catalyst in the presence of PhIO, K2CO3, and [18F]fluoride.95 The [18F]fluoride could be 
directly eluted from the ion exchange cartridge and used directly, thus shortening the 
synthesis time and negating the need for the azeotropic drying of the fluoride. This method 
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was demonstrated in a variety of substrates, including drug-like bioactive molecules (65 
and 66) (Scheme 1- 19).  
 
Scheme 1- 19 Benzylic C-H Fluorination 
 
An sp2 C-H [18F]fluorination was developed by Scott and Sanford that utilizes 
MesI(OH)OTs to form a (mesityl)(aryl)iodonium salt in situ that is then used for Cu-
mediated 18F fluorination. This was demonstrated on 18 electron rich or neutral 
(hetero)arenes, and eliminates the requirement to prepare, isolate, and store otherwise 
bench instable starting materials (Scheme 1- 20).96 
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Scheme 1- 20 Cu-Mediated C-H 18F-Fluorination 
 
Approaches to [18F]trifluoromethylation is another attractive target, as it is a 
privileged motif in small molecule drugs, found widely in an array of pharmaceuticals and 
prevalent in potential radiotracers. Historically, [18F]trifluoromethyl is typically prepared 
from the -CF2Br precursors. As one would expect, separation of the radiolabeled product 
from the precursor can be a challenging endeavor, often leading to low specific activity 
radiotracers. A common theme here, the development of a method to increase the 
specific activity and ease of labeling was desired. Approaches include [18F]alkyl and 
[18F]aryl-CF3.97–99 An efficient preparation from difluorovinylsulfonate (67) to the 2-
[18F]fluoro-2,2,-difluoroethyltosylate (68); the resultant [18F]fluoroethylating agent (69) 
was used in the preparation of couple bioactive molecules, including the neurofibrillary 
tangle imaging agent [18F]lansoprazole (71) from commercially available 70 (Scheme 1- 
21b).99  
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Scheme 1- 21 Strategies for alkyl [18F] trifluoromethylation 
 
While alkyl [18F]trifluoromethylation has good utility, [18F]trifluoromethyl arenes are 
a money maker and of sincere interest to the fluorine-18 community. Copper-mediated 
[18F]trifluoromethylation from CuI or CuCl to produce [18F]CuCF3 as a reagent has been 
the driving force of this chemistry.100–103 Gouverneur reported the preparation of 
[18F]CuCF3 from methyl chlorodifluoroacetate,CuI, N,N,N’,N’-tetramethylethylenediamine 
(TMEDA) and [18F]fluoride-K222 in DMF; this could then we cross-coupled in moderate 
to high RCY with a range of aryl and heteroaryl iodides (72-74), and 31 examples 
(Scheme 1- 22a).100 This methodology was also utilized with direct C-H oxidative 
[18F]trifluoromethylation of drug-like molecules, include indole 75 to form 76 (Scheme 1- 
22b).95 By combining difluoroiodomethane, potassium bicarbonate, DIPEA and 
[18F]fluoride-K222 in DMF the [18F]CuCF3 reagent was as produced and demonstrated by 
the Riss group. Similarly, this could be coupled to a range of aryl iodides to produce the 
desired F-18 labeled trifluoromethyl arenes (77-79), 15 examples, in good yields (Scheme 
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1- 22c). It is exciting to note that this transformation was tolerant of a free phenol 
functionality, even though the desired 18F-product was formed in lower radiochemical 
yield.98 
 
Scheme 1- 22 Strategies for [18F]trifluoromethylation of arenes 
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Finally, [18F]fluoroform, from difluorocarbene from the initial 
difluoromethylsulfonium salt, with a coppyer catalyst (CuI or CuCl) and potassium t-
butoxide was also demonstrated to produce the [18F]CuCF3 reagent. This was then 
reacted with aryl iodides or aryl boronic acids in DMF to produce the desired 
[18F]trifluoromethylated product (80-82) in high RCY, with 10 examples (Scheme 1- 
22d).102 
 While this provides a brief summary of the variety of 18F fluorination methods 
available, a more expansive review of fluorine-18 chemistry (and their applications to 
PET) may be found in, but is not limited to: Le Bars 2006, Schirrmacher et al 2007, Miller 
et al 2008, Ametamey et al 2008, Cai et al 2008, Kilbourn and Shao 2009, Littich and 
Scott 2012, Campbell and Ritter 2014, Jacobson et al 2015, Campbell and Ritter 2015, 
Brooks et al, 2014, Cole et al 2014, Richter et al 2014, Gouverneur and Seppelt 2015, 
Liang et al 2014, Liang et al 2016, Preshlock et al 2016, and Taylor et al 
2017.31,42,43,61,62,85,104–115 
 
f. Carbon-11 Labeling From Cyclotron-Produced [11C]CO2  
 
While fluorine-18 has many advantages such as a longer half-life and stability, 
carbon-11 is an attractive radionuclide for bioactive molecules because frequently its 
incorporation has minimal effect on biological activity. Moreover, the short half -life (20 
min) allows multiple PET scans to be conducted in a single hospital visit (fluorine-18 scans 
are limited to 1 scan per day). Carbon-11 is produced via proton bombardment of 
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nitrogen-14, typically with small amounts of oxygen, through the 14N(p,D)11C nuclear 
reaction. The [11C]CO2 is then delivered to a synthesis module with appropriate 
containment for the gaseous agent, where it is oftentimes trapped on a solid material 
(molecular sieves), then thermally released from the trap to the reactor or on to further 
transformation.  
Specifically, from the cyclotron, [11C]CO2 destined to be [11C]CH3I or [11C]CH3OTf, 
is trapped on a molecular sieve with nickel at room temperature. This is sealed and heated 
to 350oC with H2 to reduce the [11C]CO2 to [11C]CH4, which is trapped on a carbosphere 
methane trap cooled to -75oC (with liquid N2). When the carbosphere is heated to 80oC, 
it releases the [11C]CH4 which enters a circulation loop containing an iodine column at 
100oC. The iodine, I2, tube reactor is at 750oC and[11C]CH4 is circulated for 5 min to 
generate [11C]CH3I which is trapped on a porapak column before being delivered to the 
reactor. If a more reactive methylating agent is required, [11C]CH3I can be passed through 
a silver triflate at 190oC to generate [11C]CH3OTf. Following delivery to the reactor and 
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subsequent methylation, similar purification and reformulation using semi-preparative 
HPLC and solid-phase extraction are undertaken to generate the final dose.116 
 
 
Scheme 1- 23 Carbon-11 Chemistry Summary. (Adapted from Scott, 2009)117 
 
Common reagents as such include [11C]CO2, [11C]CO, [11C]HCN, [11C]COCl2, 
[11C]CH3I, [11C]CH3OTf (Scheme 1- 23). Drawbacks of carbon-11 chemistry include 
competing side-reactions and by-products, and competition with atmospheric carbon-12, 
short half-life (20 min), and specific activity. Even though the most common strategy for 
11C labeling is through the production of the reactive methylating species ([11C]CH3I and 
[11C]CH3OTf), [11C]CO2 is also an attractive reagent itself. [11C]CO2 can give access to 
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carboxylic aids, amides, ureas, carbamates, oxazolidinones, and other high oxidation 
state functional groups and their respective derivatives.118 
 
 
Figure 1-7 Selected C-11 Radiopharmaceuticals 
 
Standard methylation at a heteroatom via [11C]CH3I, [11C]CH3OTf is a common 
strategy for production, and desirable for simplicity considering half-life, transfers, etc. 
This includes [11C]Carfentanil (83), [11C]PBR28 (84), [11C]OMAR (85), [11C]PMP (86), 
[11C]Methionine (87), [11C]CHL, [11C]PIB, [11C]DTBZ, [11C]FMZ, [11C]Raclopride (91) 
(from a TBA hydroxide/TBA salt (e.g. 90), amine, phenol, etc) (Scheme 1- 24,Figure 
1-7).47,48  
 
46 
 
 
Scheme 1- 24 Synthesis of C-11 DASB and Raclopride 
 
Other carbon-11 labeling strategies have been adapted from traditional organic 
chemistry techniques such as Huisgen cycloaddition, click chemistry, palladium-
catalyzed cross-couplings (Stille, Suzuki, and Sonogashira reactions), and the use of 
organometallic reagents (Grignard, etc) to access carboxylic acids, amides (amines) and 
acyl chlorides have been adapted for these syntheses.43,117–125  
One example of a more complicated carbon-11 labeling synthesis is for the 
dopamine D3 receptor-preferring radiopharmaceutical, (4aR,10bR)-4-(propyl-1-11C)-
3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol ([11C]PHNO, 97). 
[11C]PHNO is produced from the release of [11C]CO2 to ethylmagnesium bromide solution 
(92), then with treatment of phthaloyl dichloride; the resultant acyl chloride ([11C]propionyl 
chloride, 94 ) is reacted with the amine precursor (95) in TEA to form the [11C]amide (96), 
and finally reduced with lithium aluminum hydride to give the desired product (97). Indeed 
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this complicated synthesis for such a short-lived isotope is not ideal, yet readily gives 
access to the desired scaffold (Scheme 1- 25).48 
 
 
Scheme 1- 25 Synthesis of [11C]-(+)-PHNO 
 
[11C]CO2 fixation chemistry utilizing Grignard reagents (Scheme 1- 26 a), such as 
the synthesis of [11C]-(+)-PHNO (97) mentioned above, as well other basic organometallic 
reagents include organolithium reagents (Scheme 1- 26b and c), and silanamines 
(Scheme 1- 26d). While organometallic/organosilicon species for [11C]CO2 fixation are 
feasible options they suffer from instability, and due to their reactivity, pose issues with 
reproducibility and automation required for translation to the clinic. Symmetrical and 
unsymmetrical ureas can also be prepared by [11C]CO2 fixation (Scheme 1- 27).118 
[11C]Urea was synthesized by Chakraborty et al through LHMDS (98) in THF and bubbling 
in [11C]CO2 to afford 99, followed by hydrolysis with aqueous ammonium chloride 
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provided [11C]urea (100); this procedure was applied in the synthesis of [11C]uracil 
(Scheme 1- 27a).126 Moreover, [11C]phosgene can been used to prepare ureas, as well 
as carbonates and isocyanates.127 Phosphoryl chloride or thionyl chloride are another 
option to generate the acid chloride or isocyanate, highly electrophilic species, that could 
be used to prepare [11C]diphenyl urea and [11C]diphenyl carboiimide (Scheme 1- 27b).128 
Through careful manipulation, [11C]ureas (105, 107) can be produced selectively through 
the use of POCl3 to trap remaining amine on the [11C]isocyanate (104) generated in situ; 
the reaction can also be controlled to favor unsymmetrical products (107) (Scheme 1- 
27b, Scheme 1- 28).118,129  
 
 
Scheme 1- 26 [11C]CO2 Fixation Reactions118 
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[11C]CO2 in this fashion was applied to radiolabeling a variety of structurally diverse 
drug-like molecules, including: [11C]GR103545, [11C]metergoline, [11C]SL25.1188, [11C-
carbonyl]AR-A014418, [11C]PF-0445785, to name a few.118 
 
Scheme 1- 27 [11C]CO2 Fixation to Access [11C]Ureas118 
 
Condensation of phosphinimines with [11C]CO2 is another way to access 
[11C]isocyanates. Phenyltriphosphinimine (108) is commercially available and can be 
used to prepare [11C]urea (110) with aliphatic and aromatic amines (Scheme 1- 28). This 
procedure was reported in a one-pot fashion, with modest to good yields and short 
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reactions times (6 min). [11C]CO2 is trapped at -60oC in THF and phosphinimine, amine, 
then heated to 60oC to complete the transformation.130 
 
 
Scheme 1- 28 Synthesis of [11C]phenylisocyanate and [11C]ureas 
 
 Carbamates are also attractive functional groups and have been labeled using 
[11C]phosgene and [11C]carbon monoxide.43 While [11C]ureas require a carbamate salt 
intermediate when electrophiles are used, O-alkyl carbamates do not necessarily require 
this and was demonstrated by Hooker and Fowler in a one-pot procedure for [11C]CO2 
into carbamates.131 They identified 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) as a 
trapping agent and catalyst, in MeCN, DMF, or DMSO, trapped >95% [11C]CO2. Benzyl 
and allyl chlorides were the best electrophiles, and reduction of the benzylamine (for 
example) was advantageous over reducing the concentrations of the other reagents 
(Scheme 1- 29).118 [11C]isocyanates are another option to access [11C-carbonyl]-
carbamates, through careful stoichiometric manipulation to prevent the formation of 
symmetrical [11C]urea(s). This was demonstrated in the synthesis of [11C]CURB, via 
[11C]CO2 fixation with cyclohexamine, 2-tert-Butylimino-2-diethylamino-1,3-
dimethylperhydro-1,3,2-diazaphosphorine (BEMP), then formation of [11C]isocyanate 
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with POCl3, and quenching with the appropriate alcohol to provide the O-aryl carbamate 
tracer.118,129 
  
 
Scheme 1- 29 [11C-carbonyl]carbamates from [11C]CO2 (left) trapping followed by amine substitution; (right) 
carbamate activation with POCl3.118 
 
 [11C-carbonyl]-oxazolidinones are another attractive functionality, found in many 
drug-like molecules, and is used in the synthesis of [11C]SL25.1188, a reversible 
monoamine oxidase-B tracer.132 Moreover, prefunctionalized metal-free conditions using 
organozinc and organoboron reagents have received attention recently and allowed 
access to [11C]carboxylic acids ([11C]ester and [11C]amide).133–135 Riss and colleagues 
reported a Cu-catalyzed (CuI-mediated) method for 11C-carboxylation of boronic acid 
esters. This was extended to an amide via an acid chloride, a succinic ester via 
carbodiimide activation, as well as a methyl ester through iodomethane. These reactions 
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proceeded with [11C]CO2, TMEDA, KF, and crypt-222, and resulted in high specific activity 
[11C]carboxylic acids.118,136  
 
[11C]CO2 fixation chemistry has been covered, but some noteworthy techniques 
and summary(s) can be found in: Rotstein et al  2013, Perrio-Huard et al 2000, Scott 
2009, and Mossine 2016. 117,118,137,138 
 
g. Automated Radiosynthesis for PET Radiochemistry 
 
With a short review of 18F and 11C labeling strategies for PET radiopharmaceuticals 
in hand, a short discussion of the logistics involved in PET radiopharmaceutical 
production is necessary. As mentioned earlier, PET radiopharmaceutical production 
exists in a unique space, where a short-lived positron-emitting radionuclide (e.g. 18F, t1/2 
= 110 min, or 11C, t1/2 = 20 min) is used to label (or tag) a bioactive molecule. These 
radionuclides, carbon-11 (14N(p,D)11C) and fluorine-18 (18O(p,n)18F), are produced in a 
medical cyclotron (at the University of Michigan, Ann Arbor, this is a General Electric (GE) 
PETTrace cyclotron) and delivered to lead-lined cells “hot cells” (Figure 1-8) for remote-
controlled automation. 
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Figure 1-8 "Hot Cells" at the University of Michigan 
 
As previously described, nucleophilic [18F]fluoride is produced via 18O(p,n)18F, or 
proton bombardment of a [18O]H2O target. Typically, the 18F- anion is delivered in a bolus 
of [18O]H2O to a lead-lined “hot cell” with a TRACERLAB-FxFN synthesis module (Figure 
1-9, Figure 1-10). The Remaining synthesis can be executed “manually” through a 
general labeling program, or a pre-programmed automation for a specific tracer. Then, 
the 18F- is loaded on to an ion-exchange column, typically a quaternary methyl ammonium 
(QMA) anion exchange cartridge to trap and recycle unused [18O]H2O. The 18F- is eluted 
to a cryptand, K222 (Kryptofix), an aminopolyether, which also acts as a phase transfer 
catalyst and used in conjunction with potassium carbonate to activate the [18F]fluoride 
through the [18F]KF.K222 complex (Figure 1-11). From here, the fluorine-18 (complex) is 
azeotropically dried (typically in water/MeCN) to remove residual water from the target, 
leaving an activated 18F nucleophile. The 18F nucleophile is then reacted with the 
precursor in aprotic, anhydrous solvents, such as MeCN and DMF.46  
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Figure 1-9 FxFN Synthesis Module for Fluorine-18 
 
 
Figure 1-10 FxFN Synthesis Module for Fluorine-18 in a Hot Cell 
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Figure 1-11 [18F]KF-K222 Complex 
 
Carbon-11 is prepared via the 14N(p,D)11C nuclear reaction and delivered to a 
(GE)TRACERLAB-FxC-Pro synthesis module (Figure 1-12, Figure 1-13) in the form of 
[11C]CO2. As previously described, [11C]CO2 can be used directly, or transformed into 
transformed into [11C]CH3I or [11C]CH3OTf for methylation at a hetero atom (i.e. N, S, O). 
The [11C]CO2 can be bubbled directly to a reactor containing another reagent (e.g. 
Grignard) before reacting with precursor, or trapped on a molecular sieve with carrier 
(CO2) and used for subsequent chemistry.116  
 The production of [11C]CH3I or [11C]CH3OTf involves trapping [11C]CO2 from the 
cyclotron on a molecular sieve that is mixed with a nickel catalyst (Shimalite) at room 
temperature. The tube containing the sieve/nickel mixture is pressurized with H2, sealed 
and heated to 350oC to reduce [11C]CO2 to [11C]CH4, which is then trapped on a 
Carbosphere methane trap cooled to -75oC with liquid N2. The [11C]CH4 is thermally 
released when the Carbosphere is heated to 80oC, and enters a circulation loop 
containing an iodine column at 100oC. [11C]CH4 and iodine vapor circulate through a 
furnace at 750oC for 5 min. to generate [11C]CH3I, which is trapped on a porapak column 
before delivery to the reactor. If a more reactive methylating agent is required, the 
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[11C]CH3I can be passed through a silver triflate column at 190oC to generate 
[11C]CH3OTf.116 
 
 
Figure 1-12 FxC-Pro Synthesis Module for Carbon-11 
 
 
Figure 1-13 FxC-Pro Synthesis Module for Carbon-11 in a Hot Cell 
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Carbon-11 chemistry has two core reaction methods: reactor and loop chemistry. 
The reactor chemistry is as briefly described earlier; this is such that [11C]CO2 [11C]CH3I 
or [11C]CH3OTf is bubbled into a reactor containing a reagent (such as an organometallic 
reagent) prior to reacting with precursor, or directly in a solution of solvent and precursor. 
Loop chemistry, on the other hand, reduces solvent volume through thin-film chemistry. 
The precursor, dissolved in ethanol, is loaded on the semi-preparative HPLC and 
conditioned with nitrogen gas to coat the loop. Following this, the methylating agent such 
as [11C]CH3OTf, is blown rapidly, 40 mL/min for ~3-5 min, through the loop containing the 
precursor.139 
For the preparation of 18F and 11C-labeled PET radiopharmaceuticals, both 
undergo similar purification and reformulation, such as semi-preparative HPLC and solid-
phase extraction to generate the final dose. The final dose is an ethanolic saline solution, 
suitable for IV injection, upon passing appropriate quality control (QC). Further discussion 
of PET radiopharmaceutical quality control can be found in Chapter 3. 
 
h. An Introduction to PET Scan Data Acquisition: Photon Detection and 
Scintillation Detectors 
 
 The 18F and 11C-labeled PET radiopharmaceuticals decay via emission of a 
positron (β+) and electron neutrino (Qe). The positron travels in tissue, up to a couple mm 
depending on the radionuclide, until it loses enough energy to remain in the vicinity of its 
antiparticle, the electron (e-), long enough to allow annihilation of the two particles to 
58 
 
occur. This event produces two 511 KeV gamma ray photons (J) that project 180o from 
the event location. If both photons of the pair are detected by the PET scanner (within ~5 
nsec), this is termed a coincident event (Figure 1-14).18,140 These annihilation events are 
detected when they reach the scanning device that uses scintillation crystals for 
absorbing the 511 KeV photons. Examples of scintillation crystals used in PET include: 
bismuth germanate/BGO, lutetium oxyorthosilicate doped with cerium/LSO, sodium 
iodide doped with thallium (NaI(Tl)), barium fluoride, yttrium oxyorthosilcate doped with 
cerium/YSO, and gadolinium oxyorthosilicate doped with cerium/GSO. A burst of light 
(visible or near UV) is then converted by photomultiplier tubes (Figure 1-15) to an 
electrical signal. The amount of light in these scintillation bursts is proportional to the 
energy deposited by the annihilation photon.140,141  
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Figure 1-14 PET Scan Scheme © Public Domain, https://en.wikipedia.org/wiki/Positron_emission_tomography 
 
In a standard PET scan, there are thousands of detectors configured in a series of 
rings around the patient (typically 400-600 crystals per ring, and 24-50 or more rings). All 
of these events/signals are fed through amplifiers and localized by storing which detectors 
recorded the pair of events.141 The ~180o, or co-linearity, path that these photons travel 
is the property that is exploited in PET, allowing a line-of-sight/coincidence (also called a 
Line of Response, or LOR) of the localized event to be determined (Figure 1-16).18,140 In 
general, millions of these coincidence events give information on the spatial location and 
concentration of these positron emitters within the patient.141 
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Figure 1-15 Simple PET Detector 
 
 In theory, these coincidence photons travel in opposite directions (180o) from the 
annihilation event, and are called True Coincidences. In this case, the detector pair should 
produce signals simultaneously, or within 4-8 ns. If, however, unrelated coincidence 
events are registered within this time frame, they are called ‘accidental’ (or ‘random’) 
coincidences (Figure 1-16). These create noise and increased background within the PET 
scan images and need to be accounted for by removing them from the raw data 
measures.141 Attenuation and the scattering of photons by a process called Compton 
scattering complicates the measured signal. Compton scattering is an interaction 
between a photon and a loosely bound electron, such that the out-going photon (after the 
interaction) is of lesser energy than the incoming photon and is diverted from the original 
direction (“scattered”); and is termed a ‘scatter coincidence’ and leads incorrectly 
assigned or misplaced LOR. These events make up roughly 40% of total recorded 
coincidences of a PET scan, but can be discriminated based on energy as measured by 
the light output from the scintillators.141  
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Figure 1-16 Types of Coincidence Events 
  
 The four main properties required of a PET detector/scintillator are: (1) light output, 
(2) signal decay time, (3) high probability for stopping or absorbing 511 KeV photons, (4) 
and its intrinsic energy resolution.  
• (1,4) A high light output scintillator achieves higher energy resolution, and 
is related to the amount of light produced per each absorbed photon. Having 
good energy resolution is required to efficiently identify scattered events. 
With that, it is important to have only minor fluctuations in the measured 
energy of a detected photon (coupled with light output) to distinguish true 
coincidence photons from scattered photons.  
• (2) The decay time of light determines how accurately in time the coincident 
photons are detected by the detectors; this is such that a faster production 
of signal is achieved after each complete photon absorption (shorter decay 
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constants to allow for higher photon counting rate). As the timing resolution 
improves, the signal-to-noise ratio improves.18  
• (3) The sensitivity of the detector is related to the probability of absorbing a 
511 KeV photon.140,141 
As previously mentioned there are several available PET scintillators. BGO is a 
popular choice, as 95% of 511 KeV annihilated photons that enter a scintillation crystal 
are detected. Conversely, on the 3 cm block of the NaI detector, only 36% of the 
annihilated photons interact, yet it has a shorter decay time constant and the light output 
surpasses that of BGO. LSO, lutetium oxyorthosilicate, is another (newer and more 
expensive) option that has higher light output, hence better energy resolution (better 
discrimination of scattered events), as well as a shorter decay time constant.141 Crystals 
(e.g. BGO) are limited by size (smaller size yields better spatial resolution), and as such, 
a matrix of crystals are often coupled to several photomultiplier tubes. 
Following detection of these scintillation events, the next step in the process 
involves photomultiplier tubes (PMTs). PMTs are typically vacuum tubes with a photo 
cathode, whereby the incoming light signals are accelerated and amplified. The electrical 
current generated is proportional to the light output from the scintillation events, and by 
extension, to the initial annihilation photons in the initial scintillation crystals.18  
Spatial resolution of PET is determined by many factors, including photon non-
colinearity (photon trajectory deviating from the 180o), positron range, as well as detector 
size. As previously discussed, non-colinearity (Figure 1-16) can produce error within the 
detected coincidence events and can deteriorate the resolution by ~0.2 cm. The positron 
range is the distance the positron travels in tissue before being annihilated, and this is 
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different for each radionuclide, and to a lesser extent, the tissue type. For example, the 
energies of positrons from 18F have a maximum energy of 0.63 meV, and the error in 
spatial location can be ~0.2 mm – this is in stark contrast to 15O that can have error as 
high as 1.2mm.141 
 
i. General PET Scan Data Processing & Analysis 
 
 The raw data from the LORs are stored as sinograms, and these are the starting 
point for image reconstruction, data processing and analysis, and it is the sinograms 
where the necessary corrections are made prior to reconstruction.32 The data required to 
produce reconstructed images from the raw data are the emission scan, a normalization 
scan, which corrects for detector non-uniformities, and a transmission/blank or CT scan, 
for calculating attenuation and scatter corrections. There are a variety of reconstruction 
algorithms available, including many iterative methods, and the analytic filtered back-
projection (FBP) which was the long-time standard for both PET and CT. Reconstruction 
methods are beyond the scope of this introduction.32,140,142,143 Localization of the 
radiopharmaceutical is thereby determined by reconstruction of all the annihilation events 
that occurred during a PET scan into a set of 2D images or 3D single image (Figure 1-14, 
Figure 1-17).144  
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Figure 1-17 PET Scan of Human brain © Public Domain: https://en.wikipedia.org/wiki/Positron_emission_tomography 
 
A Region of Interest (ROI) or voxel can be drawn around specific areas and a time-
activity curve (TAC) generated (Figure 1-18). These values can be normalized to standard 
uptake values (SUV) to normalize for organism (patient) size and injected dose (Figure 
1-19).145 
 
 
Figure 1-18 Time-Activity Curve (TAC) 
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Figure 1-19 TAC in Standard Uptake Value (SUV) 
 
PET scans can offer valuable information through static scans, to address spatial 
information (where are particular receptor populations, for example). With dynamic 
imaging data, kinetic modeling and quantitative, temporal information can be gained. This 
can include rate of trapping of the tracer, or how many receptors are in a volume of 
tissue.146 Kinetic modeling and quantification of the tracer’s in vivo behavior is an 
essential element in the development of new PET radiopharmaceuticals, imaging 
techniques, and their subsequent translation into clinical applications.147 
The time-activity curves can be analyzed by a chosen pharmacokinetic model and 
modeled as a nonlinear function of rate parameters.148 PET tracer kinetic modeling 
techniques can be model-driven or data-driven, to return the desired biologically based 
parameters.147 Graphical analysis techniques for reversible and irreversible, include the 
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initial work in the Patlak plot for irreversible tracers, and an extended method to reversible 
kinetics called the Logan plot.149,150 
 
Figure 1-20 General Three-Compartment Model 
 
 Compartment models (such as Figure 1-20) are used to describe the dynamics of 
the PET scan – these are described by a series of differential equations with input 
functions and rate constants, or rather the entering/exiting of mass to/from (a) 
compartment, as previously shown. In PET tracer studies, several assumptions are made: 
the tracer amount injected is indeed a trace amount and does not elicit a change in 
physiology (this lends important to injecting high-specific activity PET radioligands), the 
tracer is in a steady state with the endogenous substrate, and the isotope does not 
inherently alter the tracer.146 Several key values are of interest when describing tracer 
behavior. This includes distribution volume ratio (DVR): which is a ratio of the distribution 
volume of a region containing receptors to a nonreceptor region, to help determine 
receptor availability, or free receptor concentration. This is often done with an arterial 
input function, but can also be graphically modeled without the need for blood sampling. 
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This relates to the binding potential, or BP, which is proportional to the receptor density 
and binding affinity (KD).146,151–154  
Moreover, PET data helps bridge the gap between pharmacokinetics and 
pharmacodynamics through not just the determination of binding potential, but also 
receptor occupancy (taking the aforementioned BP a step further) and drug dosing.152 
Administration of the PET tracer, in a bolus injection, infusion (and etc) are other important 
characteristics to consider when planning a PET study and data analysis.146 While the 
intricacies of compartmental modeling will not be discussed in this introduction, it is 
important to have an appreciation for the biomathematicians and kinetic modelers that 
describe the in vivo behavior of PET tracers. 
j. Advancing Medicine and Drug Development Through PET 
 
Figure 1-21 General PET Work Flow 
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Functional imaging offers unparalleled utility in drug development and medicine. 
PET differs fundamentally from other imaging modalities in that it deals at a molecular 
level, allowing one to see biochemical changes – and in many instances, chemical 
changes precede anatomical changes (as would be seen in other imaging modalities such 
as CT or MRI). A PET scan can assist nuclear medicine physicians, in the evaluation and 
staging of cancers, aid in the diagnosis and differentiation of dementias and related 
diseases/disorders, help identify damaged cardiac tissue and blood flow, aid in the 
planning of radiation therapy, and in monitoring patient response to therapy. It has 
applications in oncology, neurology, cardiology, infection and inflammation. Moreover, 
PET is a vital research tool to help understand (biochemically, physiologically, 
pharmacologically, etc) and “map” normal and diseased processes, and guide drug 
discovery programs.18,21,140,155 
Formal training and education in nuclear medicine in the US is at a shortage, 
including radiopharmaceutical chemists. Most radiochemists are recruited from graduate 
and postgraduate training programs in organic, medicinal, and analytical chemistry, for 
example. Many doctoral studies are completed with a co-adviser in radiopharmaceutical 
chemistry, but lack formal training, and are relatively unspecialized. This means that 
radiochemical skills are gained largely at the postdoctoral training level. An estimated 5-
10 new doctoral degrees in radiochemistry are awarded per year, and these values are 
declining. Even so, a recent study reported that an average of 2-3 positions per institution 
(in a survey of 20 institutions) went unfilled due to lack of unqualified applicants in 
radiopharmaceutical chemistry. The recruitment of students into radiopharmaceutical 
chemistry and nuclear medicine continues to be a challenge largely due to the fact that 
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many of the chemists in the field do not hold academic positions that have access to 
chemistry graduate students.21 
It is with sincere gratitude that this work is put forth as the result of 5 years of 
mentorship and guidance by Professor Peter J.H. Scott, a radiopharmaceutical chemist 
and Director of PET Radiochemistry and Cyclotron Facility, and his appointment in the 
University of Michigan’s Interdepartmental Program in Medicinal Chemistry. Without Dr. 
Scott’s efforts to mentor chemistry graduate student(s) through their doctoral studies as 
the next generation of PET radiopharmaceutical chemists, this work would not have been 
possible. 
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Chapter 2 
Motivation For This Work 
 
 The Scott lab is involved in all aspects of radiopharmaceutical development, 
including the development and optimization of novel radiolabeling methods for small 
molecules, the synthesis and pre-clinical evaluation of PET radiotracers for CNS diseases 
and disorders and the cGMP compliant production of PET radiotracers for clinical use. 
The work described in this thesis encompass, to some extent, each of these steps in the 
path to advance the field of nuclear medicine and human health. Firstly, a green approach 
to late-stage 18F-fluorination (using only ethanol and water) of radiopharmaceuticals will 
be described. The goals were to (1) simplify quality control (QC) testing, (2) improve 
patient safety and (3) simplify waste disposal by eliminating hazardous solvents from 18F-
radiosynthesis. The work also raises important questions pertaining to the perceived 
reactivity of fluoride in green, protic solvents and/or aqueous media.  
Secondly, PET radiotracer discovery for the interest of dopaminergic imaging in 
neurodegenerative diseases and disorders has been investigated. There exists a need to 
fully characterize the pharmacology at the dopamine-D3 receptor and its utility in 
therapeutic application has yet to be fully explored and capitalized on. The availability of 
PET radiotracers for this purpose are limited and currently there are only non-selective 
tracers with affinity to both D2 and D3 receptors, including [11C]raclopride and 
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[18F]fallypride; even the more recent D3 preferring radioligand [11C](+)-PHNO offers only 
~20-fold selectivity. Efforts to synthesize novel D3 selective PET radioligands based upon 
pramipexole and BP-897 are described, as well as preliminary pre-clinical evaluation in 
rodents using in vitro autoradiography and in vivo microPET imaging. 
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Chapter 3 
Applying the Principles of Green Chemistry to 18F Fluorination 
 
a. PET Radiopharmaceutical Production 
 
 [18F]Fludeoxyglucose ([18F]FDG (3)) is the most widely used PET 
radiopharmaceutical, at roughly 90% of the scans worldwide, making it nearly 
synonymous with PET (Figure 3- 1). [18F]FDG is used widely in imaging oncology, 
neurology, and cardiology, with innovative uses for this tracer emerging every year. At 
the University of Michigan alone, [18F]FDG is synthesized onsite twice daily and delivered 
to the clinic. This [18F]FDG is used to scan approximately 20-30 patients every day, 
generating ~$40-60K/day in revenue. [18F]FDG is a glucose analog that is preferentially 
taken up into cells with high energy requirements or high metabolic activity (brain, kidney, 
etc) by glucose transporters (in tumor cells, typically: GluT-1 and GluT-3) and 
phosphorylated by hexokinase, thus trapping it in the cell. This phosphorylated product, 
[18F]FDG-6-phosphate, is unable to enter the glycolysis pathway and is not a substrate 
for glucose-6-phosphate isomerase, and so radioactivity gets trapped at a rate 
proportional to the consumption of glucose by the cell (Figure 3- 2). 18F- is converted to 
18O- (please see pages 9-15 in Chapter 1for a discussion on nuclear decay), where it 
becomes protonated in its environment and becomes 2-18O-deoxyglucose-6-phosphate. 
95 
 
Even with its heavy oxygen, it enter the glycolysis pathway where it is metabolized like 
glucose, with non-radioactive products.13 
 
 
Figure 3- 1 Synthesis of [18F]FDG 
 
 PETNET solutions, a subsidiary of Siemens Medical Solutions USA, and Cardinal 
Health are two industry-related entities that deliver minimally processed or “raw” 
radionuclide to facilities equipped to do radiochemical syntheses, or deliver already 
synthesized radiopharmaceuticals (e.g. [18F]FDG) to a nearby facility with PET 
scanner(s). Other independent, privately or publicly owned medical facilities, such as 
universities and university-affiliated hospitals with an on-site cyclotron and/or generator 
can perform similar functions. 
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Figure 3- 2 Proposed Mechanism for [18F]FDG 
 
 The approval of PET radiopharmaceuticals, their synthesis and use therein exists 
in a unique space compared to traditional pharmaceuticals. PET radiopharmaceuticals 
are administered in microdose amounts, typically nanomolar, (for radioactive and mass 
dose with carrier). As diagnostic pharmaceuticals, they do not elicit a pharmacological 
response and fall under unique federal, and otherwise related, guidelines for production 
and administration. Even with the use of animals in research, these tracer quantities still 
qualify animals as “pharmacologically naïve” and can be used for multiple experiments 
across a variety of PET probes and radiopharmaceuticals (unlike traditional 
pharmaceuticals which may permanently change receptor populations, etc.). 
 PET (diagnostic) radiopharmaceuticals manufactured in the USA under unique 
regulatory mechanisms and are regulated by the U.S. Food and Drug Administration 
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(FDA). In the case of investigational drug development, an exploratory IND 
(Investigational New Drug) application is required for clinical trials, just like any other 
pharmaceutical. Alternatively, PET radiopharmaceuticals already used safely in humans 
may be used for basic science clinical studies upon approval of an institutional 
Radioactive Drug Research Committee (RDRC).  
Along the same lines of the use of traditional pharmaceuticals, a New Drug 
Application (NDA) allows PET radiopharmaceutical manufacturers authorization to 
market a particular radiopharmaceutical after completion of appropriate clinical trials (this 
information is from data gathered during the IND phase and includes information such as 
animal pharmacology, toxicology, clinical experience, trial outcomes etc.). The NDA 
documents the production and manufacturing of the PET drug, as well as its safety and 
efficacy profile, and describes specific indications for its use in the clinic. Once the NDA 
is reviewed by the FDA, the radiopharmaceutical may be approved for routine clinical use. 
An Abbreviated New Drug Application (ANDA) is another option that negates the need 
for the submission of preclinical and clinical data to meet the aforementioned safety 
concerns; instead this argues that the generic radiopharmaceutical will be prepared in the 
same manner as its innovator drug product approved under the parent NDA.14  
 All of these drug applications require that manufacturing is conducted in 
compliance with current Good Manufacturing Practice (cGMP). For studies under INDs, 
radiopharmaceutical need to be prepared according to the U.S. Pharmacopeia. However, 
once an NDA (or ANDA) is approved, more stringent manufacturing requirements are 
necessary, according to PET drug cGMP regulations issued in Title 21, Code of Federal 
Regulations part 212 (21 CFR 212).15–17  
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PET radiopharmaceutical production exists in a unique space. A short-lived 
positron-emitting radionuclide (e.g. 18F, t1/2 = 110 min, or 11C, t1/2 = 20 min) is used to label 
(or tag) a bioactive molecule. These radionuclides, carbon-11 (14N(p,D)11C) and fluorine-
18 (18O(p,n)18F), are produced in a medical cyclotron (General Electric PETTrace 
cyclotron) and delivered to lead-lined cells (“hot-cells”) that contain an automated 
synthesis module. For a discussion of automated radiochemistry, synthesis modules, 
please see Chapter 1. 
Fluorine-18 is delivered to a TRACERLab-FxFN synthesis module in a bolus of 
oxygen-18 water, trapped on a quaternary methyl ammonium (QMA) anion exchange 
cartridge to recycle the oxygen-18 water. The fluorine-18 is eluted with aqueous base, 
typically K2CO3,(to generate K18F) into the reactor, and then azeotropically dried in MeCN 
with phase-transfer catalyst, Kryptofix-2.2.2 (K222). The activated F-18 complex (Figure 3- 
3) is then used for subsequent nucleophilic fluorination with an appropriate precursor. 
These reactions typically take place in aprotic, anhydrous organic solvents. After 
subsequent deprotections (as needed), the reaction mixture is purified on semi-
preparative HPLC. Solid-phase extraction on a C-18 cartridge allows reformulation into 
ethanolic saline, and sterile filtration through a 0.22 μm filter provides the final injectable 
dose as a sterile isotonic solution suitable for intravenous injection.  
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Figure 3- 3 [18F]KF - K222 Complex 
 
Carbon-11, on the other hand, is delivered to a TRACERLab-FxC-Pro (page 51) in 
the form of [11C]CO2. If the [11C]CO2 is the desired reagent, this can be bubbled directly 
into a reactor containing another reagent (e.g. Grignard) before reacting with precursor, 
or trapped on a molecular sieve with carrier (CO2) and utilized for further chemistry in a 
similar fashion. Typically, however, [11C]CO2 is transformed into [11C]CH3I or [11C]CH3OTf 
for methylation at a hetero atom (i.e. N, S, O).18,19 
 From the cyclotron [11C]CO2, destined to be converted to [11C]CH3I or 
[11C]CH3OTf, is trapped on a molecular sieve with nickel at room temperature. This is 
sealed and heated to 350oC with H2 to reduce the [11C]CO2 to [11C]CH4, which is trapped 
on a carbosphere methane trap cooled to -75oC (with liquid N2). When the carbosphere 
is heated to 80oC, it releases the [11C]CH4 which enters a circulation loop containing an 
iodine column at 100oC. The iodine, I2, tube reactor is at 750oC and[11C]CH4 is circulated 
for 5 min to generate [11C]CH3I which is trapped on a porapak column before being 
delivered to the reactor. If a more reactive methylating agent is required, [11C]CH3I can 
be passed through a silver triflate at 190oC to generate [11C]CH3OTf. Following delivery 
to the reactor and subsequent methylation, similar purification and reformulation using 
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semi-preparative HPLC and solid-phase extraction are undertaken to generate the final 
dose. 
The short shelf-life carbon-11 and fluorine-18 (20 and 110 min respectively) 
demand an on-site production at manufacturing facilities capable of these radiochemical 
syntheses, and in close range to a facility with a PET scanner. Current Good 
Manufacturing Practices (cGMPs), therefore, are complicated in terms of PET 
radiopharmaceuticals.  
PET radiopharmaceutical quality control (QC) is completed in accordance with 
21CFR212 – Current good Manufacturing Practice for Positron Emission Tomography 
Drugs or the U.S. Pharmacopeia Chapter 823 – Standards for PET drugs.15–17 
Radiopharmaceutical doses are analyzed as follows (including but not limited to): visual 
inspection, pH, chemical and radiochemical purity (HPLC or TLC), radionuclide identity 
(half-life), radionuclide purity, sterile filter integrity, bacterial endotoxins, sterility, and 
residual solvent analysis (GC). Failure of any of these check points (failed QC) means 
that the batch is rejected and the synthesis must be repeated.  
In an effort to address failed doses as the result of failed QC due to contamination 
with residual solvents (Table 3- 1) used in the radiochemical synthesis, we sought to 
address the solvent selection. An extension of addressing the solvent selection, we 
pursued a green/sustainable approach to the design. While the definition of “green” 
chemistry and how it is applied is debatable, we sought to combine the principles of green 
chemistry and sustainability in the manufacturing of PET radiopharmaceuticals 
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b. Green Chemistry 
 
Chemistry is “a science that deals with the composition, structure, and properties 
of substances and with the transformations that they undergo.”20 The long history of 
organic chemistry, the foundation of the pharmaceutical industry, has largely been 
dictated by reactions roughly 50-100 years old, that did not necessarily take into account 
the large scale to which reactions are done today and how they are influence the world 
around us. These reliable reactions are inundated in chemistry curriculum and training, 
heralding the many synthetic procedures for atom efficiency. However, environmental and 
sustainable science, and toxicology are not a core course for traditional chemistry 
training.21 
While the practice of green chemistry began years prior, ‘green chemistry’ is a 
relatively new term in the chemical sciences, adopted in the 1990s by the Environmental 
Protection Agency (EPA).22 Green or sustainable chemistry is intentionally integrating 
hazard/toxin reduction in these transformations – it is not a form of chemistry unto itself, 
but is a practice that is incorporated into the chemical sciences.23  
There are twelve principles of green chemistry, all guided by the idea that products 
and processes are “benign by design”.24 The twelve principles of green chemistry, which 
also have the same underlying features of green engineering, can be summarized as 
follows22,25,26: 
1. Waste prevention rather than remediation (avoid creating waste, rather than 
having to clean up to treat waste after its production). 
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2. Atom efficiency (synthetically design methods to maximize incorporation of all 
materials into the desired, final product). 
3. Less hazardous chemicals (synthetic methods should be designed to produce 
materials that are benign or minimally toxic to the environment and human health). 
4. “Benign by Design” (products should be designed such that serve their appropriate 
function and minimize toxicity). 
5. Safer auxiliaries and solvents (make an innocuous choice for these elements 
whenever possible). 
6. Design processes that are energy efficient (environmental and economic impacts 
should be minimized, and synthetic methods conducts at ambient temperature and 
pressure whenever possible). 
7. Use renewable feedstocks or raw materials. 
8. Avoid derivatization/shorter syntheses (lengthy syntheses utilizing many 
protection/deprotection and chemical/physical temporary modifications should be 
minimized as to avoid additional use of reagents and generation of waste). 
9. Catalysis (catalytic reagents are preferred over stoichiometric reagents). 
10. Design for Degradation (at the end of their function, chemical products should be 
designed to break down into innocuous degradation products). 
11. Analysis for pollution prevention (analytical methodologies need to be developed 
and utilized to monitor and control prior to the formation of hazardous substances). 
12. Inherently safer chemistry processes (substances and usage should be chosen 
and designed to minimize accidents, including explosions and fires). 
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Green/sustainable chemistry, therefore, challenges current chemical processes to 
drive a sense of responsibility and planning toward a safer future (environmental impact, 
while also considering chemical yield, cost of building blocks/solvents, energy demands, 
breakdown products, etc).  
The initial applications of green chemistry had the environmental benefit as a mere 
side effect, taking backseat to efforts to minimize cost and optimizing efficiency.23 In 2013, 
R&D costs were roughly $51.1 billion, compared to $1.2 billion in 1980. Costs are on the 
rise, with roughly 20% of drugs that make it to market return revenues that equal or 
surpass the R&D costs to get there. Cutting costs and reconstructing has become norm, 
with mergers and acquisitions (110 companies to roughly 30 companies over 30 years), 
decreasing R&D, minimizing risk by acquiring biotech/start-ups and experimental drugs 
already through initial evaluation. This includes Abbott spin off for R&D to create AbbVie, 
and significant downsizing at Lilly R&D (down 15-20%), and Merck personnel (20% 
reduction) from 2013-2014.23  
While the drug discovery pipeline is one driven by timely and robust production 
and methodologies, something was surely missing.21 In pharmaceutical chemistry, 
companies need “more bang for their buck”, and green chemistry lets you do just that.23,27 
Julie Manley summarizes this as: 
“By viewing the entire life cycle of material and energy processes as an opportunity 
for design innovation, green chemistry enables the design of drug candidates to 
not just minimize unintended consequences, but more importantly to empower 
sustainability. Efficient and selective utilization of resources during the discovery, 
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development, and manufacture of medicines enables the opportunity to meet the 
needs of today without limiting future generations to achieve theirs”.23 
Green chemistry was discussed in the 2000s, and met major players nearly 5 years 
later by the formation of the ACS GCI (American Chemical Society’s Green Chemistry 
Institute®) Pharmaceutical Roundtable.28 Beyond pharmaceutical chemistry, there are 
also roundtables for: Formulators’, Chemical Manufacturers, Hydraulic Fracturing, and 
Biochemical Technology Leadership.29 The Pharmaceutical Roundtable was developed 
as a partnership between the ACS GCI and industry to implement green chemistry and 
engineering in industrial practice. From 2005, Lilly, Merck and Pfizer, this non-competitive 
partnership has grown to 16 members in 2014. Some notable roundtable members 
include: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, 
GlaxoSmithKline (GSK), Johnson & Johnson, Lilly, Merck, Novartis, Pfizer and F. 
Hoffman-La Roche Ltd.23  
While membership in this roundtable does not necessarily correlate with active 
implementation of green chemistry principles, it opens up the conversation across 
corporations to address sustainability, meet environmental regulations, and cost saving 
measures for a common (noncompetitive) goal. It has sparked communication among 
these powerhouses to discuss collaborations, tool development, chemical alternatives 
and waste reduction. In 2015, the Roundtable sustainability report for Lilly reported the 
construction of a new 40-acre solar array to generate 12.6 million kWh of energy per year, 
improved their energy efficiency by 17%, reduced water intake by 35%, and reduced their 
waste to landfill by 73% from 2007-2013 alone.30 Several publications regarding solvent 
selection, including those from Pfizer, GSK, and Astra Zeneca, are now touting words 
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often not associated with organic/medicinal chemistry. This includes a “holistic” approach 
to solvent selection, and releasing solvent and reagent guides for sustainability when 
planning syntheses.21,31–33  
From industrial to academic institutions, green and sustainable initiatives are 
taking action to work toward this common goal. Environmental chemistry, green 
chemistry, and sustainability training are formally offered in 26 US states (and Puerto 
Rico) at the undergraduate and graduate training level.34 This further extends to campus-
wide initiatives across the US involving training and research laboratories, in reducing 
waste and energy requirements (including, but not limited to the University of Michigan, 
Ann Arbor).35,36 By applying green chemistry principles, notably green alternative to 
reagents, solvents, and end products, “being green” offers itself as an alternative for both 
industry and manufacturing costs and safety, and as a way for chemistry to evolve with 
our increasing population and diminishing resources. 
 
c. PET Radiopharmaceutical Production meets Green Chemistry: Carbon-11 
 
This “benign by design” approach to chemical syntheses shares many qualities 
with a similar “quality by design” (QbD) approach to pharmaceutical development.37 While 
the manufacturing of PET radiopharmaceuticals involves less use of mass materials and 
solvents than that of industrial levels of traditional therapeutics, applying the principles of 
green chemistry in the manufacturing of PET radiopharmaceuticals offers a unique space 
to explore quick syntheses and on-site QC considerations and safety. 
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Table 3- 1 Residual Solvents - Selected Guidelines 
 
 
 
 
 
Previous work involving ethanolic “green” carbon-11 chemistry was recently 
reported by the Scott group in 2013 and 2014.39,40 In these reports, ethanol (a “green” 
solvent) was the only organic solvent used throughout the entire synthesis, HPLC 
purification, reformulation, and module cleaning. This is in stark opposition from the usual 
solvents used for C-11 labeling: N, N-dimethylformamide (DMF), DMSO, 3-pentanone, 
methyl ethyl ketone, n-propanol, acetone, and MeCN. This extended to HPLC purification 
as well, as typically MeCN is used as the mobile phase, ethanol is a suitable HPLC mobile 
phase and a greener substitute for MeCN, and has been widely used throughout our lab 
for “green synthesis” as well as for other labile or sensitive compounds. 
Using protic solvents with methylations is unusual, and typically thought of as 
incompatible with these reactions due to solvation of the nucleophile.41 Nevertheless, 
[11C]DASB (89) and [11C]raclopride (91), were demonstrated by Shao and Scott in their 
C-11 ethanolic loop method (a discussion of loop chemistry can be found on page 56. 
Their method negated the need for residual solvent analysis, saved significant time during 
Class Solvent Exposure Limit (per dose) 
1 Most Hazardous Benzene 2 ppm 
2 Limited Exposure MeCN 410 ppm 
DMF 880 ppm 
3 Lowest Toxic Potential DMSO 5000 ppm 
EtOH 5000 ppm 
U.S. Pharmacopeial Convention, General Chapter <467> Residual Solvents, 
ICH Guidelines on Residual Solvents38 
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synthesis which resulted in overall higher yields and specific activities for [11C]raclopride, 
and similar yields for [11C]DASB compared to traditional methods (Scheme 3- 1).40  
 
Scheme 3- 1 Green Carbon-11 Synthesis of [11C]Raclopride and [11C]DASB 
 
Applying the proof-of-concept method utilizing ethanol through the entire 
manufacturing process of [11C]raclopride and [11C]DASB, this was then extended to 
several other radiopharmaceuticals routinely synthesized for clinical use. This was 
designed in part to move the manufacturing facility to a “green laboratory”, and explore 
the substrate compatibility (Figure 3- 4).42 
Eleven different tracers were demonstrated, with radiochemical yields comparable 
to traditional methods, and radiochemical purities all above 95% (Figure 3- 4). The 
methylating agents and methods used were [11C]MeOTf (loop, and reactor), and [11C]MeI 
(reactor, and sep-pak) at several precursor preparations (including the free base and TBA 
salt). Here it was exciting to see that the C-11 loop method could be expanded to reactor 
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labeling of several tracers. The “Loop chemistry”, used for [11C]DASB and [11C]raclopride, 
is a special method that reduces solvent volume through thin-film chemistry; this is such 
that the precursor (dissolved in ethanol) is loaded on the semi-preparative HPLC loop 
(and conditioned with nitrogen gas for 20 sec at 10 mL/min), and [11C]MeOTf blown 
rapidly through the loop (3 min at 40 mL/min). The reactor-based (5) and solid-support 
(sep-pak) (1) chemistry was demonstrated on 6 radiopharmaceuticals, and all produced 
doses suitable for clinical imaging at the end of synthesis.40,42 
 
 
Figure 3- 4 Selected C-11 Radiopharmaceuticals Synthesized via "Green Radiochemistry" 
 
Notable limitations to carbon-11 (ethanol) green chemistry is the solubility of the 
precursor in ethanol. Otherwise, these reactions were shown to proceed at room 
109 
 
temperature, in low solvent volumes, and simplified overall manufacturing in shortened 
synthesis time, and end of synthesis quality control (QC).42 These mild reaction conditions 
are desirable for synthetic procedures, to not only save time and energy requirements 
(heating etc.), but also allows for more labile substrates to be evaluated. 
 
d. PET Radiopharmaceutical Production meets Green Chemistry: 18F and 19F 
 
The two most commonly used positron emitters used in PET radiopharmaceuticals 
(as small molecules), as mentioned before, are C-11 and F-18. While carbon-11 has 
many advantages including its incorporation having minimal biological effects in drug-like 
molecules, fluorine-18 PET diagnostics are widely used and desired for their longer half 
life (20 vs 110 min). Indeed, in synthetic organic chemistry, water is often considered a 
chemist’s worst nightmare. Many of these synthetic transformations are typically sensitive 
to the presence of water, and often requires rigorous and pain-staking drying of glassware 
and solvents.  
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Scheme 3- 2 New set of SN2 fluorinations catalyzed by protic solvents43 
 
 
Scheme 3- 3 Nucleophilic Fluorinations in Alcohols44 
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Typically F-18 fluorinations ([18F]KF) take place in aprotic, anhydrous solvents, as 
the fluoride anion is thought to be highly hydrated and, thus, poorly nucleophilic and poorly 
chemically reactive in protic solvents.9 Indeed these reactions are typically done in MeCN, 
DMF (etc). As a result, the [18F]fluoride is azeotropically dried to remove residual water 
left over from the oxygen-18 water from the target and the K2CO3 used to generate K18F. 
Subsequent nucleophilic fluorination reactions are typically carried out in polar aprotic 
solvents such as MeCN, DMSO or DMF, usually with the inclusion of a phase-transfer 
catalyst for solubility considerations. Nevertheless, spurred on by the compatibility of 
carbon-11 methylations with ethanol, we investigated the possibility of developing green 
approaches for fluorine-18 radiochemistry. 
Approaches to fluorine chemistry that fall under green, sustainable, or non-
additive/metal-free have been previously explored.45–47 We were gratified to see that 
methods challenging the need for rigorously dried [18F]fluoride have been reported. For 
example, Chi reported SN2 fluorinations in bulky, protic and alcohol-containing solvents 
(Scheme 3- 2,Scheme 3- 3).43,44,48,49 These results show promising yields of the 
fluorinated product, with minor to modest formation of the elimination product in alcohol-
containing solvents and alcohol-mixtures. Other work by Hooker and Ritter demonstrated 
nickel-mediated oxidative fluorination using aqueous 18F (Scheme 3- 4). 50  
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Scheme 3- 4 Nickel-Mediated Oxidative Fluorination with Aqueous 18F 
 
Additional work was done by Sergeev and van Dam that showed titanium 
nanoparticles can promote fluorination of tosylate precursors in aqueous-containing 
media (Scheme 3- 5). They demonstrated that titania nanoparticles in 1:1 (v/v) 
acetonitrile-thexyl alcohol solution and tetra-n-butylammonium bicarbonate allowed for 
direct nucleophilic 18F fluorination without an azeotropic drying step. This was shown in 
aromatic, aliphatic, and cycloaliphatic tosylated starting materials, in addition to the 
synthesis of [18F]Fallypride.51 
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Scheme 3- 5 Titania-Catalyzed 18F Fluorination of Tosylated Precursors in Highly Aqueous Media51 
 
  A report from Zhao and Gabbai, focused on nucleophilic fluorinations with 
aqueous fluoride ion solutions utilizing a cationic borane (2+) to sequester F- anions in 
aqueous conditions. Moreover, the 2+ species (Scheme 3- 6) is also being tested in 
[18F]fluorination reactions.52 Zhao and Gabbai’s method was in part inspired by Sun and 
DiMagno’s work with TBAF53–55, as a way to offer a new fluorination method that could 
proceed in aqueous conditions. 
 
 
Scheme 3- 6 Aqueous Fluoride Ion Solutions and Nucleophilic Fluorination Reactions52 
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 Sun and DiMagno showed that in situ generated TBAF is a powerful nucleophilic 
fluorinating reagent on a range of desirable substrates. One such work demonstrated 
fluorobenzene derivatives (111) with tetra-n-butylammonium cyanide (TBACN) in THF 
produced fluoride anions with “naked” character, denoted TBAF* (113) (Scheme 3- 7).53 
Sun and DiMagno went on to show that their TBAF* reagent was efficient in halex and 
fluorodenitration reactions.55 By comparing TBAF* and KF side by side as fluorinating 
reagents, it was evident that KF(as KF-Kryptofix 222) was a poor reagent compared 
TBAF* - this is such that KF-Kryptofix 222 aromatic fluorodenitration reactions in DMSO 
at reflux in 10 min gave ~5% yield, to TBAF* at room temperature, >95% yield.54,55  
 
 
Scheme 3- 7 Fluorinations in TBAF*53 
 
The in situ generated TBAF* (113) reagent was then applied to the preparation of 
anhydrous tetraalkylammonium fluoride salts from KF. Sun and DiMagno describe the 
fluoride relay system as one such that the first fluoride is transferred from KF to a 
purifiable hydrophobic arene (115), the anhydrous fluoride salt is then generated from 
SNAr with a cyanide salt (Scheme 3- 8).54 
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Scheme 3- 8 K and TBAF* Fluoride Relay54 
A last interesting example was a recent work from Chun and Pike that reported F-
18 fluorination of diaryliodonium tosylates in water-DMF mixtures, with 14-42% (v/v) 
water, without the use of a phase transfer catalyst (Scheme 3- 9).56 
 
Scheme 3- 9 F-18 Fluorination of Diaryliodonium Tosylates  in Aqueous-Containing Solvents56 
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When taken with other reports of nucleophilic fluorination reactions in aqueous 
media from the mainstream 19F-fluorine chemistry literature52, these remarkable results 
suggest the generally accepted incompatibility of fluoride with polar protic solvents does 
not hold up. While all of these reports provide valuable insight into the utility and 
nucleophilicity of the fluoride anion, there exists several imitations to radiopharmaceutical 
production. This includes the need to purify out catalysts (TiO2), and to purify and remove 
residual solvents (DMF, thexOH, MeCN) and tetrabutylammonium cations. Aligned with 
the spirit of green chemistry, we sought to avoid these components all together. This fits 
in previous work within the group, as the group moves toward a green radiochemistry 
program for C-11 and F-18, with a new take on late-stage F-18 fluorinations.39,40,57 
 
e. Results and Discussion:  
i. Approaches to Late-Stage F-18 Fluorination in Ethanol/Water 
 
 The goal of this work is to explore [18F]fluorinations in polar, protic solvents without 
additional additives (catalysts, etc). Aligned with green chemistry principles, we sought to 
use ethanol/water, avoiding hazardous solvents all together. Following azeotropic drying 
in MeCN, F-18 fluorinations are typically carried out in MeCN, DMF, and DMSO (Table 3- 
2), which require residual solvent analysis (RSA).38 Using ethanol/water would negate 
this need for RSA. 
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Table 3- 2 Residual Solvent Analysis - and 18F Tracer Examples 
 
We sought to apply a step-wise approach to the development of green late-stage 
F-18 fluorination, (1) address the need for azeotropic drying of the [18F]fluoride in MeCN, 
and (2) explore the reactivity of [18F]fluoride in green solvents. Taken together, we sought 
to explore several fluorine-18 radiopharmaceuticals (Scheme 3- 10) commonly prepared 
at the UMich PET center ([18F]FDG (3), [18F]fluoroazomycin arabinoside ([18F]FAZA) (121) 
, [18F]fluoroethyl tosylate  ([18F]FET) (64) , [18F]Flubatine (13), [18F]Nifene (125), and 4-
(2’-methoxyphenyl)-1-[2’(N-2’’pyridinyl)-p-[18F]fluorobenzoamido]ethylpiperazine 
([18F]MPPF) (17). As previously described, the fluorine-18 is eluted from a quaternary 
methylammonium (QMA) sep-pak using aqueous K2CO3 (3.5 mg in 0.5 mL water); to this 
is added Kryptofix/K222 (15 mg in 1 mL MeCN). This mixture is azeotropically dried to 
generate [18F]KF.58 
 
 
 
Class Solvent Exposure Limit (per dose) Tracer Example 
1 Most Hazardous Benzene 2 ppm  
2 Limited Exposure MeCN 410 ppm [18F]FDG, [18F]FET 
DMF 880 ppm [18F]Flumazenil 
3 Lowest Toxic Potential DMSO 5000 ppm [18F]FAZA, [18F]FLBT, 
[18F]MPPF 
EtOH 50 mg/day  
U.S. Pharmacopeial Convention, General Chapter <467> Residual Solvents, 
ICH Guidelines on Residual Solvents38 
118 
 
ii. Addressing Azeotropic Drying, from MeCN to EtOH 
 
Table 3- 3 Azeotropic Drying: MeCN/water vs EtOH/water 
Entry Product Azeotrope Reaction 
Solvent 
% RCY or % RCC 
1 [18F]FDG (3) H2O-MeCN MeCN 74±12 (n = 3)A 
2 [18F]FDG (3) H2O-EtOH MeCN 70±10 (n = 3)A 
3 [18F]FAZA (121) H2O-MeCN DMSO 6±1 (n = 3)B 
4 [18F]FAZA (121) H2O-EtOH DMSO 5±1 (n = 3)B 
5 [18F]FET (64) H2O-MeCN MeCN 70±10 (n = 3)C 
6 [18F]FET (64) H2O-EtOH MeCN 68±4 (n = 2)C 
7 [18F]Flubatine (13) H2O-MeCN DMSO 25±10 (n = 3)B 
8 [18F]Flubatine (13) H2O-EtOH DMSO 15±10 (n = 20)B 
9 NBoc- [18F]Nifene (124) H2O-MeCN DMSO 50 (n = 1)C 
10 NBoc- [18F]Nifene (124) H2O-EtOH DMSO 83 (n = 1)C 
11 [18F]MPPF (17) H2O-MeCN DMSO 70±10 (n = 3)C 
12 [18F]MPPF (17) H2O-EtOH DMSO 78±18 (n = 3)C 
A) Radiochemical conversion (RCC) as determined by radioTLC 
B) Isolated radiochemical yield (RCY) 
C) RCC determined by radio-HPLC 
 
 First, we performed a straightforward switch of MeCN to ethanol, given that the 
azeotrope boiling points for these organic/water mixtures were comparable at 76.5oC and 
78.17oC, and ethanol was our green solvent of choice.59 As with the synthesis of [18F]FDG 
(3), we saw comparable radiochemical conversions (RCC) from a water/MeCN azeotrope 
74±12% to our new solvent system with water/ethanol 70±10% (Table 3- 3, Entries 1-2). 
By replacing MeCN with EtOH in the azeotropic drying without detrimental effects to final 
yield, we applied the same solvent replacement to the azeotropic drying step in the 
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synthesis of [18F]FAZA (121), [18F]FET (64), [18F]Flubatine (13), [18F]Nifene (125), and 
[18F]MPPF (17), with similar results. 
 
iii. Exploring [18F]Fluorinations of Radiopharmaceuticals in EtOH & 
Aqueous EtOH 
 
 As the workhorse of PET imaging, [18F]FDG (3) was chosen as the initial and major 
test substrate reaction conditions going forward. The next phase of this work was to 
investigate nucleophilic fluorination reactions in ethanol, or ethanol/water, as the primary 
reaction solvent. In neat ethanol, acetyl protected-[18F]FDG ([18F]FDG-Ac4 (2)) gave a 
notable 23±10% RCC (Table 3- 4, Entry 1). Even though the reaction in neat ethanol was 
lower than the same conditions in MeCN (Table 3- 3, Entry 2), we were encouraged to 
test the solvent tolerance further. With that, we sought to explore water/ethanol mixtures, 
to see if this would improve these reactions, as it was previously shown that small 
amounts of water can have a positive effect on fluorination reactions.60 
 We screened ethanol/water mixtures ranging from 3 to 100% water (Figure 3- 5) 
to explore how well water was tolerated. In this screen we found the optimal reaction 
solvent to be 15% water in 85% ethanol, (Figure 3- 5; Table 3- 4, Entry 2) and the RCC 
for [18F]FDG-Ac4 (2)was 37±5% (n = 3). When the water content went above 15%, a 
steady drop in RCC was observed. Even more remarkable was that such fluorination 
reactions were still possible in neat water, albeit in low RCC of 2-3%. Since these 
reactions were proceeding with water in the reaction solvent, we were motivated to 
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explore the need to dry the [18F]fluoride (the aforementioned reactions were performed 
using azeotropically dried [18F]fluoride). 
 
 
Figure 3- 5 Radiochemical Conversion of [18F]FDG-Ac4 using different ethanol/water mixtures as the reaction solvent 
 
 Even though the role of water in improving these reactions yields is not clear, the 
need to dry the fluoride seems to be unnecessary if the addition of water (in these 
ethanol/water mixtures) show that these reactions still proceed. So we next explored the 
need to trap/release the [18F]fluoride on the QMA cartridge, and subsequent drying step, 
by adding a solution of [18F]fluoride in [18O]water (0.15 mL) to a solution of K2CO3, K222 
and mannose triflate precursor in ethanol (0.85 mL) to provide a final reaction solvent 
concentration of the optimal 15% water in ethanol. This resulted in 3±1% (n = 3) RCC to 
[18F]FDG-Ac4 (2) and we attribute this to impurities, such as metal ions capable of 
sequestering [18F]fluoride, in the cyclotron target water (Table 3- 4, Entry 3). To 
investigate this, the [18F]fluoride was trapped on a QMA and eluted into the reactor using 
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a mixture of K2CO3/K222 in 15% water in ethanol (0.5 mL). The mannose triflate precursor 
was dissolved in 15% water in ethanol (0.5 mL) and added to the [18F]fluoride / K2CO3 / 
K222 mixture, totaling 1 mL. This mixture was heated to 1000C for 30 min to yield [18F]FDG-
Ac4 (2) in 58±5% (n = 3) RCC (Table 3- 4, Entry 4).  
 
Table 3- 4 Nucleophilic Fluorinations in Ethanol/Water Mixtures 
Entry Product QMA/Azeotrope Reaction Solvent % RCC 
1 [18F]FDG-Ac4 (2) QMA/H2O-EtOH EtOH 23±10 (n = 3) 
2 [18F]FDG-Ac4 (2) QMA/H2O-EtOH 15% H2O:85% EtOH 37±5 (n = 3) 
3 [18F]FDG-Ac4 (2) No QMA/None 15% H2O:85% EtOH 3±1 (n = 3) 
4 [18F]FDG-Ac4 (2) QMA/None 15% H2O:85% EtOH 58±5 (n = 3) 
5 [18F]FDG-Ac4 (2) QMA/None 15% H2O:85% EtOHA 16±4 (n = 3) 
6 [18F]FDG-Ac4 (2) QMA/None 15% H2O:85% EtOHB 4±1 (n = 3) 
7 [18F]FAZA (121) QMA/None 15% H2O:85% EtOH 3 (n = 1) 
8 [18F]FET (64) QMA/None EtOH + 1 drop DMSO 52 (n = 1) 
9 NBoc- [18F]Flubatine 
(122) 
QMA/None 15% H2O:85% EtOH 0 (n = 3) 
10 NBoc- [18F]Nifene (124) QMA/None 15% H2O:85% EtOH 0 (n = 1) 
11 [18F]MPPF (17) QMA/None EtOH 0 (n = 3) 
11 [18F]MPPF (17) QMA/None EtOH + DMSOC 0 (n = 3) 
A) 2 mL reaction volume 
B) Reaction without Kryptofix-K222 
C) DMSO added as co-solvent to improve precursor solubility 
 
 Increasing the reaction volume from 1 mL to 2 mL had detrimental effect on the 
reaction yields, providing only 16±4% RCC (n = 3) to [18F]FDG-Ac4 (Table 3- 4, Entry 5), 
suggesting that reaction concentration is important. We also explored the need to include 
Kryptofix-K222 as a phase-transfer catalyst, and whether the aqueous conditions would 
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negate the need for a phase transfer catalyst. However, the RCC of [18F]FDG-Ac4 (2) 
decreased significantly to 4±1% (n = 3) (Table 3- 4, Entry 6) when Kryptofix-K222 was 
omitted. This result was likely the due to the improved nucleophilicity of the [18F]fluoride 
as the result of the Kryptofix-K222 complexing with the potassium counter ion, and not the 
phase transfer properties of the Kryptofix-K222. 
 
 
Scheme 3- 10 Green Radiosynthesis of [18F]Radiotracers 
 
 Having shown that [18F]FDG can be made with this methodology, we pursued to 
apply this radiofluorination to other radiopharmaceuticals of clinical relevance (Table 3- 
4). [18F]FAZA (121) is used for imaging of hypoxia in tumors, as well as myocardia 
ischemia. 2-Nitroimidazoles are taken up in hypoxic environments and undergo 
intracellular reduction, where these fragments are trapped in the cell.13 [18F]FET (64) is a 
123 
 
prosthetic group, or “building block” [18F]fluoroalkylating agent, and has been used to label 
a variety of PET tracers, including muscarinic receptor, N-methyl-D-aspartate (NMDA) 
receptor, dopamine D2 receptor, and gamma-aminobutyric acid (GABA) transporter 
ligands.61 [18F]Flubatine (13) and [18F]nifene (125) are D4β2-nicotinic acetylcholine 
receptor (D4β2-nAChR) imaging agents for the staging and diagnosis of Alzheimer’s 
disease, dementia, and Parkinson’s disease.62–64 [18F]MPPF (17) is a PET radioligand for 
imaging serotonin-1A (5-HT1A) receptors, in the case mood and other cognitive disorders 
(such as anxiety, depression, dementia, schizophrenia, etc).13,65,66 
 
 
Scheme 3- 11 Applying the principles of green chemistry to SNAr of [18F]Radiopharmaceuticals 
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We next explored the synthesis of [18F]FAZA (121) and [18F]FET (64) via aliphatic 
fluorination. Green radiosynthesis of both [18F]FAZA, (Table 3- 4, Entry 7, + 1 drop DMSO 
to help solubilize the precursor), and [18F]FET (Table 3- 4, Entry 8) in ethanol or 
ethanol/water mixtures (etc) gave comparable yields to the traditional syntheses of these 
tracers conducted in DMSO (Table 3- 3, Entries 3 and 4) and MeCN (Table 3- 3, Entries 
5 and 6). In the case of aromatic fluorination reactions (), such as the preparation 
of[18F]Flubatine (122) (Table 3- 4, Entry 9), [18F]nifene (124) (Table 3- 4, Entry 10), and 
[18F]MPPF (17) (Table 3- 3, Entry 10), unfortunately no product was obtained. 
 For the [18F]fluorination of [18F]MPPF, we attribute this result to poor solubility of 
the precursor, even though attempts to use DMSO As a co-solvent with EtOH still did not 
improve the reaction. Additionally, SNAr reactions are typically performed in DMSO at 
120-150oC for 15-30 min, but the boiling point for these water-ethanol mixtures are much 
lower at roughly 70-80oC. As such, these conditions may simply be incompatible with the 
harsher fluorination conditions normally required for these substrates. Although, we 
acknowledge that lower temperature SNAr reactions have been reported.67 
 In the essence of green chemistry, it should be noted that the fluoro(hetero)arene-
containing products can be prepared in DMSO (Table 3- 3). DMSO is otherwise known 
as a bio-innocuous solvent, and one of the least toxic organic chemicals known, making 
it a green solvent.68 The combination of azeotropic drying in water/ethanol and fluorination 
in DMSO also eliminates the need for residual solvent analysis during QC testing 
according to recent updates to the US Pharmacopeia (Table 3- 1). 69 
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iv. Clinical Utility of Green [18F]Fluorinations in Ethanol and 
Water/Ethanol 
 
 For our purposes and to apply this methodology to routine radiopharmaceutical 
production use in the clinical, these reactions should ideally be fully automated using a 
remote-controlled synthesis module. A General Electric TRACERLab FXFN synthesis 
module was programmed to synthesize [18F]FDG (3) using the optimized conditions 
described above (Table 3- 4, Entry 4). Following [18F]fluorination, the acetate groups were 
deprotected by treatment with 1M NaOH at room temperature, followed by neutralization 
with 1M HCl, and formulation.70 This yielded [18F]FDG in 33±2% isolated and formulated 
radiochemical yield (decay corrected, n = 3), which compares to 68±1% isolated and 
formulated yields of [18F]FDG using the traditional acetonitrile reaction solvent conditions 
(decay-corrected, n = 3). 
 While the green reaction yields are somewhat lower than the traditional method, 
and may be too low for routine and large commercial production of [18F]FDG, they indeed 
demonstrate solid proof-of-concept for the use of water/mixture and ethanol-based 
reaction solvents in automated synthesis and production of clinical radiopharmaceuticals. 
One should note that these are preliminary studies and not had the benefit of decades of 
optimization work that has gone into the current synthesis and methods in practice to 
date.  
As with the principles of green chemistry, one should also consider the balancing 
act one plays in choosing reagents for their transformations in regard to their “long term” 
application. Indeed time saving in this instance is a huge advantage of the traditional 
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methods (given no need for azeotropic drying, which is a 15-20 min procedure). 
Moreover, it may be worthwhile to sacrifice yield with the option to choose safer, less 
hazardous solvents associated with more straightforward QC testing. An instance would 
be with the goal of developing single automated modules for conducting QC testing, as a 
way to simplify radiopharmaceutical production in remote/developing/ markets that only 
have the need and requirement of producing a few doses a day or week, which could 
benefit significantly from negating the need for residual solvent analysis from the required 
(rather long) list of QC tests.71  
 
v. Conclusions 
 
With this work, preliminary studies and the exploration of green chemistry in late-
stage fluorination for the synthesis of F-18 radiopharmaceuticals has been developed. 
This includes the preparation and activation of nucleophilic [18F]fluoride in an ethanol-
water azeotrope (in place of the traditional MeCN-water azeotrope) without detrimental 
effect on radiochemical yields. Aliphatic fluorination reactions can be conducted in 
ethanol/water mixtures with an optimal composition of 15% water and 85% ethanol. Even 
though these reaction yields are lower in polar protic solvents, this challenges the idea 
that nucleophilic fluoride is incompatible with polar protic reaction solvents. As such, this 
work encourages further exploration and studies in green fluorine chemistry and 
methodology.72 
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f. Experimental Methods and Supporting Data 
 
i. General Considerations 
 
[18F]Fluoride (100 – 1500 mCi / 3.7 – 55.5 GBq) was produced via the 18O(p,n)18F 
nuclear reaction using a GE PETTrace cyclotron and dried using a TRACERLab FXFN 
automated radiochemistry synthesis module (General Electric, GE). Production of 
fluorine-18 labeled radiotracers was carried out using the reaction vessel of the 
TRACERLab FXFN or in bullet vials using a sand bath. Precursor solutions were gently 
warmed with a heat-gun to aid dissolution as needed. Radio-TLC analyses were 
conducted using Merck Glass-backed TLC Silica Gel 60 F254 plates and analyzed using 
a Bioscan AR-2000 TLC scanner. Radio-HPLC analyses were conducted on a Shimadzu 
LC-2010A HT system equipped with a Bioscan B-FC-1000 radiation detector using HPLC 
conditions outlined below. The identity of all 18F product peaks were confirmed by 
comparison to unlabeled 19F reference standards. 
Unless otherwise stated, reagents and solvents were commercially available and 
used without further purification: sodium chloride, 0.9% USP and Sterile Water for 
Injection, USP were purchased from Hospira; ethanol was purchased from American 
Regent; anhydrous acetonitrile, potassium carbonate, kryptofix-2.2.2, sodium hydroxide, 
hydrochloric acid, sodium dihydrogenphosphate, ammonium acetate and DMSO were 
purchased from Sigma Aldrich; HPLC grade acetonitrile was purchased from Fisher 
Scientific. 
Precursors and standards were commercially available as follows: FDG precursor 
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(mannose triflate), FET precursor (ditosyl methane) and reference standard, flubatine 
(standard and precursor), MPPF (standard and precursor) and nifene (standard and 
precursor) were purchased from ABX Advanced Biochemicals. FDG reference standard 
was purchased from Sigma Aldrich. FAZA precursor and reference standard were 
purchased from Prof. Friedrich Hammerschmidt (Universität Wien, Austria) and Prof. 
Hans-Jürgen Machulla (Steinbeis Transfer Center Radiopharmacy, Germany). All 
precursors and reference standards were used as received. 
Other synthesis components were obtained as follows: sterile filters were obtained 
from Millipore; sterile product vials were purchased from Hollister-Stier; [18O]H2O was 
purchased from ABX Advanced Biochemical Compounds or Rotem Inc.; Alumina, C18-
light and QMA-light Sep-Paks were purchased from Waters Corporation – C18-light and 
alumina Sep-Paks were flushed with 10 mL of ethanol followed by 10 mL of sterile water 
prior to use, while QMA-light Sep-Paks were flushed with 10 mL each of ethanol – water 
– 0.5 M sodium bicarbonate – water. 
 
ii.  Synthesis Procedures 
 
General Procedure for Drying [18F]Fluoride 
 
[18F]Fluoride was delivered to the synthesis module (in a 1.5 mL bolus of 
[18O]water) and trapped on a QMA-light Sep-Pak to remove [18O]water. [18F]Fluoride was 
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then eluted into the reaction vessel using aqueous potassium carbonate (3.5 mg in 0.5 
mL of water). A solution of kryptofix 2.2.2 (15 mg in 1 mL of acetonitrile or 1 mL of ethanol) 
was then added to the reaction vessel and the [18F]fluoride was dried by evaporating the 
azeotrope. Azeotropic drying was achieved by heating the reaction vessel to 80 °C and 
drawing full vacuum for 4 min. After this time, the reaction vessel was cooled to 60 °C 
and subjected to both an argon stream and vacuum draw simultaneously for an additional 
4 min. 
 
[18F]FDG-Ac4 
 
 
Table 3-4, Entry 1 
 
[18F]Fluoride was dried using the general method described above. Following 
drying, a solution of mannose triflate (40 mg) in ethanol (1 mL) was added to the reaction 
vessel and heated at 100 oC for 30 min. After this time, the crude reaction mixture was 
cooled and analyzed by radio-TLC (plate: silica gel TLC plate, solvent system: MeCN : 
H2O = 95 : 5; Rf 0.008 = [18F]fluoride, 0.650 = [18F]FDG-Ac4a typical chromatogram is 
shown in Figure S1). Typical RCC were 23±10% (n = 3). 
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Figure 3S- 1 
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Table 3-4, Entry 2 
 
[18F]Fluoride was dried using the general method described above. Following 
drying, a solution of mannose triflate (40 mg) in 15% water in ethanol (1 mL) was added 
to the reaction vessel and heated at 100 oC for 30 min. After this time, the crude reaction 
mixture was cooled and analyzed by radio-TLC (plate: silica gel TLC plate, solvent 
system: MeCN : H2O = 95 : 5; Rf -0.004 = [18F]fluoride, 0.779 = [18F]FDG-Ac4; a typical 
chromatogram is shown in Figure S2). Typical RCC were 37±5% (n = 3). 
 
 
 
Figure 3S- 2 
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Table 3-4, Entry 3 
 
A solution of [18F]fluoride in [18O]H2O (0.15 mL) was added to the reaction vessel 
of the synthesis module. To this was added a mixture of potassium carbonate (3.5 mg), 
kryptofix (15 mg) and mannose triflate (40 mg) in ethanol (0.85 mL), and the reaction 
vessel was heated at 100 oC for 30 min. After this time, the crude reaction mixture was 
cooled and analyzed by radio-TLC (plate: silica gel TLC plate, solvent system: MeCN : 
H2O = 95 : 5; Rf 0.009 = [18F]fluoride, 0.864 = [18F]FDG-Ac4; a typical chromatogram is 
shown in Figure S3). Typical RCC were 3±1% (n = 3). 
 
 
 
Figure 3S- 3  
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Table 3-4, Entry 4 
 
The [18F]fluoride was delivered to the synthesis module (in a 1.5 mL bolus of 
[18O]water) and trapped on a QMA-light Sep-Pak to remove [18O]water. [18F]Fluoride was 
then eluted into the reaction vessel using a solution of potassium carbonate (3.5 mg) and 
kryptofix (15 mg) in 15% water in ethanol (0.5 mL). A solution of mannose triflate (40 mg) 
in 15% water in ethanol (0.5 mL) was then added to the reaction vessel and the reaction 
was heated at 100 oC for 30 min. After this time, the crude reaction mixture was cooled 
and analyzed by radio-TLC (plate: silica gel TLC plate, solvent system: MeCN : H2O = 95 
: 5; Rf -0.011 = [18F]fluoride, 0.824 = [18F]FDG-Ac4; a typical chromatogram is shown in 
Figure S4). Typical RCC were 58±5% (n = 3). 
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Figure 3S- 4  
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Table 3-4, Entry 5 
 
The [18F]fluoride was delivered to the synthesis module (in a 1.5 mL bolus of 
[18O]water) and trapped on a QMA-light Sep-Pak to remove [18O]water. [18F]Fluoride was 
then eluted into the reaction vessel using a solution of potassium carbonate (3.5 mg) and 
kryptofix (15 mg) in 15% water in ethanol (1.0 mL). A solution of mannose triflate (40 mg) 
in 15% water in ethanol (1.0 mL) was then added to the reaction vessel and the reaction 
was heated at 100 oC for 30 min. After this time, the crude reaction mixture was cooled 
and analyzed by radio-TLC (plate: silica gel TLC plate, solvent system: MeCN : H2O = 95 
: 5; Rf -0.001 = [18F]fluoride, 0.817 = [18F]FDG-Ac4; a typical chromatogram is shown in 
Figure S5). Typical RCC were 16±4% (n = 3). 
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Figure 3S- 5  
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Table 3-4, Entry 6 
 
The [18F]fluoride was delivered to the synthesis module (in a 1.5 mL bolus of 
[18O]water) and trapped on a QMA-light Sep-Pak to remove [18O]water. [18F]Fluoride was 
then eluted into the reaction vessel using a solution of potassium carbonate (3.5 mg) in 
15% water in ethanol (0.5 mL). A solution of mannose triflate (40 mg) in 15% water in 
ethanol (0.5 mL) was then added to the reaction vessel and the reaction was heated at 
100 oC for 30 min. After this time, the crude reaction mixture was cooled and analyzed by 
radio-TLC (plate: silica gel TLC plate, solvent system: MeCN : H2O = 95 : 5; Rf 0.014 = 
[18F]fluoride, 0.841 = [18F]FDG-Ac4; a typical chromatogram is shown in Figure S6). 
Typical RCC were 4±1% (n = 3). 
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Figure 3S- 6  
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[18F]FDG 
Table 3-3, Entries 1 and 2 
 
[18F]Fluoride was dried using the general method described above. Following 
drying, a solution of mannose triflate (40 mg) in acetonitrile (1 mL) was added to the 
reaction vessel and heated at 100 oC for 30 min to yield [18F]FDG-Ac4 (2). After this time, 
1N NaOH was added and the reaction was stirred at room temperature (rt) for 5 min. 
Following neutralization (HCl/citrate buffer), the crude reaction mixture was analyzed by 
radio-TLC to determine RCC (plate: silica gel TLC plate, solvent system: MeCN : H2O = 
95 : 5, Rf -0.018 = [18F]fluoride, 0.390 = [18F]FDG; a typical chromatogram is shown in 
Figure S7). Typical RCC were 74±12% (H2O-MeCN azeotrope, n = 3) or 70±10% (H2O-
EtOH azeotrope, n = 3). 
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Figure 3S- 7 
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Fully-automated Synthesis of [18F]FDG 
 
The [18F]fluoride was delivered to the synthesis module (in a 1.5 mL bolus of 
[18O]water) and trapped on a QMA-light Sep-Pak to remove [18O]water. [18F]Fluoride was 
then eluted into the reaction vessel using a solution of potassium carbonate (3.5 mg) and 
kryptofix (15 mg) in 15% water in ethanol (0.5 mL). A solution of mannose triflate (40 mg) 
in 15% water in ethanol (0.5 mL) was then added to the reaction vessel and the reaction 
was heated at 100 oC for 30 min. After this time, 1N NaOH was added and the reaction 
was stirred at room temperature (rt) for 5 min. Following neutralization (HCl/citrate buffer), 
the crude reaction mixture was diluted and purified using alumina and C18 Sep-Paks, as 
previously described70, to yield [18F]FDG in 33±2% radiochemical yield (decay-corrected, 
n = 3). Analysis of the final product by radio-TLC confirmed product purity (plate: silica 
gel TLC plate, solvent system: MeCN : H2O = 95 : 5, Rf 0.417 = [18F]FDG; a typical 
chromatogram is shown in Figure S8). 
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Figure 3S- 8 
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[18F]FAZA 
Table 3-3, Entries 3 and 4 
 
[18F]Fluoride was dried using the general method described above. [18F]FAZA was 
then synthesized as previously described58, and typical non-corrected radiochemical 
yields were 6% (H2O-MeCN azeotrope, n = 3) or 5% (H2O-EtOH azeotrope, n = 3). 
Radiochemical purity and identity were confirmed by radio-HPLC (column: Phenomonex 
Luna  C8(2) 5µ, 100 x 2.0 mm; mobile phase: 5% acetonitrile: 95% 20mM aqueous 
ammonium acetate, pH 4.5; flow rate: 0.5 mL/min; UV wavelength = 254 nm; tR [18F]FAZA 
= 6.2 min; a typical chromatogram is shown in Figure S9). 
UV  
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RAD  
Figure 3S- 9 
 
Table 3-4, Entry 7 
 
[18F]Fluoride was dried using the general method described above. Following 
drying, a solution of precursor 4 (8 mg) in 15% water in ethanol (2 mL) was added to the 
reaction vessel and heated at 100 oC for 10 min. After this time, the reaction was cooled 
to 40 oC and 0.1 M aqueous sodium hydroxide (1 mL) was added. The reaction was stirred 
for 5 min at 40 oC to hydrolyze the acetate protecting groups. The crude reaction mixture 
was then cooled and analyzed by radio-HPLC (column: Phenomonex Luna  C8(2) 5µ, 
100 x 2.0 mm; mobile phase: 15% acetonitrile: 85% 50mM aqueous ammonium acetate, 
pH 4.5; flow rate: 0.5 mL/min, UV = 254 nm, tR [18F]FAZA = 4.561 min; a typical 
chromatogram is shown in Figure S10). RCC was 3% (n = 1). 
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UV Detector Ch1-
254nm Results 
     
Retention Time Area Area % Height Width S/N (ASTM) 
2.158 113813 4 10311 0.583 42.51 
2.975 1283566 41 163832 0.625 675.45 
4.525 38520 1 4877 0.233 4.71 
4.850 1594457 51 171960 0.767 165.93 
7.075 69664 2 5817 0.417 12.64 
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Retention Time Area Area % Width 
2.477 11058513 97 2.24 
4.561 321900 3 0.81 
Figure 3S- 10 
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[18F]Fluoroethyl tosylate ([18F]FET) 
 
Table 3-3, Entries 5 and 6 
 
[18F]Fluoride was dried using the general method described above. Following 
drying, a solution of ditosyl methane (5 mg) in acetonitrile (1 mL) was added to the 
reaction vessel and heated at 110 oC for 10 min. After this time, the crude reaction mixture 
was cooled and analyzed by radio-HPLC (column: Phenomenex Luna C18 150 x 4.6 mm, 
mobile phase: MeCN : H2O = 60 : 40; flow rate: 1.0 mL/min; UV wavelength = 254 nm; tR 
[18F]FET = 2.608 min; a typical chromatogram is shown in Figure S11). Typical RCC were 
70±10% (H2O-MeCN azeotrope, n = 3) or 68±4% (H2O-EtOH azeotrope, n = 2).  
 
UV Detector Ch1-
254nm Results 
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Retention Time Area Area % Height Width S/N (ASTM) 
2.608 2998 23 647 0.200 0.04 
2.917 10288 77 1635 0.225 0.1 
 
RAD Results    
Retention Time Area Area % Width 
1.783 119733 24 0.81 
2.117 20910 4 0.22 
2.275 8823 2 0.20 
2.608 318364 64 0.65 
3.300 20543 4 0.32 
4.583 7845 2 0.39 
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Table 3-4, Entry 8 
 
[18F]Fluoride was dried using the general method described above. Following 
drying, a solution of ditosyl methane (5 mg) in ethanol (1 mL) + 1 drop DMSO (to improve 
precursor solubility) was added to the reaction vessel and heated at 110 oC for 10 min. 
After this time, the crude reaction mixture was cooled and analyzed by radio-HPLC 
(column: Luna C18 150 x 4.6 mm, mobile phase: MeCN : H2O = 50 : 50; tR [18F]FET = 
4.87 min; chromatogram is shown in Figure S12). RCC was 52% (n = 1). 
 
 
 
UV Detector Ch1-254nm 
Results 
  
Retention Time Area Area % 
1.25 145548 30.32 
1.51 33779 7.04 
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2.66 7517 1.57 
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4.80 1641 0.34 
5.80 16368 3.41 
6.10 16152 3.36 
6.47 114957 23.95 
7.41 2488 0.52 
9.90 116162 24.20 
 
 
RAD Results   
Retention Time Area Area % 
1.45 111013 23.49 
1.80 56964 12.06 
2.80 16155 3.42 
3.22 40485 8.57 
4.87 247916 52.47 
 
Figure 3S- 12 
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[18F]Flubatine 
Table 3-3, Entries 7 and 8 
[18F]Fluoride was dried using the general method described above. [18F]Flubatine 
was then synthesized as previously described62, and typical non-corrected radiochemical 
yields were 25±10% (H2O-MeCN azeotrope, n = 3) or 15±10% (H2O-EtOH azeotrope, n 
= 20). Radiochemical purity and identity were confirmed by radio-HPLC (column: 
Phenomonex Synergi Polar-RP 4 μ, 150 × 4.6 mm; mobile phase: 50% acetonitrile : 50% 
0.1 M acetic acid; pH, 4.5; flow rate: 1.0 mL/min; oven temp: 40°C; UV wavelength: 254 
nm; tR = 5.0 min; a typical chromatogram is shown in Figure S13).  
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Figure 3S- 13 
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Table 3-4, Entry 9 
 
 [18F]Fluoride was dried using the general method described above. It was then 
attempted to synthesize [18F]flubatine as previously described,3 but using ethanol or 15% 
H2O : 85% EtOH as the reaction solvent (n = 3). In each case however, no product was 
formed as determined by radio-HPLC analysis (a typical chromatogram is shown in Figure 
S14, expected tR of [18F]flubatine = ~5 min). 
 
UV Detector Ch1-
254nm Results 
     
Retention Time Area Area % Height Width S/N (ASTM) 
1.450 90798 36 8990 0.267 2.97 
1.675 113321 45 8025 0.833 2.66 
2.925 46326 18 8848 0.267 2.93 
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RAD Results    
Retention Time Area Area % Width 
1.385 118835 19 0.48 
1.592 436345 68 1.12 
2.636 49635 8 0.30 
2.901 17060 3 0.15 
3.053 16097 3 0.33 
 
Figure 3S- 14 
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Boc-protected [18F]Nifene 
 
Table 3-3, Entries 9 and 10 
 
[18F]Fluoride was dried using the general method described above. Following 
drying, a solution of nifene precursor 12 (2 mg) in DMSO (1 mL) was added to the reaction 
vessel and heated at 125 oC for 30 min. After this time, the crude reaction mixture was 
cooled and analyzed by radio-HPLC (column: Phenomenex Synergi Polar RP 150 x 4.6 
mm, mobile phase: MeCN : H2O = 50 : 50 + 0.05% AcOH; flow rate: 1.0 mL/min; UV 
wavelength = 254 nm; tR Bob-protected [18F]nifene = 6.415 min; a typical chromatogram 
is shown in Figure S15). Typical RCC were 50% (H2O-MeCN azeotrope, n = 1) or 83% 
(H2O-EtOH azeotrope, n = 1). 
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UV Detector Ch1-
254nm Results 
     
Retention Time Area Area % Height Width S/N (ASTM) 
6.300 14160 1 1659 0.342 0.12 
6.742 1048493 99 107059 0.608 7.42 
      
 
RAD Results    
Retention Time Area Area % Width 
1.373 71187 3 0.37 
1.765 8801 0 0.40 
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2.285 171173 6 0.45 
2.796 22772 1 0.42 
4.553 118687 4 0.81 
4.690 86963 3 0.41 
6.415 2274486 83 0.91 
 
Figure 3S- 15 
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Table 3-4, Entry 10 
 
 [18F]Fluoride was dried using the general method described above. It was then 
attempted to synthesize Bob-protected [18F]nifene as described above, but using ethanol 
as the reaction solvent (n = 3). However, no product was formed as determined by radio-
HPLC analysis (Figure S16, expected tR of Boc-protected [18F]nifene = ~6.4 min). 
 
 
UV Detector Ch1-
254nm Results 
     
Retention Time Area Area % Height Width S/N (ASTM) 
1.383 372700 21 29380 0.458 119.37 
2.125 444136 25 77651 0.358 315.49 
2.492 699441 40 139470 0.450 566.66 
4.117 176449 10 28736 0.433 9.67 
7.258 61599 4 7243 0.333 13.65 
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RAD Results    
Retention Time Area Area % Width 
1.367 254428 93 0.52 
2.488 20328 7 0.33 
 
Figure 3S- 16 
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[18F]MPPF 
 
Table 3-3, Entries 11 and 12 
 
[18F]Fluoride was dried using the general method described above. MPPF 
precursor 15 (10 mg) in DMSO (0.5 mL) was added to the reactor, and the reaction was 
heated at 140 oC for 20 min. After this time, the crude reaction mixture was cooled and 
analyzed by radio-HPLC (column: Phenomenex Prodigy C8 5µ 150 x 4.6 mm; mobile 
phase: MeCN : 20 mM ammonium acetate = 35 : 50, pH 4.5; flow rate: 0.8 mL/min; oven 
temp: 40°C; UV wavelength: 254 nm; tR [18F]MPPF = 8.78 min; a typical chromatogram 
is shown in Figure S17). Typical RCC were 70±10% (H2O-MeCN azeotrope, n = 3) or 
78±18% (H2O-EtOH azeotrope, n = 3). 
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UV Detector Ch1-
254nm Results 
     
Retention Time Area Area % Height Width S/N (ASTM) 
2.208 97806 0 17202 0.233 22.13 
2.725 1268980 5 263342 0.425 338.76 
4.575 2867369 11 266439 0.542 97.83 
8.900 21201104 83 1061339 1.275 615.01 
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Retention Time Area Area % Width 
2.318 1967 4 0.21 
8.784 47150 96 0.57 
 
Figure 3S- 17 
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Table 3-4, Entry 11 
 
 [18F]Fluoride was dried using the general method described above. It was then 
attempted to synthesize [18F]MPPF as described above, but using ethanol (n = 3) or 
ethanol/DMSO [50:50] (n = 3) as the reaction solvent. However, no product was formed 
in either case as determined by radio-HPLC analysis (Figure S18, expected tR of 
[18F]MPPF = ~8.78 min). 
 
 
 
UV Detector Ch1-
254nm Results 
     
Retention Time Area Area % Height Width S/N (ASTM) 
2.325 1282831 5 271845 0.325 169.87 
2.675 5381206 22 784338 0.558 490.12 
3.858 54488 0 8850 0.208 4.01 
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4.375 18028968 72 680339 2.000 308.46 
9.633 168280 1 13148 0.483 17.04 
 
RAD Results    
Retention Time Area Area % Width 
2.048 13238 37 0.44 
2.515 22386 63 0.37 
 
Figure 3S- 18 
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Chapter 4 
Synthesis & Initial Evaluation of a Dopamine D3 Receptor-Selective PET Tracer 
 
a. The Dopaminergic System & The Central Nervous System 
 
The dopaminergic system and subsequent dysfunction in dopamine transmission 
is implicated in several neurologic, neurodegenerative, and psychiatric disorders; 
specifically, this includes depression, schizophrenia, Parkinson’s disease (PD), and 
drug/substance abuse disorders. The receptors for this major neurotransmitter, dopamine 
(DA), are of interest because they are the principal target of drugs for these diseases and 
disorders.1–4  
 
Scheme 4- 1 Biosynthesis of Dopamine 
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The biosynthesis of dopamine (Scheme 4-1) begins with the essential amino acid 
L-phenylalanine that is hydroxylated by a biopterin-dependent aromatic amino acid 
hydroxylase, AAAH (specifically phenylalanine hydroxylase) to form L-tyrosine. non-
essential amino acid tyrosine (abbr. Tyr or Y). L-tyrosine is further hydroxylated by this 
same class of AAAH enzymes, specifically by tyrosine hydroxylase, in the rate-limiting 
step of catecholamine biosynthesis to form L-DOPA. L-DOPA, which cannot pass the 
Blood-Brain-Barrier (BBB), is then decarbcateoxylated by the aromatic L-amino acid 
decarboxylase, known as DOPA-decarboxylase, to produce dopamine. Dopamine is then 
packaged into vesicles to protect it from oxidation by monoamine oxidase (MAO) to await 
neurotransmission (Scheme 4- 1).5,6 Mediated by an electrical impulse, these vesicles 
fuse with the presynaptic membrane and dopamine is released in to the synaptic cleft 
where it binds to its receptor(s).7 
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Figure 4- 1 Dopaminergic Synapse. Image: © Permissions granted from Creative Commons/Free Usage 
https://commons.wikimedia.org/wiki/File:Dopaminergic_synapse.svg 
 
When dopamine is released into the synapse as the result of an action potential, it 
interacts with postsynaptic receptors. Dopamine concentrations are mediated via 
reuptake by the dopamine transporters (DAT). This regulation ensures the concentration 
of dopamine at the synapse to be low/nanomolar and at steady state concentrations. 
Moreover, dopamine is removed by MAO A or MAO B oxidation; this occurs in neurons 
(MAO A) and the glia (MAO B), which encompass the dopaminergic nerve terminals. 
Catecholamine O-methyltransferase (COMT) is another enzyme which inactivates DA by 
methylating at the catecholamine (donated by S-adenosyl methionine, aka SAM). In this 
situation, dopamine is transformed into 3-methoxytyramine by COMT (Figure 4- 1).8,9 The 
final end product is homovanillic acid (HVA), which currently has no known biological 
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activity. Dopamine can also be transformed into norepinephrine by dopamine β-
hydroxylase (DBH), which is then transformed into epinephrine by phenylethanolamine 
N-methyltransferase (PNMT).9 
 
 
Scheme 4- 2 (General) Dopamine Metabolism 
 
There are five dopamine receptors which mediate dopamine transmission, all of 
which are G protein-coupled receptors (GPCRs) with their characteristic 7-
transmembrane domain region. These receptors are classified as D1-like (D1, D5), and 
D2-like (D2, D3, D4). The dopamine receptor population were once thought to only include 
subtypes D1 and D2 until 1990.10–12 Once the D1 and D2 receptor families were cloned,13–
15 the subtype receptors were later identified and cloned, D3 and D4, and D5.16–18 The D3 
receptor was cloned by Sokoloff in 1990 using rat cDNA and probes design from D2 
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receptor sequence.16 Not long behind was the human D3 receptor cloned19, then the 
murine D3 receptor20.21 These are classified according to homology in sequence, and 
signal transduction and biochemistry (Figure 4- 2, Table 4- 1).22–25  
 
 
Figure 4- 2 (a) Classification of Dopamine Receptors (cAMP = cyclic adenosine monophosphate), (b) General 
Dopamine Receptor. Image: © CNSforum.com, Free Use. 
 
Members of the same family share considerable homology In the D1-like family, 
D1, and D5 share 80% identity in their trans-membrane domains. Within the D2-like family, 
D2 and D3 receptors have a striking 75% identity; D2 and D4 receptors share 52% identity 
in their trans-membrane domains; this extends to D2 and D3 receptors sharing 39% and 
41% homology with the D4 receptor, respectively.17,23,26 The presence/absence of introns 
is another key distinctive feature of these receptor subtype classifications (Table 4- 1).22,27 
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Moreover, these receptors are further classified based on their coupling to the effector 
adenylyl cyclase (AC): D1-like receptors are positively coupled to AC through G-protein, 
Gs; D2-like receptors inhibit AC through coupling to inhibitor G-proteins, Gi/Go (Figure 4- 
2).25 
 
 Table 4- 1 Summary: Molecular Biology of the Dopamine Receptors22,23 
 D1-Like D2-Like 
D1 D5 D2 D3 D4 
Chromosomal 
Localization 
5q 35.1 4p 15.1-16.1 11q 22-23 3q 13.3 11p 15.5 
Introns No No 6 5 3 
Amino Acids 446 (rat) 
446 (human) 
457 (rat) 
477 (human) 
*415, **444 (rat) 
*414, **443 
(human) 
446 (rat) 
400 (human) 
385 (rat) 
387 (human) 
mRNA size 3.8 kb 3.0 kb 2.5 kb 8.3 kb 5.3 kb 
D2 isoforms: *short, ** long 
 
The dopaminergic neurons are defined by three main pathways: i) mesolimbic, ii) 
nigrostriatal, and iii) tuberoinfundibular. Dopaminergic neurons are localized mainly in the 
substantia nigra pars compact, the hypothalamus, and the ventral tegmental area.28 The 
dopamine receptor subtypes can be troublesome to target in intact tissue due to their co-
expression in the same brain region. However, molecular cloning has made it possible to 
isolate these receptors in cell lines and examine them via pharmacological agents.23  
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Figure 4- 3 Dopaminergic Pathways Image: © Permission granted from: GNU Free Documentation License, and 
Creative Commons https://commons.wikimedia.org/wiki/File:Dopaminergic_pathways.svg 
 
A drawback to the in vitro approach is that the effectors and G-proteins present 
physiologically for these receptors may not be properly represented. For example, while 
a dopamine receptor may behave a certain way in cells, the behavior may not translate 
to an in vivo system where those G-proteins and effectors are differentially expressed.22,29 
Selective pharmacological agents are not readily available (for all subtypes), making 
traditional autoradiographic methods to determine dopamine receptor distribution 
challenging. However, a common, yet laborious, method to study the localization of the 
various receptor mRNAs is through in situ hybridization and has been used extensively 
for this purpose.22 In the case of in vivo systems, competition with the endogenous ligand, 
dopamine, and confirming target engagement of these receptors by pharmacological 
means is similarly challenging due to limited BBB permeability, and for reasons 
mentioned above.30–32 
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The complete characterization and current understanding of dopamine receptors 
remains largely unknown due to the inability to selectively target these receptor(s). Given 
the clinical relevance of D2-like receptors, the ability to utilize the pharmacological 
potential of these receptors is also largely unrealized.  
 
b. The Dopamine D2-Like Receptors: D2 and D3 
 
In addition to the inhibition of cyclic adenosine monophosphate (cAMP), D2-like 
receptors are known to modulate other second messenger pathways, such as ion 
channels, Na+/H+ exchanger, phosphatidylinositol hydrolysis, arachidonic acid release, 
and cell growth and differentiation.22,23,33 D2 receptors and, more prominently, the D3 
receptors also play an important role in the reinforcing properties of different drugs of 
abuse (e.g. cocaine), as well as in other neuropsychiatric disorders such as schizophrenia 
and depression.33–37 The D2-like receptors, more importantly the D3/D2 receptors, have a 
well-recognized clinical importance as a target for neuroleptic (antipsychotic) drugs based 
on the observed in vitro affinity for this compound class (Table 4- 2).38 
The dopamine D3 receptor was cloned and characterized by Sokoloff and 
coworkers in 1990.16 This ground-breaking work not only expanded the family of the 
dopamine receptor subtype, but also reported a higher affinity for dopamine and its 
agonists for the D3 receptors compared to the D2 receptor.16,19,22,38 The pivotal paper 
characterizing the D3 receptor by Sokoloff reports a dopamine KiD2 474±33 nM and KiD3 
25±3 nM, or roughly 19-fold (KiD2/KiD3) higher affinity at the D3 receptor.26 The D2 receptors 
are found mainly in the nucleus accumbens, striatum, and olfactory tubercle, as well as 
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the substantia nigra pars compact and the ventral tegmental area (Figure 4- 3).22,39 The 
D3 receptor is expressed in brain regions associated with reward, motivation, emotion, 
and motion.37,38,40 This includes a more restricted distribution in the nucleus accumbens 
and islands of Calleja, supporting its role in limbic brain functions.29,32,38,41,42  
The dopamine D2-like receptors exist in two states: a high affinity (D2 high or D2High) 
which is linked to second messenger systems (G-protein uncoupled) and a high affinity 
for agonists, and a low affinity state (D2 low or D2Low) which has a lower affinity for agonists 
and is functionally inert.43 In this case, D2R antagonists have equal affinity to both states, 
while the endogenous ligand dopamine, preferentially binds to the D2High.44,45 In the case 
of D3 receptors, the existence of G protein-coupled/uncoupled and high vs. low affinity 
states is still debated and remains controversial.26,46 This phenomena will be discussed 
further with regard to PET ligands. Regardless, it is well established that the D3 receptors 
have roughly 20-fold higher affinity for dopamine than the D2 receptor.26 
Dopamine D3 receptors also appear to function as autoreceptors (presynaptic 
receptor), with an inhibitory effect on dopamine release and on impulse flow.47,48 This was 
further demonstrated in D3R-null mice (D3R-/-), whereby these animals had extracellular 
dopamine twice as high as their wild-type littermates. Consistent with the idea that these 
receptors are also located presynaptically, the release of dopamine would be inhibited in 
the wild-type animal.49–51 
Translating a nonselective D2/D3 ligand into a D3 selective ligand has had mixed 
success. In addition to overcoming mixed binding of D2/D3,  other major struggles to 
developing a D3 selective PET tracer and pharmaceutical include off target binding to 5-
HT receptors and/or sigma receptor subtypes, as well as BBB permeability.33,52 Moreover, 
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the ability to study these receptors (D2 and D3) independently remains a challenge due to 
their high sequence homology (52%), and a striking 75% sequence homology in the 7 
transmembrane domain (which contains the ligand binding domain).26,33,38,52 The human 
D3R (D3 Receptor) was crystalized in 2010 by Chien and workers in complex with the 
D2/D3 antagonist eticlopride, with a resolution of 3.15Å.53 From here, structure-based 
drug design and structure-activity-relationship (SAR) studies were given a platform to 
blossom small molecule drug design off of.32,53 
 
c. The Dopamine D3 Receptor as a Drug Target 
 
Neurotransmitter systems, such as the serotonergic and dopaminergic systems, 
are common pharmacological targets for therapeutics as well as PET imaging agents. 
Most antipsychotics do not show profound selectivity at the D2/D3R, but some show mixed 
binding or some D3R preferring capacity (Table 4- 2) (a discussion of imaging agents at 
these systems is forthcoming).  
Considerable work has been done in developing a D3 selective ligand, building on 
computation screening of large compound libraries using a D3R (D3 Receptor) crystal 
structure or homology model, then utilizing a medicinal chemistry SAR approach to 
improve selectivity properties. Some notable groups targeting this receptor for substance 
use, neuropsychiatric disorders (for therapeutic or PET diagnostic purposes) include the 
Newman (largely therapeutic pursuits, with some interest in PET), Sokoloff (basic science 
and therapeutic interests), Micheli (therapeutic & diagnostic) and Mach (PET) 
group’s.3,19,26,32,35,36,53–77 PET is a valuable technique to quantify receptor populations and 
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confirm target engagement (a struggle with traditional drug design); as such, Mach and 
Volkow/Fowler are groups notable for their work in this area.8,24,28,30,31,33,34,46,52,78–96 In an 
effort to identify vital pharmacophore features to develop D3R selective agonists, 
extensive work has previously been done.57,59,97–108 D3R agonists, such as Pramipexole 
for treatment of Parkinson’s Disease, mimic the action of dopamine at these receptors; 
D3R antagonists essentially block this receptor and are typically antipsychotics used in 
such conditions as schizophrenia and bispolar disorder.38,78,109,110 Even so, a distinct 
pharmacophore with full intrinsic activity and selective for the DA-D3R has remained 
intangible. 
 
pKi 5-
HT1A 
5-HT2A 5-
HT2B 
5-HT2C D1R D2LR D2SR D3R D4R D5R 
Asenapine 8.6 (a) 10.15 
(a) 
9.75 
(a) 
10.46 
(a) 
8.85 
(a) 
8.9 (a) 8.84 
(a) 
9.38 (a) 8.95 
(a) 
ND 
Aripiprazole 8.57 
(a)  
8.02 
(a) 
9.59 
(a)  
7.55 
(a) 
6.09 
(a) 
8.94 
(a) 
8.91 
(a) 
8.85 (a) 6.89 
(a) 
5.77 
(b) 
Ziprasidone 9.01 
(a) 
9.51 
(a) 
9.08 
(a)  
9.01 
(a) 
8.45 
(a) 
8.09 
(a) 
7.99 
(a) 
8.35 (a) 7.33 
(a) 
6.81 
(b) 
Quietapine 6.78 
(a) 
6.81 
(a) 
7.33 
(a) 
5.98 
(a) 
6.71 
(a) 
6.38 
(a) 
6.32 
(a) 
6.41 (a) 5.5 
(a) 
7.8 
(b) 
Olanzapine 5.82 
(a) 
8.88 
(a) 
8.41 
(a) 
8.41 
(a) 
7.93 
(a) 
7.67 
(a) 
7.58 
(a) 
7.46 (a) 7.75 
(a) 
7.04 
(b) 
Risperidone 6.75 
(a) 
9.69 
(a)  
7.99 
(a) 
8.17 
(a) 
7.68 
(a) 
8.21 
(a) 
8.07 
(a) 
8.16 (a) 8.21 
(a) 
7.8 
(b) 
Clozapine 7.06 
(a) 
8.39 
(a) 
8.79 
(a) 
8.56 
(a) 
7.64 
(a) 
6.87 
(a) 
6.81 
(a) 
6.66 (a) 7.33 
(a)  
6.63 
(b)  
Haloperidol 6.29 
(a) 
7.28 
(a) 
6.48 
(a) 
5.79 
(a) 
8.2 
(a) 
8.84 
(a) 
8.76 
(a) 
8.56 (a) 8.83 
(a) 
6.9 
(b) 
Amisulpride 5.8 (b) 5.08 
(b) 
7.88 
(b) 
5 (b) 5 (b) 8.89 
(b) 
ND 8.62 (b) 5.63 
(b) 
5 (b) 
Sulpiride 5 (b) ND ND ND 5 (b) 8 (b) ND 8.07 (b) 7.26 
(b) 
ND 
Remoxipride ND 5.31 
(b) 
ND ND ND 7.21 
(c) 
ND 6.73 (c) 6 (b) ND 
Cariprazine 8.59 
(d) 
7.73 
(d) 
9.24 
(d) 
6.87 
(d) 
ND 9.31 
(d) 
9.16  
(d) 
10.07  
(d) 
ND ND 
Table 4- 2 Selected Antipsychotics & Binding (pKi) to Serotonergic and Dopaminergic Receptors 
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Trazodone 6.93 
(b) 
7.35 
(b) 
7.11 
(b) 
6.65 
(b) 
5.42 
(b) 
5.38 
(b) 
ND ND 6.15 
(b) 
5 (b) 
Blonaserin 6.09 
(e) 
9.09 
(e) 
ND 7.57 
(e)  
5.97 
(e) 
9.84 
(e) 
ND 9.3 (e) 6.82 
(e) 
5.58 
(e) 
Buspirone 7.54 
(b) 
6.86 
(b) 
6.67 
(b) 
6.31 
(b) 
ND 7.2 (f) ND 7.52 (f) 6.97 
(b) 
ND 
Figure Adapted from Leggio, et al, 2016.51 
(a) Shahid, 2009111, (b) Roth 2000112, (c) Burstein 2005113, (d) Kiss 2010114, (e) Tenjin 2013115, (f) Leggio 2014116, (ND) Not 
Determined 
 
Shortly after the D3 receptor was cloned, 7-hydroxy-N,N-di-n-propyl-2-
aminotetralin (7-OH-DPAT, Figure 4- 4), an aminotetraline derivative, was reported as 
being D3R selective and used for the design of antagonists.117 However, this strategy was 
abandoned due to quick in vivo clearance.37,51,117 However, another design strategy 
utilizing the alkyl-chain-linked phenylpiperazine of the (currently known as) “classic D3 
receptor agonists/antagonists” included compound 126, which displayed a 122-fold 
selectivity over D2 receptors and Ki = 1.75 nM.118 The distribution of the D3 receptor is 
more limited than the D2 receptor and its distribution was elucidated through the use of 
[3H](+)-7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin ([3H]-7-OH-DPAT). In transfected 
Chinese hamster ovary (CHO) cells, it was found that [3H]-7-OH-DPAT is 100-fold more 
selective for D3 over D2, and the resultant autoradiography showed D3 populations 
restricted to the islands of Calleja, lobules 9 and 10 of the cerebellum, nucleus 
accumbens, and the olfactory tubercle; moreover, while the D2 binding in the dorsal 
striatum is high, D3 binding is significantly low.42,117 
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Figure 4- 4 D3-selective 7-OH-DPAT 
 
The tetrahydroisoquinoline derivative SB277011(A) was developed by 
GlaxoSmithKline (SmithKline Beecham) and characterized as a D3R antagonist.36,51,119,120 
SB277011 was optimized to improve bioavailability and improve selectivity at the D3 
receptor (Figure 4- 7). To improve selectivity over 5-HT receptors, Stemp and colleagues 
added structural rigidity between the amide and azacyclic terminus, incorporated 
heteroatoms in the required aryl terminus, and included a cyano substitution to improve 
oral bioavailability and reduce lipophilicity.36,120 Initial evaluation of this 2nd generation 
compound showed high D3 receptor affinity (Ki = 10 nM) and > 100-fold selectivity over 
D2, 5HT1B and 5HT1D receptors (Figure 4- 7).36,119,120 However, this compound was not 
developed further as a therapeutic due to poor bioavailability in cynmolgus monkeys.51,121 
 
 
Figure 4- 5 Well-known D2/D3-preferring Pharmaceuticals 
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Regardless, the dopamine D3R has proven to have therapeutic value for a variety 
of disorders (either by serendipity or design). For example, D3 partial agonist aripiprazole 
(Abilify®) is used for treatment in schizophrenia, bipolar disorder, and manic depression, 
while agonist pramipexole (Mirapex®), an aminothiazole with negligible binding at 
serotonin receptors, is used for treating symptoms of Parkinson’s disease (Figure 4- 
5).122,123 Indeed major therapeutic interest for the D3 receptor lies in Parkinson’s disease, 
substance abuse/addiction, and other neurological diseases/disorders.36,51,124,125 Based 
on promising findings with pramipexole, the scaffold has been utilized in several drug 
discovery programs to develop additional D3 agonists / partial agonists (127, 128) (Figure 
4- 6).126–130 The development of these compounds demonstrated the heteroaryl tolerance 
of binding selectively at the D3 receptor (a summary of SAR at these receptors can be 
found in Figure 4- 9 and Figure 4- 10).131–136 
Even with dedicated efforts by industry and academic research institutions 
(including 157 filed patents for novel D3 antagonists from 2008-2012 alone), D3-selective 
agonists and antagonists remain elusive and none are available for human therapeutic 
(or diagnostic) use.124,137 
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Figure 4- 6 Pramipexole-containing D3-selective compounds130 
 
Some notable first generation D3-selective agents include BP897 (Figure 4- 7), 
which was first reported in a French drug discovery program and identified as a dopamine 
D3 receptor partial agonist. It was advertised to have potential in treating neuropsychiatric 
disorders, including depression, substance abuse and addiction, and Parkinson’s 
disease.36 Later, in 1999, BP897 was reported as a selective dopamine D3 receptor partial 
agonist, exhibiting high-affinity binding at D3 (Κi = 0.92 ± 0.2 nM), and 70-fold selectivity 
over D2 receptors (Κi = 61 ± 0.2 nM). BP897 also has low affinities for D1, D4, D1, D2, 
5HT1A, 5HT7, muscarinic, histamine, and opiate receptors. However, in vivo studies 
suggest that BP897 may behave as an antagonist.55 Conflicting behavior in vivo and 
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discrepancies in ligand evaluation at the D3 receptor across laboratories will be discussed 
later. 
 
Figure 4- 7 “First Generation" D3-selective Agonists/Antagonists36 
 
S33084 was defined as a potent, competitive, D3-selective antagonist with >100-
fold selectivity at the receptor, as demonstrated in over 20 receptor systems, 
characterized in vitro and in vivo. In a separate discovery synthetic drug discovery 
program, NG 2904 was identified as a lead for novel antipsychotic medications. NG 2904 
shares the butylamide linker with BP897 and S33084, and demonstrated >150-fold 
selectivity over D2 receptors (and similar selectivity over D1 and 5HT2 receptors). The 
butylamide functionality has shown to be optimal,56,64,138 and reducing or increasing the 
linker length significantly decreases D3 binding affinity and/or selectivity, as does the size 
of the terminal aromatic ring (Figure 4- 10).36,64 
Moreover, Reilly and Mach recently reported a series of D3 selective (264-905-fold 
selective over D2) antagonists with diazaspiro alkane cores.139 
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Figure 4- 8 Novel D3-Selective Antagonists With Diazaspiro Alkane Cores139 
 
The SAR of the most selective D3 compounds follow a strict skeleton. The phenyl 
piperazine, or 1,4-disubstituted aromatic piperadine/piperazine, is considered a 
“privileged scaffold” at these GPCRs, and the amide moiety is preferred for selectivity. 
The aryl ring system is tolerant of heteroatoms, to aid in optimizing logP and BBB 
permeability, and sometimes improving D3 binding affinities (Figure 4- 9, Figure 4- 10). 
Constraints of the linker are associated with loss of selectivity at the receptor.36 
Computational and SAR studies to further explore the selectivity at these receptors 
continue to be reported.89,102,107,131,132,140,141 
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Figure 4- 9 Toward Dopamine Receptor Subtype Selectivity: The Anatomy of 1,4-disubstituted Aromatic 
Piperidines and Piperazines 
 
Figure 4- 10 General SAR of DAD3R Partial Agonists & Antagonists36 
 
d. Challenges to The Development of a D3-Selective Ligand 
 
 It should be noted that several discrepancies in binding affinities/selectivity’s 
across laboratories have been reported. Comparing affinity and selectivity binding data 
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from in vitro to in vivo data, and with different assay conditions and model systems, have 
been vastly different. In short, “[t]he absolute values were vastly different, which provides 
a significant challenge to medicinal chemists trying to identify pharmacophores and 
functional groups that will optimize both pharmacological specificity and bioavailability” 
(Newman, et al 2005).36 Newman and colleagues go on to argue that the binding data 
collected from cloned receptors expressed in cell lines and subsequently tested under 
non physiological conditions are useful tools to guide discovery; however, functional 
assays are more valuable predictors of in vivo action and selectivity at the receptor.36,142  
A more creative approach to designing D3 ligands is lacking, and is further limited 
by the narrow range from which the selectivity skeleton (pharmacophore) of these ligands 
rise from. Designing ligands that contain the desired pharmacophore features and which 
have reasonable lipophilicities for brain penetrance (cLogD < 5, or cLogP < 5) has proven 
difficult, and continues to challenge the utility of the currently available agents. Lastly, 
inconsistent in vitro and in vivo data across laboratories make comparisons and further 
development an ongoing challenge. Because of the limited and inconsistent evaluation of 
these ligands in multiple assays, in vitro and functional, utilizing SAR to predict selectivity 
and efficacy is deficient. All of these challenges have hindered the development of 
selective therapeutics and PET radioligands for in vitro assays in brain tissue instead of 
in cloned receptors.  
Examining these receptors in vivo through PET and brain receptor occupancy 
studies has also been problematic (further hindered by inadequate selectivity and 
unfavorable lipophilicities). Non-selective D2/D3 PET ligands are available and may 
provide some insight. However, radioligands (as well as antipsychotic therapeutics, for 
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example) suffer from competition with endogenous dopamine at the receptor. This raises 
the concentration required to inhibit these receptors. In terms of therapeutics (e.g. 
antipsychotics), the drug concentration needed to occupy 75% of D2 receptors is roughly 
three times higher than occupying 50% of the receptors.143 Dopamine has a higher affinity 
for the D3 receptor (vs D2), further complicating the requirements to adequately engage 
the target of interest.144,145 
 “D3-preferring” compounds are defined as those that bind primarily to D3 receptors 
with at least 10-fold higher affinity than the second best target (in vitro).124 Selectivity 
values for D3 over D2 are expressed as a ratio of D2/D3; in regard to in vivo selectivity, this 
ratio should be >100 fold.36,39 Within this realm, the D3-preferring D2/D3 mixed agonist 
pramipexole as well as ropinirole, can be dosed in the low effective dose range to primarily 
bind the D3 receptors, and deliver the specific, desired pharmacodynamic effects; this 
was successfully shown with these compounds and in patients with restless leg 
syndrome.124,146,147  
Dopamine receptors are a well-known target for antipsychotics, and as such, PET 
tracers can aid drug discovery by confirming target engagement and quantifying receptor 
occupancy. Roughly 75% receptor occupancy of the D2 receptors at therapeutic 
maintenance (concentrations) of antipsychotics is required.143,148 In vitro estimates of 
D2:D3 selectivity of selected antipsychotics and the predicted occupancy at these 
receptors were also reported (Table 4- 3), supporting a role for the D3 receptor in the 
development of therapeutics.21,42,43,149,150 
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Table 4- 3 D2:D3 selectivity for selected antipsychotic drugs42 
Antipsychotic # Studies  D2:D3 
Selectivity 
D2 Occupancy  **D3 Occupancy  
Clozapine 9 2.82 ± 2.01 60% 35% 
Haloperidol 11 3.03 ± 4.42 75% 50% 
Risperidone 3 4.9 ± 3.71 75% 38% 
Olanzapine 1 3.18 75% 49% 
Amisulpride lo 3 2.29 ± 0.58 67% 47% 
Amisulpride hi 3 2.29 ± 0.58 80% 64% 
Raclopride 3 1.16 ± 0.53 * * 
*No occupancy estimated for raclopride.**Predicted 
Values based on previous reports, Levant, 1997, Schotte, 1996.21,150 
 
A selective D3 receptor PET ligand would provide insight in the 
pharmacological/therapeutic utility at this receptor, assess receptor occupancy in real 
time, and evaluate the effects of substance abuse (and further boost the development of 
therapeutics for this purpose). 
 
e. Functional Imaging of Neurotransmitter Systems & Other Considerations 
  
PET and SPECT are non-invasive, functional imaging techniques that can provide 
valuable information on receptor densities, neurotransmitter synthesis, and give insight 
into the underlying mechanisms and pathogenesis of diseases and disorders in vivo. 
Imaging neurotransmitter systems is widely conducted in nuclear medicine, and a variety 
of tracers exist for this purpose. These include radioligands for dopaminergic 
neurotransmission, serotoninergic neurotransmission, norepinephrine 
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neurotransmission, acetylcholine, central/peripheral or direct benzodiazepine site 
receptor ligands, glutamate neurotransmission, cannabinoid neurotransmission and 
opioid receptors. While all of these systems will not be discussed in depth, a 
representative list of PET radioligands used for functional neuroimaging is provided in 
Table 4- 4 (and Table 4- 5).39,151,152 
 
Table 4- 4 Neurotransmitter System and Selected PET Radioligands39,151 
Neurotransmitter System Tracer/Ligand 
Serotonin 5-HT1A [Carbonyl-11C]-WAY-100635, [11C]DWAY, [11C]FCWAY, [11C]NAD299, 
[18F]MPPF 
Serotonin 5-HT2A [11C]NMSP, [11C]MDL100907, [18F]Altanserin, [18F]Setoperone 
Serotonin Transporter (5-
HTT) 
[11C]DASB, [11C]MADAM, [11C]McN5652, [11C]nor-β-CIT 
Norepinephrine Transporter [11C]MENER, [18F]FMeNER, [18F]FD2MeNER, [11C]Desipramine, 
[11C]Talopram, [11C]Talsupram 
Glutamate [11C]MPEP, [11C]JNJ-16567083 
Opiate [11C]Diprenorphine, [11C]Carfentanil, [18F]Clyclofoxy, [11C]LY2795050 
Muscarinic [11C]NMPD, [11C]3-MPB, [11C]Benztropine 
Nicotinic [11C]-Nicotine, [11C]Mecamylamine, 2-[18F]Fluoro-A-85380, [18F]Nifene, (-)-
[18F]Flubatine 
Histamine [11C]Doxepin, [11C]Pyrilamine 
Adenosine [11C]MDPX, [18F]CDFPX 
GABA-benzodiazepine [11C]-Flumazenil, [11C]-RO 5-4513 
Peripheral benzodiazepine [11C]-Vinpocetine, [11C]DAA1106 
 
For our purposes, as with any CNS drug discovery undertaking, certain 
considerations are taken when designing ligands or selecting lead compounds for further 
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evaluation. Important parameters to consider with regard to in vivo imaging of 
neurotransmitter systems with PET include, but are not limited to: selectivity (relative to 
competing binding sites, >100-fold is desired), and sufficient affinity to the target 
dependent on target expression level, binding potential (BP), occupancy, receptor 
saturation, target affinity/nonspecific affinity ratio, toxicity, low plasma protein binding, 
concentration in binding sites (Bmax), low nonspecific binding, and BBB permeability (log 
P < 5). Considerations for logP are in terms of specific binding for functional PET 
radiotracer development, certainly as the range of logP for CNS therapeutics and tracers 
is wide ranging.153 Other parameters and criteria include the presence of labeled 
metabolites. This is, such that if they occur, they are found in low concentrations, ideally 
do not penetrate the CNS and are cleared rapidly. This consideration follows the design 
of the compound such that the radiolabeled position is not subject to rapid metabolism 
and passes the BBB.39 
 
f. Functional Imaging of the Dopaminergic System: PET & SPECT 
 
 Several radiotracers exist in imaging the dopaminergic system. This includes 
imaging dopamine synthesis and turnover, imaging the dopamine transporter (DAT), 
dopamine receptors, and the vesicular monoamine transporter type-2 (VMAT2) (Table 4- 
5.). 
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Table 4- 5 Selected PET and SPECT Tracers Targeting the Dopaminergic System 
Target PET or SPECT 
Tracer 
Clinical studies/Relevance 
Dopamine Synthesis & Turn 
Over 
[18F]DOPA PD, gene therapy for PD, ADHD, Schizophrenia 
[18F]FMT Gene therapy for PD 
Dopamine Transporter [11C]CFT Heroine abuse 
[11C]altropane ADHD 
[123I]-β-CIT 
(Dopascan) 
PD, PM, cocaine abuse 
[123I]-FP-CIT 
(DaTSCAN) 
PM, ET, PD, DLB, ADHD, Schizophrenia 
[99mTc]-TRODAT-1 PD, MSA, PM, VP, DRD, PSP, genetic study of PD and 
MJD, cocaine and opiate abuse, nicotine dependence, 
ADHD 
[123I]altropane PD, ADHD 
[123I]IPT ADHD 
Dopamine D1 Receptor  [11C]NNC-112 Schizophrenia 
[11C]SCH-23390 Schizophrenia 
Dopamine D2 Receptor [11C]Raclopride Drug abuse (cocaine, methamphetamine, opiate), alcohol 
dependence, ADHD, antipsychotics 
[123I]IBZM PM, schizophrenia, antipsychotics 
Vesicular monoamine 
transporter type-2 (VMAT2) 
[11C]DTBZ PD 
[18F]RP-DTBZ (AV-
133) 
PD, DLB, AD 
Abbreviations: Parkinson’s Disease (PD), Parkinsonism (PM), multiple-system atrophy (MSA), progressive 
supranuclear palsy (PSP), essential tremor (ET), vascular Parkinsonism (VP), Machado-Joseph disease (MJD), 
DOPA-responsive dystonia (DRD), dementia with Lewy bodies disease (DLB), Alzheimer’s disease (AD), attention 
deficit hyperactivity disorder (ADHD).  
Table adapted and appropriate clinical references can be found in Shen et al, 2012.154 
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i. SPECT and DaTSCANTM 
 
SPECT, while it is not as sensitive as PET (limited primarily by technology: 
collimators and detectors in gamma cameras), allows for a longer time window of 
observation due to the longer half-life of the single photon emitters.155 SPECT is an 
attractive imaging modality due to the reduced scan cost, and availability of ligands 
(longer half-life makes for easier transport). A common SPECT radionuclide is iodine-
123, which has a half-life of roughly 13 hours and produces 159 keV gamma photon 
energy.  
 
 
Figure 4- 11 Selected DAT Radioligands156 
 
A hallmark of Parkinson’s disease (PD) is a notable reduction in striatal 
dopaminergic neurons, as such, these imaging agents allow for a quantitative and spatial 
distribution of these transporters. SPECT ligands used clinically to detect high striatal 
DAT binding for the diagnosis of Parkinson’s disease include: 123I-β-CIT (Dopascan), 123I-
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PE21, 123I-IPT, 123I-FP-CIT (123I-ioflupane, DaTScanTM), and 99mTc-TRODAT-1 (Figure 4- 
11.154,157 In the nigrostriatal pathway, the plasma membrane dopamine transporter (DAT) 
mediates dopamine re-uptake.158  
123I-β-CIT (Dopascan) was the first widely used DAT imaging agent, but suffered 
from lack of selectivity. 123I-β-CIT (Dopascan) binds to DAT, as well as the serotonin 
transporter (SERT) and norepinephrine transporter (NET). The kinetics of this tracer are 
non-optimal, as scan times should be performed 20-30 hours post injection. The 
development of 123I-FP-CIT (123I-ioflupane, DaTScanTM), a cocaine analog (Scheme 4- 3), 
helps combat these issues with faster kinetics which allow imaging as early as 3 hours 
following injection.154 DaTSCAN is a relatively new imaging procedure, approved by the 
FDA in 2011, and is widely used to distinguish Parkinson’s disease from essential tremor 
(Figure 4- 12).159  
 
 
Figure 4- 12 DaTScan. Grades characterized by appearance of the striata, or the progressive loss of neurons in the 
caudate and putamen. Image: Public Domain © FDA prescribing website for DaTScan. 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022454Orig1s004lbl.pdf 
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While it has >97% diagnostic sensitivity for PD, other diseases that also experience 
a loss in dopaminergic neurons will be non-distinguishable with this method, including 
Progressive Supranuclear Palsy (PSP), Multiple Systems Atrophy (MSA) and 
Corticobasal Degeneration (CBD) (Michael J. Fox Foundation for Parkinson’s Research). 
Other uses for DaTSCANTM are being explored, including depression and other 
neuropsychiatric disorders, however patient heterogeneity continue to contribute to 
conflicting results.160  
 
 
Scheme 4- 3 DaTSCANTM,[ 123I]ioflupane 
  
Another option for SPECT imaging of these neurons is [123I]IBZM (Scheme 4- 4).161 
[123I]IBZM is a D2/D3 (D2 preferring) antagonist used to measure postsynaptic DA. It was 
used effectively to measure density in nonhuman primates and human SPECT 
studies.162–165  
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Scheme 4- 4 Electrophilic Iodination of [123I]IBZM 
 
ii. Positron Emission Tomography & The Dopaminergic System 
 
PET offers a higher sensitivity (by two to three orders of magnitude) over SPECT, 
allowing for the ability to detect a higher number of emitted events. Spatial resolution in 
PET is limited by physics (whereas in SPECT it is limited by collimator design), such as 
photon non-collinearity and positron range; this, however, can be modeled in the 
reconstruction phase of imaging analysis. Another advantage of PET is the shorter half-
lives of the radionuclides, which allows for higher activities injected in the patient. The 
concern here is radioactive accumulation over time with regard to dosing.155 Multiple 
scans per day are also an option when using a radionuclide with a shorter half-life, such 
as carbon-11. PET has a clear advantage of quantitative instrumentation, versatile 
radionuclides, and selection of tracers. Moreover, PET is a useful tool in the development 
of CNS drugs to asses BBB permeability, target engagement, occupancy, and PD/PK 
considerations.166 For these reasons, and due to the enhanced resolution and spatial 
clarity of PET, our focus is on developing a selective PET radioligand for imaging the D3 
receptor in neurological diseases and disorders,.6  
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Figure 4- 13 Pre-synaptic DA Imaging with [18F]DOPA and [18F]FMT 
 
Pre-synaptically, 6-[18F]fluoro-3,4-dihydroxyphenylalanine ([18F]DOPA) is a widely 
used tracer for the imaging of dopaminergic metabolism and was first used in human 
studies in 1983.167 [18F]DOPA is an L-DOPA analog, and is used to visualize the activity 
of AAAD or AADC (aromatic L-amino acid decarboxylase (Scheme 4- 1, Figure 4- 13). 
When [18F]DOPA is taken up in the dopaminergic neuron by the amino acid transporter, 
LAT-1 (large-neutral-amino-acid transporter), it is decarboxylated by AADC to generate 
[18F]fluorodopamine (or [11C]dopamine if [11C]DOPA is used) which is stored in vesicles. 
However, a shortcoming of this approach is that [18F]DOPA in the periphery and CNS is 
methylated by catecholamine-O-methyltransferase (COMT), producing 6-[18F]fluoro-3-O-
methyl-DOPA. This labeled product crosses the BBB and needs to be kinetically modeled 
to address its interference in imaging. 
 6-[18F]Fluoro-L-m tyrosine ([18F]FMT) is an alternative tracer that is still a substrate 
for AAAD/AADC, but not COMT, thus reducing the requirement for multicompartment 
kinetic modeling.151,168 While AADC in dopaminergic neurons is of interest, it is important 
to note that this enzyme also plays a role in other monoamine transmitters (5-HT), and 
[18F]DOPA and [18F]FMT (Figure 4- 13) are also converted in serotonergic and 
noradrenergic neurons. Even so, the accumulation of these tracers in the striatum is 
predominantly in nigrostriatal dopaminergic neurons.151 
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 In a more general sense, a useful way to image neurodegenerative diseases 
characteristic to the loss of a particular type of neuron (such as the loss of dopaminergic 
neurons in the basal ganglia as a marker of Parkinson’s disease), is through targeting of 
the membrane-bound protein, vesicular monoamine transporter type 2 (VMAT2). Imaging 
of VMAT2 can be pursued via [11C]DTBZ ((+)-D-[11C]dihydrotetrabenazine). VMAT2 
functions to transport monoamines from the cytosol into storage vesicles prior to release 
into the synapse – this transporter is not specific, but rather it is used in the handling of 
dopamine, norepinephrine, serotonin, and histamine.151,169  
 
 
Scheme 4- 5 Synthesis of [11C]DTBZ 
 
The imaging of VMAT2 in neurodegenerative disease has significant utility due to 
the compartmentalization of the neuronal type in the human brain. [11C]DTBZ (Scheme 
4- 5) was developed out of the University of Michigan, Ann Arbor (Michael R. Kilbourn, 
Robert A. Koeppe, and David E. Kuhl). An analog labelled with fluorine-18, 
[18F]Fluoropropyl-(+)-DTBZ, has also been developed for potential commercialization (the 
longer half-life of fluorine-18 is suited to transport). This tracer has been licensed to Avid 
Radiopharmaceuticals (as [18F]AV-133), and has been employed in a number of clinical 
trials from 2012 to 2016 (including “A trial of 18F-AV-133 Positron Emission Tomography 
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(PET) Imaging to Differentiate Subjects with Parkinson’s Disease (PD) From Other 
Movement Disorders”; Clinical Trials as reported by the U.S. National Institutes of Health, 
NCT01550484).169 
 Targeting the dopamine D1 receptors is another ongoing pursuit in developing PET 
radioligands for the dopaminergic system. Even though the D1 receptor was the first of 
the subtypes to be identified, the functional and pharmacological profile of this receptor 
is largely unknown.170 The most widely used of the available radioligands antagonists 
including (R)-(+)-[11C]SCH 23390, (+)-[11C]NNC 112, and (+)-[11C]A-69024, and 
full/partial agonists including the SKF series and (S)-[11C]N-Methyl-NNC 010259 (Figure 
4- 14).171–175 The first of these, benzazepine [11C]SCH 23390, showed only moderate D1 
to 5-HT2A receptor selectivity in vitro, but was found to be D1-selective in vivo. Radioligand 
[11C]NNC 112 has better specific/nonspecific ratios in humans compared to [11C]SCH 
23390, but both ligands have been used to better understand dopamine activity in 
neuropsychiatric diseases/disorders, including schizophrenia.176  
Unlike the D2 receptors, the D1 receptor does not show sensitivity to 
(pharmacological modulation of) endogenous dopamine release. This could be due to 
several reasons: (1) that these receptors are located largely extra-synaptically, (2) that 
these receptors have a lower affinity to their endogenous ligand, dopamine (compared to 
the D2 receptor), and that (3) a small fraction of this receptor is in the high-affinity state.171 
Moreover, differences in the distribution of the D1 receptors, as identified by agonists and 
antagonists, is not well understood. The affinity state of this receptor is speculated as the 
main reason for the discrepancy. 
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As with the D2 receptor, the D1 receptor also exists in a high or low affinity state. 
Richfield, et al177 used quantitative autoradiography to determine the affinity states of the 
D1 and D2 receptor. They found that the D1 receptor, without exogenous guanine 
nucleotides and nonselective dopamine competitors, is primarily in the low affinity agonist 
state (~80%), while the D2 receptor exists primarily in the high affinity (agonist) state at 
~77%. Receptor occupancy from D1 to D2 (with agonist or antagonist) did not influence 
the affinity states of either one, showing that an interaction between these two receptor 
types is not responsible for the different affinity states. Difficulties with assigning a specific 
role to the D1 receptor may be the result of the low proportion of the receptor in the high 
affinity state.177 The identification of D2 selective ligands has shed light on the biological 
role of this receptor class, while the D1 receptor still suffers from conflicting results due to 
many complicating factors in the dopaminergic system and behavior of these receptors.176 
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Figure 4- 14 Dopamine D1 Receptor PET radioligands171 
 
Post-synaptically, the dopamine D2 receptor is most widely imaged via ”the gold 
standard” [11C]raclopride (previously known as S-(-)-[11C]FLA 870), as well as 
[18F]fallypride (an analog of epidepride), and [11C]3-N-methyl-spiperone; and the 
dopamine D3 receptor with 4aR,10bR)-4-(propyl-1-11C)-3,4,4a,5,6,10b-hexahydro-2H-
naphtho[1,2-b][1,4]oxazin-9-ol  ([11C]-(+)-PHNO) (Figure 4- 15, Figure 4- 
16).46,142,169,178,179 
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Figure 4- 15 Other D2/D3 Radioligands46  
 
The radiosyntheses of [11C]raclopride (91) and [18F]fallypride (129) are 
straightforward, with [11C]MeOTf methylation at the tetrabutyl ammonium phenoxide 
precursor (90) for [11C]raclopride (91), and a one-step aliphatic nucleophilic substitution 
of the tosylate precursor (130) with [18F]KF for [18F]fallypride (129) (Scheme 4- 6).169 
[18F]Fallypride and [11C]raclopride are high affinity D2/D3 antagonists. While (the gold 
standard) [11C]raclopride is used for the imaging of D2 receptors, it still has modest affinity 
for D3 receptors (Kd D2 =1.6 nM, and Kd D3 = 18 nM as measured with 
[13H]raclopride).90,180 
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Figure 4- 16 Postsynaptic Dopamine Receptor Radiotracers: In the Clinic 
 
 [11C]raclopride (91) is used extensively in the clinic to study neuropsychiatric 
disorders associated with D2 receptors, including schizophrenia, Parkinson’s disease, 
stress, and depression.45,169,181–188 Other interests in imaging the dopamine receptors is 
in respect to understanding their underlying role in substance abuse, behavioral 
reinforcement and reward, and to support development of antipsychotic 
therapeutics.185,189,190 
 
 
Scheme 4- 6 Radiosynthesis of [11C]Raclopride and [18F]Fallypride for Dopamine D2 Receptor PET Imaging 
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Similar to other G-protein-coupled receptors, dopamine D2 receptors exist in a 
high- and low-affinity state for agonists (D2H and D2L), regardless of which type of G-
protein they couple to (Gs, Gi/o, etc). Agonists bind with higher affinity to the G protein-
coupled state, a process involving Mg2+ ions. This is such that Mg acts to lock the D unit 
of the G protein into conformation from where the GD dissociates from the GβJ.191 In this 
way, Mg2+ and other cations (such as Na+) act as allosteric modulators at GPCRs.192,193 
Interestingly, guanine nucleotides (guanosine diphosphate/GDP, guanosine 
triphosphate/GTP) were found to convert high affinity to low affinity D2 receptor binding 
to agonist [3H]spiperone.194 Taken together, given the role of guanine nucleotides and 
ions, experimental conditions and methods can promote or hinder the detection of the 
high-affinity (dopamine) receptor state (Mg2+ to detect the high affinity state, and Na+ to 
hinder the high-affinity state). While the D3 receptor is not reported to have a high/low-
affinity state, it is important to note experimental conditions when evaluating selectivity of 
these ligands from in vitro to in vivo behavior.194–196 [11C]-(+)-PHNO, an agonist, shows 
no preferential binding to the high or low affinity D2 state, perhaps due to its preferential 
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binding at the D3 receptor.197 Selected radioligands that readily distinguish between the 
high and low-affinity D2 state are listed in (Figure 4- 17).46 
 
 
Figure 4- 17 Radioligand D2/D3 Agonists: D2High vs D2Low46 
 
Other D2-selective compounds, such as [18F]N-Methylbenperidol and [11C]SV-III-
130 have shown recent improvement in efforts to develop a selective radioligand at the 
D2 receptor. [18F]N-Methylbenperidol was shown to be roughly 200-fold selective for the 
D2 receptor over D3, and initial PET studies have demonstrated that this tracer reflects a 
D2 binding pattern, as opposed to D2/D3.198 [11C]SV-III-130 on the other hand has a 
roughly 60-fold D2 preferring character, but also binds with high affinity to serotonergic 
receptors, hindering its progress as a selective tracer for dopamine receptors.199 
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Figure 4- 18 Other D2-Selective Radioligands 
 
iii. PET Imaging of the Dopamine D3 Receptor: [11C]-(+)-PHNO & Recent 
Efforts 
 
The current best clinical option in dopamine D3 receptor imaging, with modest 
selectivity, at roughly 20-fold, is (4aR,10bR)-4-(propyl-1-11C)-3,4,4a,5,6,10b-hexahydro-
2H-naphtho[1,2-b][1,4]oxazin-9-ol ([11C]-(+)-PHNO, 97), which was developed as a PET 
ligand in 2005 (Figure 4- 16, Scheme 4- 7).200 The non-radioactive compound was initially 
developed as a therapy for Parkinson’s disease in the 1990s.201–203 Later it was labeled 
with tritium for autoradiography binding studies, and carbon-11 for PET imaging.42,204 
Wilson was the first to evaluate [11C]-(+)-PHNO as a PET radioligand, reporting in vivo 
properties and tracer behavior.200 
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Figure 4- 19 [11C]-(+)-PHNO and Dopamine Receptor D2/D3 Subtype Selectivity 
 
 The synthesis of [11C]-(+)-PHNO begins with CO2 insertion at an ethyl Grignard 
reagent (92), and consequent formation of the [11C]propionyl chloride (94) through 
treatment with phthaloyl chloride; this is then reacted with the amine precursor (95) to 
form the amide that is subsequently reduced by LiAlH4 to give the final N-propyl product 
(97) (Scheme 4- 7).178  
 
 
Scheme 4- 7 Radiosynthesis of D3-Preferring [11C]-(+)-PHNO 
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Other valiant efforts have been ongoing to develop a D3-preferring or D3 selective 
radiotracer with desirable pharmacokinetic properties for in vivo imaging with PET, but 
[11C]-(+)-PHNO (97) has been the only practical tracer for this purpose.65,81,82,94,205,206 
Extensive work has been done by the Hauck-Newman group at NIH to develop a robust 
medicinal chemistry program for identifying the major SAR for this receptor, as well as 
the Mach group at the University of Pennsylvania to develop a dopamine D3 receptor 
ligand and adapt it for PET imaging (including a Phase 0 clinical trial for [18F]fluortriopride 
in 2017).  
Indeed, [11C]-(+)-PHNO (97) is a D2 receptor agonist, but its distribution and high 
binding in the globus pallidus suggests that it is D3 preferring (consistent with postmortem 
human D3 expression patterns). Moreover, the elucidation of whether agonist or 
antagonist tracers allow for an advantage in detecting affinity states (D2High, D2Low) is an 
active pursuit in PET and was encouraged by the development of this D3 preferring 
ligand.190,197,207–210 By utilizing other D3 selective pharmacological agents, notably BP897, 
SB-277011, and GSK598809, as well as D2 tracer [11C]raclopride (or [3H]raclopride), 
several groups were able to confirm the D3-prefering nature of [11C]-(+)-PHNO.119,211–215 
Even so, this tracer exhibits a considerably high affinity for the D2High state (Figure 4- 19).46 
As the result of these studies, it was concluded that [11C]-(+)-PHNO (97) specific 
binding in the substantia nigra/ventral tegmental is due to D3 receptors, whereas the 
binding in the putamen is due to D2. Uptake in the globus pallidus, ventral striatum, and 
thalamus is attributed to mixed D2/D3 signals. The signal from the dopaminergic nuclei in 
the midbrain is due to D3 receptors, however it cannot be measured precisely due to the 
small brain region and overall low specific binding of the radioligand.42,148 Receptor 
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occupancy, D3 vs D2, was given a rough estimate by Gallezot et al in 2011, such that 
[11C]-(+)-PHNO KD(D3) = 0.02 - 0.05 nM, a very high affinity tracer.215 
A great deal of work has gone into studying the pathophysiology of psychiatric 
illness as it pertains to the function of the dopamine D3 receptor using [11C]-(+)-PHNO 
(97). [11C]-(+)-PHNO imaging is challenging in that it requires a multi-step radiosynthesis 
using a short-lived radionuclide (carbon-11, t1/2 = 20 min), making high specific activity a 
concern. Pharmacokinetic quantification is also cumbersome due to its mixed affinity at 
the D2 and D3 receptors.42 
Research efforts across groups in developing ligands based off the first reported 
D3 agonist, BP897 (Figure 4- 7) have resulted in the production of carbon-11 and fluorine-
18 compounds, Figure 4- 20, albeit with limited in vitro and in vivo data to evaluate their 
utility as PET ligands.216–218 A structure-activity relationship study on a novel series of D3 
ligands on the aforementioned 2,3-dichloro scaffold (e.g. NGB 2904, Figure 4- 7) lead to 
a carbon-11 compound reported by Turolla and Perone (Figure 4- 20), also with structural 
similarity to BP897.216,219,220 The result of this work was an optimization of carbon-11 
labeling and preliminary in vitro and in vivo evaluation. The compounds were reported to 
cross the BBB, yet accumulated in areas uncharacteristic for D3 receptors – despite the 
promising in vitro findings. This finding is not uncommon when comparing in vitro and in 
vivo behavior.221,222 The ClogP of the compounds is argued to be the reason for poor 
specific binding, and noise as the result of high blood circulation causing image 
degradation.219 This is further complicated by (potential) competition from endogenous 
dopamine at the receptor.223 As such, these compounds were not deemed suitable for 
future in vivo imaging.216  
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Figure 4- 20 Representative BP897 Derived Radioligands 
 
Another development in BP897-derived ligands lead to [18F]FAUC346, and  
another interesting work reported by Hocke and Gemeiner, et al (Figure 4- 21).217 
Receptor binding studies were performed and confirmed with 3D-QSAR models. These 
methods revealed sub-nanomolar D3 affinities (Ki values 0.12-0.69 nM) and good 
selectivity’s (> 100 fold) at these derivatives.217 A series of other D3 subtype selective 
compounds based on BP897 and FAUC346 were synthesized and initially 
evaluated205,224–226  
217 
 
 
Figure 4- 21 [18F]FAUC346 and BP897 derived ligands 
 
The carboxamide BP897 derived series is, still, a common scaffold to pursue and 
modest SAR was pursued and labeling efforts reported in 2005 and 2008 by Gao and 
colleagues ([11C]BP897, Figure 4- 20). High radiochemical yields and short synthesis 
times were reported, as well as drawing upon the previously biological data to encourage 
further in vivo evaluation.218,227 
 
Figure 4- 22 [18F]Fluortriopride (FTP) 
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 A considerable effort in the progress of a dopamine D3 receptor-selective PET 
radioligand by the Mach group has resulted in the recent development of [18F]fluortriopride 
([18F]LS-3-134) (Figure 4- 22). This potential PET tracer has sub-nanomolar affinity for 
the D3 receptor (D2 = 27.7 nM, D3 = 0.17 nM) (and is >150-fold selective at the receptor 
(compared to D2).87 Currently this compound is being evaluated in a Phase 0 clinical trial, 
NIH ID 14119, at the University of Pennsylvania as of July 2017.46,86  
 
g. Toward the Development of a Dopamine D3 Receptor-Selective PET 
Radioligand 
 
The identification of a specific, high affinity dopamine D3 receptor PET radioligand 
is of urgent need in the field of nuclear medicine for the characterization and 
pharmacological evaluation of this receptor, to explore its role in disease, and as a way 
to fully utilize it as a diagnostic and therapeutic target. The development of a PET tracer 
will provide functional data and insight into three key areas: (1) this will provide functional 
data to support treatment efforts as well as valuable insight into normal and abnormal D3 
receptor activity as it relates to normal brain function, the aforementioned disorders, and 
any change that occurs via the result of drug therapy; (2) additionally, this will allow for 
better understanding of the differential availability between D2 and D3 receptors, 
previously complicated by dual receptor binding by currently available radioligands such 
as [11C]-(+)-PHNO; (3) lastly, upon synthesis of a radioligand that shows in vivo sensitivity 
to endogenous levels of dopamine, the functional role of D3 receptors would finally be 
accessible. 
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Several antagonists and agonists have been used to characterize the pharmacology of 
the D3 receptor in vitro, but have fallen short due to the aforementioned homology and 
resultant specificity problems with the radioligand, as well as the expression system or 
tissue and assay system chosen for study. A list of the research groups who have done 
significant, notable work toward the development of D3 selective ligands for therapeutic 
or PET diagnostic purposes can be found in the “The Dopamine D3 Receptor as a Drug 
Target“ section of this chapter. With these shortcomings, however, the need for the 
development of a selective D3 agonist still exists.  
Recently, several compounds have been identified that are selective agonists at 
the D3 receptor with >100 fold selectivity for D3 over D2 and low nanomolar 
affinity.107,108,130 The goal of the research described in this Chapter was to synthesize a 
series of selective D3 receptor agonists and utilize them as lead compounds for the 
synthesis, radiosynthesis and initial evaluation of novel D3-selective PET radioligands. 
 
h. Results & Discussion Part 1: Pramipexole-Containing Compounds 
 
i. Design & Synthesis 
 
 The D3-prefering agonist, pramipexole, was used as the pharmacophore in a drug 
discovery program to develop a D2/D3 agonist for the treatment of Parkinson’s disease, 
and was then used as it provided good selectivity at the D3 receptor (as opposed to the 
naphthyl amide head group on BP897).130,134,228–230  
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As a result of these efforts, several potent D3 preferring agonists emerged. These 
compounds, reported by Modi, Dutta and colleagues130, contain the characteristic alkyl 
linker from the pramipexole moiety to the piperazine (bi)phenyl, and follows with good 
selectivity and affinity at the receptor: 3-methoxy 127 (D2/D3: 147; Ki = 2.33 ± 0.26 nM) or 
3-hydroxy 128 (D2/D3: 213; Ki = 1.73 ± 0.14 nM) (Scheme 4- 8, Scheme 4- 11).130 
 
 
Scheme 4- 8 Pramipexole-Containing C-11 Lead 127 and Proposed Radiotracer 129  
 
Using compound 128 as a starting point, we wished to synthesize the carbon-11 
isotopalog 129 for PET imaging. The unlabeled reference standard, to confirm identity of 
the radiolabeled product by HPLC, was prepared as previously described (Scheme 4- 9) 
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from phenyl piperazine, and the carbon-11 precursor (also lead, 128) prepared with 
modest variation (Scheme 4- 10).231  
 
 
Scheme 4- 9 Synthesis of Standard 135231 
 
Phenyl piperazine (130) was iodinated with ICl in acetic acid, followed by standard 
Boc protection of the piperazine amine, in 70% yield over two steps (131). Suzuki coupling 
with 3-methoxy phenyl boronic acid gave 132 in 47% yield. Deprotection of the amine in 
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TFA (69% isolated yield), followed by alkylation with 2-(bromoethoxy)-(tert-butyl)-dimethyl 
silane gave 133 in 45% yield. Deprotection in TBAF to the alcohol (134) (64% yield), 
followed by Swern oxidation gave the desired aldehyde (non-isolated), that was reacted 
with (S)-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amine (aka Pramipexole) 
in reductive amination conditions (NaBH(OAc)3) to provide the final compound, 135, in 
28% yield. 
To obtain labeling precursor 128, O-demethylation of the carbon-12 standard (135) 
was initially pursued as previously reported231, but was unsuccessful in our hands 
(reagents explored for demethylation: BBr3, BCl3, TMS-I). Protecting group compatibility 
was explored at the piperazine and phenyl boronic acid, including Fmoc, Boc and 
dioxolane, as well as the 3-hydroxyphenyl boronic acid and MOM-protected boronic 
acids. As a result, we took a similar approach with a MOM-protected boronic acid, and 
related synthetic approach thereafter (Scheme 4- 10). 
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Scheme 4- 10 Synthesis of Precursor 139 and C-11 Labeling 
 
 Synthesis of the precursor 139 (Scheme 4- 10) therefore started with a common 
intermediate, 131, and 2-(bromoethoxy)-(tert-butyl)-dimethyl silane was added to provide 
protected alcohol 136 (43% yield) prior to Suzuki coupling with MOM-protected phenyl 
boronic acid to generate 137 in 50% yield. While Swern oxidation followed by reductive 
amination with pramipexole was a robust option in previous reports130, the formed 
aldehyde was not isolatable (unable to identify on NMR, and difficult to monitor via IR lead 
us to believe it was unstable) and the reductive amination was challenging. Therefore an 
alternative synthesis was developed. Following deprotection of 137 with TBAF (82% 
yield), the alcohol was converted to the tosylate (138) (66% crude yield). The tosylate 
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was not isolated but used directly in the alkylation with pramipexole to form the final 
product (before MOM deprotection), 139 in 70% yield. Final deprotection of the MOM 
ether in HCl/MeOH gave labeling precursor, 128, in 77% yield. 
  
 
 
Scheme 4- 11 Pramipexole Containing Lead for F-18 Labeling 
 
 The synthesis of the fluorine-19 reference standard (Scheme 4- 12) was adapted 
from the previously reported procedure, and modified as follows: from the previously 
mentioned intermediate, tert-butyl 4-(4-iodophenyl)piperazine-1-carboxylate (131), 
Suzuki coupling with 3-fluoro phenyl boronic acid gave (142) in 43% yield. After 
deprotection with TFA (99%), alkylation with 1-bromo-2-chloroethane provided 
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intermediate 143, which was directly reacted with pramipexole in base to provide the 
standard (144) in 31% over two steps. 
 
 
Scheme 4- 12 Synthesis of Fluorine-19 Standard 
 
 Radiofluorination of the unactivated arene, to generate the 18F radiotracer 
(Scheme 4- 13) , was pursued through recently reported transition metal-mediated F-
19/F-18 chemistry from Scott and Sanford utilizing stannane, boronic acid/Bpin (Bpin = 
boronic acid pinacol ester), or (mesityl)(aryl)iodonium salt precursors.232–236 For our 
interests, we sought to pursue the Bpin and stannane precursors for F-18 fluorination 
(Scheme 4- 13). Initial attempts to synthesize the Bpin precursor for nucleophilic F-18 
fluorination involved Suzuki coupling with a 1-3 di-Bpin on a common intermediate (142), 
however the desired product was never obtained and spectra analysis suggested 
dimerization of the products. Recent reports, however, demonstrate borylation via C-F 
bond cleavage.237–240 As such, we sought to synthesize of the fluorine-19 reference 
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standard first, and to save on time and reagents, to form the Bpin precursor that would 
be used directly in nucleophilic [18F]fluorination (Scheme 4- 14). 
 
 
Scheme 4- 13 F-18 Fluorination Strategies 
 
 
Scheme 4- 14 Strategy: Transition metal-mediate borylation via C-F bond cleavage -To- F-18 fluorination 
 
In lieu of using precious standard, an appropriate intermediate was used to screen 
conditions (Scheme 4- 15).237 Careful examination of the substrate scope 
defluoroborylation of haloarenes, 4-(4'-fluoro-[1,1'-biphenyl]-4-yl)morpholine and tert-
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butyl (4-fluorophenyl)(methyl)carbamate is transformed into the appropriate Bpin using 
conditions described in Scheme 4- 15A, in 76% and 52% yield respectively (Scheme 4- 
15-B) and carry significant structural similarities to the intermediate of interest. Utilizing 
the conditions described, and extending the reaction from 24-72 h (Scheme 4- 15A, x = 
1 and 3, x representing a multiplication factor of reagents described) on the model 
substrates, no desired Bpin was isolated, and starting material recovered (Scheme 4- 
15C, D). While most of these transition-metal mediated reactions require a glove box for 
working in an inert atmosphere, these were performed carefully in a standard fume hood. 
Ni(cod)2 is known to rapidly oxidize to Ni2+ in the presence of air241 (turning from a canary 
yellow to dark brown); and while this reagent did not have a rapid color change, this 
possibility should not be ruled out. 
In another effort to obtain the Bpin precursor, another recent report demonstrated 
a metal and additive-free photoinduced borylation procedure of haloarenes.240 Again, 
using a common intermediate, 142, these conditions were tried using a 254 nm lamp 
under a closed and open vial system (Scheme 4- 16). While monitoring via TLC gave 
promising results, however after extraction and/or purification, starting material was 
recovered. Given the lamp used for this transformation is used for TLC analysis, and not 
specifically for photochemistry, it is likely that the 254 nm lamp used is not the optimum 
equipment required of this transformation. 
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Scheme 4- 15 Toward a Bpin precursor via C-F bond cleavage 
 
 
Scheme 4- 16 Toward a Bpin precursor: Metal and Additive-free, photoinduced borylation of haloarenes 
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Since access to BPin precursor 145 was proving challenging, the synthesis of 3-
bromophenyl precursor 146 for end-stage stannylation was prepared. Starting from a 
common intermediate, 131, Suzuki coupling with 3-bromophenyl boronic acid provided 
148 in 26% yield. Deprotection of the N-Boc group using TFA (149), and subsequent 
alkylation with chloroacetyl chloride, gave 150 in 80% yield. To this was added base, 
catalytic KI and pramipexoleto produce 151 in over 50% yield. Reduction of the carbonyl 
in borane-THF provided bromide 146 in 68% yield.136 This was, by far, the most robust 
and easy to purify means to access 146. Unfortunately, efforts to stannylate 146 using a 
number of different conditions did not provide the desired product 147 (Scheme 4- 18).232 
(Scheme 4- 17). 
 
Scheme 4- 17 Other methods toward a stannane-containing precursor for F-18 fluorination 
 
 Intermediate, 148, was then used to explore other means to produce the stannane. 
Stannylation of intermediate 148 with bis(tributyl)tin, Pd(PPh3)4 and LiCl proceeded in 
reasonable yield (20%) (Scheme 4- 19). However, deprotection of the Boc group in the 
presence of the stannane proved to be challenging. Reagents and conditions tried 
included: traditional Boc deprotection in TFA/DCM, which both deprotect and 
destannylated the product. DCM with a couple drops of TFA gave the destannylated 
product via TLC, but an intact Boc group. Other methods tried include water at 100oC and 
150oC for 10-20 min but no reaction occurred under these conditions.242,243  
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Scheme 4- 18 Toward a Stannane-containing precursor for F-18 Fluorination 
 
 
Scheme 4- 19 Stannane trial & error 
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Concurrent with these metal-mediated late-stage fluorination efforts, isotopic 
exchange with the fluorine-19 containing standard, 144, was also being explored as a 
means of radiolabeling (Scheme 4- 21).  
 
ii. Radiochemistry 
 
Carbon-11 labeling of phenol precursor 128 was performed in a General Electric 
(GE) TracerLab FXC-Pro synthesis module. Initially, the carbon-11 was produced as 
[11C]CO2 with a GE PETTrace cyclotron via the 14N(p D)11C nuclear reaction, and was 
delivered to the synthesis module for loop or reactor chemistry. Loop and reactor 
chemistry was performed and the synthesis modules modified as described by Shao and 
colleagues.244 The carbon-11 sources utilized were standard [11C]CH3I and [11C]CH3OTf 
(a discussion of the formation of these carbon-11 methylating reagents can be found in 
the Chapter 1). Methylation of phenol 128, using 1 mg of precursor, was pursued in 
DMSO or DMF, and using several bases (KOH, potassium carbonate, TBA-OH) or by 
formation of the TBA-salt (briefly, 1 mg precursor in 150 μl MeCN/water to 10 μl 1M 
tetrabutylammonium hydroxide in MeOH was added, vortexed, diluted with 5-6 mL water 
and passed through a C18 extraction disk; the disk was washed with water 2 x 5 mL and 
tried under nitrogen gas. The precursor was eluted in MeCN to a fresh vial after drying 
overnight in vacuum).  In each instance, no product was obtained. Analysis of the reaction 
mixture following radiosyntheses confirmed intact precursor so it was not considered a 
stability issue. Alkylation at the free amine on the headgroup was not a concern, as the 
synthesis of pramipexole was previously reported, and the primary product was at the 
anticipated amine; while utilizing a protecting group in the pramipexole synthesis 
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decreased the mixture of products obtained, it was not required and the desired product 
was easily purified (Scheme 4- 20).245 
 
Table 4- 6 Carbon-11 Labeling of 128 
Methylating 
Agent 
Solvent Precursor Method Base Reaction Notes Result 
[
11
C]CH
3
OTf DMSO 1mg Reactor TBA-OH 3 min bubble through reactor NR 
[
11
C]CH
3
OTf DMSO 1mg Loop TBA-OH Addition of TBA, color change to yellow. 5 min through loop. 
NR 
[
11
C]CH
3
OTf MeCN 1mg Loop TBA salt 5 min through loop. NR 
[
11
C]CH
3
I DMSO 1mg Reactor KOH Subtle color change after addition of base. 3 min bubble 
through reactor 
NR 
[
11
C]CH
3
I DMSO 1mg Reactor KOH 3 min bubble through reactor, 
then heat 3 min, 85
o
C 
NR 
[
11
C]CH
3
I DMF 1mg Reactor K2CO3 Subtle color change after addition of base. Line cut from 
31, bubbled into product vial. 
NR 
[
11
C]CH
3
I DMF 1mg Reactor K2CO3 Line cut from 31, bubbled into product vial, then heat 5 min, 
85
o
C 
NR 
NR = No Reaction 
 
 
Scheme 4- 20 Synthesis of Pramipexole245 
 
Similarly, the development of a fluorine-18 tracer at the D3 receptor is highly 
desired due higher specific activity and longer half-life. The same group also reported a 
D3 selective 3-hydroxy phenyl compound 128 with nanomolar affinity for D3 and 213-fold 
over the D2 receptor, (Scheme 4- 11).130 Utilizing the -OH, 128 as a bioisostere for fluorine 
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(a discussion of fluorine as a bioisostere for this moiety in medicinal chemistry can be 
found in the Chapter 1), 144, we sought to pursue this scaffold and utilize the recent 
advances in fluorine-18 chemistry to access unactivated arenes through transition-metal 
mediated F-18/F-19 fluorination methods.232–234,246  
 
Scheme 4- 21 Isotopic Exchange: fluorine-19/fluorine-18 
 
Fluorine-18 was produced as [18F]fluoride with a GE PETTrace cyclotron via the 
18O(p,n)18F nuclear reaction, and delivered to a TracerLab FXFN synthesis module in a 
1.5 mL bolus of [18O]H2O. The process to prepare and activate the nucleophilic F-18 anion 
proceeds as follows: 
1. This was delivered to TracerLab FXFN synthesis modules, where the 
fluorine-18 was trapped on a QMA light Sep-Pak to remove [18O]H2O. The 
QMA light Sep-Pak is preconditioned with 10 mL NAHCO3 (10 mL deionized 
water, 10 mL ethanol, 10 mL deionized water – this is to aid is desorption 
(releasing) of the 18F- anion from the QMA resin). 
2. Typically the 18F- is eluted into the reaction vessel using a solution of 
aqueous potassium carbonate (3-3.5 mg in 0.5 ml water), then a solution of 
kryptofix-2.2.2. (K222) (15 mg in 1mL MeCN) added to the reaction vessel. 
Flourine-18 prep considerations: potassium carbon 3 mg per 15 mg K222, or 
1 mg per 10 mg are standard preparation. Moreover, TEA-HCO3 
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(tetraethylammonium hydrogen carbonate) has proven to be a reliable 
fluorine-18 preparation for halex, or isotopic exchange (11-11.5 mg).  
3. This mixture is then azeotropically dried by heating the reactor to 80oC, 
applying vacuum for 4 min, then cooled to 60oC and put under a stream of 
argon and under vacuum for another 4 min. 
Azeotropic drying is performed to get rid of unwanted water from the initial 
radionuclide production and aqueous base elution. Otherwise, the fluorine-18 anion is 
thought to be hydrated and inadequately nucleophilic; as such, this drying process and 
complex with a phase transfer reagent enhances the fluorine-18 anion reactivity (Figure 
4- 23 for [18F]KF). [18F]KF and [18F]TEAF are the fluorine-18 discussed herein. 
After azeotropic drying, the activated F-18 fluoride can be brought up into a desired 
solvent and used for use in multi-reactions manually, or the appropriate precursor (in an 
aprotic, anhydrous solvent) is added to the reactor and subsequent chemistry performed 
within the synthesis module of a lead-lined hot cell. For the current purpose, the fluorine-
18 was brought up into DMSO or DMF and used for manual reactions.  
 
 
Figure 4- 23 "Exposed" F-18 anion as the result of the K222/K+ complex 
 
An exploration of solvent, precursor amount, and temperature yielded no desired 
fluorine-18 product, as demonstrated through radioTLC or HPLC. A summary of these 
conditions can be found in Table 4- 7.  
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Table 4- 7 F-19/F-18 Isotopic Exchange on 144 
 
[18F]Fluoride Prep Solvent Precurs
or 
Temp 
(
o
C) 
Time Reaction Notes Result 
1 15mg K222, 3.5mg 
K2CO3, DMF 
DMF, 0.5 mL 0.5 mg 120 20 min TEA-HCO3 11.5mg/reaction, 
100uCi/reaction 
NR 
2 15mg K222, 3.5mg 
K2CO3, DMF 
DMSO,0.5mL 0.5 mg 170 20 min TEA-HCO3 11.5mg/reaction, 
100uCi/reaction 
NR 
3 15mg K222, 3.5mg 
K2CO3, DMF 
DMF, 0.5 mL 1 mg 120 20 min TEA-HCO3 11.5mg/reaction, 
100uCi/reaction 
NR 
4 15mg K222, 3.5mg 
K2CO3, DMF 
DMSO,0.5mL 1 mg 170 20 min TEA-HCO3 11.5mg/reaction, 
100uCi/reaction 
NR 
5 11.5 mg TEA-
HCO3 
DMSO, 1mL 1 mg 160 20 min 150 uL F-18/DMSO + 850 uL 
DMSO 
NR 
6 11.5 mg TEA-
HCO3 
DMSO, 1mL 2 mg 170 20 min 150 uL F-18/DMSO + 850 uL 
DMSO 
NR 
7 11.5 mg TEA-
HCO3 
DMSO, 1mL 1 mg 160 20 min 150 uL F-18/DMSO + 850 uL 
DMSO 
NR 
8 11.5 mg TEA-
HCO3 
DMSO, 1mL 2 mg 170 20 min 150 uL F-18/DMSO + 850 uL 
DMSO 
NR 
 
In these initial F-18 radiolabeling test reactions, the stability of the F-19 compound, 
144, came into question. A curious phenomenon occurred in the stability of this compound 
in solution: DMSO or MeCN, as it decomposed to 68% and 31%, respectively. Aliquots 
of 1.5 mg of 144 were stirred with 11.5 mg TEA-HCO3 in 1 mL DMSO, at 160oC for 0-60 
min, and analyzed via HPLC. Decomposition of the standard was such that 21% of the 
standard was remaining after 5 min, and less than 1.5% was remaining after 1 hour (Table 
4- 8, Table 4- 9). A prospective labile site may be from the piperazine to pramipexole, as 
the retention time of pramipexole in this system begins to increase as the standard 
appears to break down. The fragmentation of the standard is shown alongside 4 main 
236 
 
fragmentation peaks (Table 4- 9). Moreover, temperature, solvent, “cold” KF, and K222 
were reacted with 144 and analyzed via HPLC, also showing breakdown of the standard. 
Table 4- 8 Stability of 144 
 
Table 4- 9 F-19 Standard 144 in TEA-HCO3 + DMSO 
 
 
The cold Standard 144 was also heated to 145oC in K222 (15 mg/reaction) and cold 
KF (1-2 mg/reaction). The K222 and KF were added in MeCN and heated to 120oC under 
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a stream of argon to mimic the drying step in the traditional F-18 preparation. Dried 
fluoride was then mixed with precursor 144 (0.5 mg) in DMSO (0.5 mL), and heated to 
145 oC. Samples were taken initially (after mixing), then at 20 and 40 minutes into the 
reaction. The K222/KF/precursor mixture turned amber within 20 minutes, while the 
K222/precursor mixture turned yellow within a similar time frame. Within 40 minutes, the 
K222/KF/precursor mixture changed to a green/yellow, while the K222/precursor turned 
from yellow to orange. These were analyzed on a Luna C8 5 micron, 100 Å, analytical 
HPLC column 150x4.6 mm, with 40% MeCN, 20 mM NH4OAc, 2 mL HOAc, mobile phase. 
 
Table 4- 10 F-19 144 Stability in Kryptofix-K222 
 
 
The stability of 144 in the presence of K222 was such that after initial mixing >90% 
of the compound was intact (retention time = 7.2 min). After 20 and 40 min, only 50% was 
remaining (Table 4- 10). A similar strategy was employed for the stability in K222/KF (Table 
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4- 11). Upon initial mixing, 83% of the standard was intact, but was found to decompose 
after 20 and 40 min.  
Table 4- 11 F-19 144 Standard Stability in Kryptofix-K222 and KF 
 
 
The pramipexole-containing compound, X, designed as a bioisostere out of the 3-
hydroxy phenyl compound previously shown to be 213 -fold selective at the D3 receptor 
(Figure 4- 17) was also evaluated in whole rat brain tissue to explore the selectivity from 
OH to F substitution and that selectivity and affinity was not reproduced.231  
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iii. Summary 
 
 Given the instability of the precursors to a range of radiolabeling conditions, further 
efforts to develop D3-selective radiotracers based upon this scaffold were abandoned. 
The selectivity of 144 at the D3 and D2 receptors was evaluated in whole rat brain tissue 
against [3H]R-(+)-7-OH-DPAT and [3H]Spiperone. In our system, 144 is roughly 5-fold 
selective at the D3 receptor, compared to 213-fold of the 3-hydroxy phenyl in previous 
reports106; the affinity at these receptors are Ki 21.0 ± 11.4 nM, Bmax 0.2 ± 0.024 fmol/µg 
(D3) and Ki 104.1 ± 34.2 nM, Bmax 0.363 ± 0.023 fmol/µg (D2) respectively. A discussion 
on the differences in selectivity is forthcoming. Other scaffolds were then pursued as 
discussed below, building off previously reported D3-selective compounds recently 
reported in the literature. 
 
i. Carbon-11 Pramipexole 
 
The pharmacophore for several of our previously explored compounds was the D3-
agonist, pramipexole (Figure 4- 24). To our knowledge, pramipexole itself has never 
never been radiolabeled for in vivo PET imaging. We reasoned that this could be 
accomplished using carbon-11, and enable us to explore the reactivity of the amine off 
the tetrahydrobenzothiazol moiety. 
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Figure 4- 24 Pramipexole 
 
Our approach to synthesize [11C]pramipexole was to employ a similar labeling 
strategy used for the preparation [11C]-(+)-PHNO, although we recognize it has a 
“complicated synthesis” when considering the short half-life of carbon-11 (Scheme 4- 7, 
Figure 4- 25). Since the Scott group has applied complicated, multi-step, and water 
sensitive synthesis to carbon-11 labeling in this project and beyond,247 we attempted to 
adapt the synthesis of [11C]-(+)-PHNO to [11C]pramipexole. 
 
 
Figure 4- 25 General Strategy for C-11 labeling 
 
 The desired precursor and reference standard  were both commercially available, 
and carbonyl-containing intermediate was synthesized as previously reported (Figure 4- 
25).245 Two major strategies were employed, both starting with an ethyl Grignard and 
[11C]CO2 to produce [11C]-magnesium bromide priopionate (Scheme 4- 22). Approach 1 
planned to utilize thionyl chloride to produce [11C]prionyl chloride that would be reacted 
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with the amine precursor in base to give the desired amide. Subsequent reduction with 
lithium aluminium hydride (LAH) would then provide [11C]pramipexole. Approach 2, 
deviated at the point of the [11C]-magnesium bromide priopionate where, treatment with 
HCl, would provide [11C]propioninc acid. With amide coupling reagents, N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide (EDC)/1-Hydroxybenzotriazole hydrate 
(HOBt), and N-[(Dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-
methylmethanaminium hexafluorophosphate N-oxide (HATU) and the pramipexole amine 
precursor, this would give the amide intermediate. As with approach 1, this would also 
require another reduction step before producing the final [11C]pramipexole. 
 
Scheme 4- 22 Approaches to [11C]Pramipexole 
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 These reactions were tackled in a stepwise formation, to show formation of new 
radiolabeled intermediates via HPLC. The formation of carbon-11 labeled N-(2-amino-
4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)propionamide was monitored via HPLC alongside 
the previously synthesized cold standard intermediate; however it was never obtained. 
The coupling reagents, EDC (LDA, DMF, 2,3,4 eq) and HATU, alongside several amine 
and non-nucleophilic bases (TEA, DIPEA, DBU, LDA) and solvents (THF, DMF, 1,2 
dimethoxyethane, 1,4-dioxane, trimethyl acetonitrile, 1,1,2,2-tetrachloroethane, 1,2 
dichloroethane) were screened. Given that the carbon-11 amide intermediate was never 
obtained, no breakdown products were observed, the focus was shifted to another 
pramipexole-containing scaffold with superior selectivity at the D3 receptor, in hopes that 
it would further shed light on the reactivity and stability of this compound class. 
 
j. Results & Discussion Part 1: Pramipexole-Containing Compounds, 
Continued 
 
 Wang and colleagues reported a new series of pramipexole-containing 
compounds with exceptional selectivity and affinity at the D3 receptor.107 The compound 
of interest, has 451-fold selectivity at D3 over D2 and roughly 0.38 nM affinity (Figure 4- 
26). Given the 2-chloropyridine structure we sought to do a simple switch from chloro to 
fluoro without anticipation of a significant loss of affinity or selectivity. It should be noted 
that the chloro precursor and unlabeled fluorine standard were synthesized by the 
University of Michigan’s Vahlteich Medicinal Chemistry Core. 
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Figure 4- 26 Pramipexole-containing Compound for F-18 Fluorination 
 
 Like before, the screening of reaction conditions started with standard F-18 
preparation in Kryptofix-222 and K2CO3, first in DMSO with no desired product (Entry 1-
4, Table 4- 12). Using the same preparation of F-18, but changing solvent to DMF showed 
an initial 67% RCC (Entry 5), however this result could not be reproduced. Using :[18F]-
TEA-HCO3, DMF, 120oC, 40 min gave consistent and reproducible results from manual 
to automated synthesis, n = 3, 5.37±1.09% RCC (Table 4- 12, Entries 6-8). 
 
 
Scheme 4- 23 F-18 Fluorination of 161 
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 Going forward, while the initial radiochemical conversions are promising, reaction 
conditions would benefit from further optimization. So far, no fragmentation or instability 
issues are apparent on HPLC or radioTLC from this pramipexole-containing compound 
from the standard or during radiolabeling. Prospective stability could be gained from 
replacement of the piperazine moiety.  
 
Table 4- 12 Preliminary F-18 Fluorination of Pramipexole-containing Compound 161 
Entry RCC (%) Precursor Solvent Prep Solvent 
Volume 
T (°C) Time Analysis Type 
1 X 1 mg DMSO K222, K2CO3 0.5 mL 100 15 min HPLC Automated 
2 X 1 mg DMSO K222, K2CO3 1.0 mL 100 15 min HPLC Automated 
3 X 1 mg DMSO K222, K2CO3 0.5 mL 100 20 min HPLC Automated 
4 X 1 mg DMSO K222, K2CO3 1.0 mL 120 20 min HPLC Automated 
5 67.21* 2 mg DMF K222, K2CO3 1 mL 130 30 min HPLC Automated 
6 4.27 1 mg DMF TEA-HCO3 1 mL 120 20 min radioTLC Manual 
7 6.85 1 mg DMF TEA-HCO3 1 mL 120 40 min radioTLC Manual 
8 5 1 mg DMF TEA-HCO3 1 mL 120 40 min HPLC Automated 
*Non-reproducible 
Non-isolated yields.  
Syntheses of Standard/Precursor: Vahlteich Medicinal Chemistry Core 
 
Given these synthetic difficulties due to suspected stability issues arising from the 
pramipexole moiety, we instead focused upon preparing radiotracers based upon the 
BP897-derived naphthamide derivative 
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k. Results & Discussion Part 2: Naphthylamide-containing Compounds 
 
i. Design & Synthesis 
 
 BP897 is a potent and D3-selective partial agonist first reported by Pilla and 
Sokoloff.55 BP897 suffered in selectivity against the human adrenergic receptor, which 
ultimately limited its clinical potential. A systematic approach to explore the SAR at these 
receptors was undertaken in an effort to improve the selectivity (over the D2 and 
adrenergic D-1 receptor, aka D), and several promising 2nd generation compounds were 
identified (Scheme 4- 24).108  
 
 
Scheme 4- 24 Improving the selectivity of "BP897" 
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Building off of these reported compounds, several other leads were designed with 
logP and ease of radiolabeling in mind (Scheme 4- 25); the -CF3 containing compound 
being a previously reported compound (Scheme 4- 24).108 
 
 
Scheme 4- 25 New D3-Selective Candidates & Synthesis  
 
The compound with the most promising selectivity at the D3 receptor is reported to 
have 1400-fold selectivity at the receptor, with a 1.1 nM affinity at D3 (Ki = 1553 nM at 
D2). The synthesis of 155 was reported previously, and was remade for evaluation in this 
work in a similar fashion, but with some deviation (Scheme 4- 25).108 The appropriately 
substituted phenyl (or pyridinyl) piperazines were commercially available. They were 
alkylated with 4-bromobutyronitrile, to form the intermediates (155-160a) in 68-98% yield. 
These were then reduced in borane-THF (26-72% yield) for 24-48 hr, to form amines 155-
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160b. The standards were synthesized by combing the amine in TEA with 2-naphtholyl 
chloride to form the amide series, 155-160c (42-87%). A detailed discussion of methods 
and reagents can be found starting on page 266.  
 
ii. In Vitro Evaluation of Selected Compounds in Whole Brain Rat 
Tissue 
 
With cold reference standards in hand, we sought to confirm binding and selectivity 
of the compounds we prepared for the D3 receptor using frozen whole rat brain tissue 
under conditions as close to physiological as possible. Binding assays were performed 
using the commercially available D3 receptor agonist [3H]-R-(+)-7-hydroxy-N,N-di-n-
propyl-2-aminotetralin ([3H]-R-(+)-7-OH-DPAT) and varying concentrations of the test 
compound in rat brain slices, with pramipexole used to identify non-specific binding. 
Similarly, D2 receptor binding assays were performed with [3H]spiperone, using (+)-
butaclamol to identify non-specific binding.20,23,135,248–250 
The naphthamide compounds (Scheme 4- 24), 155c (CF3) was shown to be 1400-
fold selective and the 3-hydroxy phenyl (bioisostere fluorine 101) to be 1900-fold selective 
at the receptor.108 The compounds selected for in vitro evaluation were chosen to confirm 
currently available binding data for the previously reported compounds, and to evaluate 
novel compounds (Figure 4- 27). 
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Figure 4- 27 Selected compounds for in vitro evaluation 
 
iii. In vitro Results 
 
In vitro evaluation of these compounds was performed with cold carbon-12 or 
fluorine-19 standards against tritiated pharmacological agents as previously described. 
Previous reports describe the use of other cofactors and additives, as discussed before.36 
We sought to perform assays under physiologically relevant conditions to mimic in vivo 
behavior, since many of these compounds perform well in vitro but fail in vivo. In our 
hands, selectivity for the D3 receptor was apparent (Table 4- 13), but it was orders of 
magnitudes less than reported in the literature. This is in line with literature reports 
describing differences in binding and selectivity data between in vitro and in vivo 
experiments.36 
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Table 4- 13 Competition of cold standards with 3H-pharmacological agents 
Compound [3H]-7-OH-DPAT [3H]Spiperone Reported 
Selectivity 
(D2/D3) 
Selectivity in 
our system  
(D2/D3) 
155c Ki 46.5 ± 10.7 nM 
Bmax 0.230 ± 0.015 fmol/µg 
 
Ki 647 ± 79 nM 
Bmax 0.627 ± 0.037 fmol/µg 
 
1400108 14 
158c Ki 4.49 ± 0.31 μM 
Bmax 0.301 ± 0.007 fmol/µg 
 
Ki 9.9 ± 1.120 μM 
Bmax 1.120 ± 0.0022 fmol/µg 
 
N/A 2.2 
159c Ki of 48.0 +/- 10.2nM  
Bmax of 0.185 +/- 0.020 fmol/µg 
 
Ki of 1.01 +/- 0.12 μM  
Bmax of 0.506 +/- 0.021 fmol/µg 
 
1900108* 21 
*bioisostere 
  
 
Figure 4- 28 Rat Brain Autoradiography Studies of 155c (CPu: caudate putamen, ACC: nucleus accumbens, OLFTU: 
olfactory tubercle) 
 
Our results demonstrate 14-fold selectivity of 155c for D3 receptors over D2. We were 
encouraged to observe that the low nanomolar affinity and D3 selectivity translated to ex 
vivo tissue samples, albeit with the expected losses in affinity and selectivity consistent 
with conducting binding affinity in true tissue samples. As expected, [3H]R-(+)-7-OH-
DPAT binding was highest in the caudate putamen (CPu), nucleus accumbens (ACC) 
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and olfactory tubercle (OLFTU), areas known to be rich in D3 receptors (Figure 4- 28).251 
Reflecting the colocalization of D2 and D3 receptors in the rat brain, [3H]spiperone binding 
was apparent in the same areas. Non-specific binding of [3H]R-(+)-7-OH-DPAT was 
determined to be minimal (Panel C) by incubating with 10 µM pramipexole, a dopamine 
D3 ligand.252 Analogous identification of [3H]spiperone non-specific binding was 
accomplished by co-incubating with 10 µM of the D2 antagonist butaclamol (Panel 
F).21,252 Notably, incubating with 10 µM 1 was found to displace [3H]R-(+)-7-OH-DPAT by 
a similar degree to pramipexole (Panel B), but did not displace [3H]spiperone (Panel E), 
confirming good D3 selectivity. 
The large differences in selectivity between these experiments could be due to 
receptor availability. The literature values were largely from cell-derived (transfected HEK 
293 cells) or membrane-based assays, whereas our system utilizes whole rat brain tissue 
(Table 4- 13).108,130,253Transfected cells are the main choice for the drug discovery platorm 
since they allow for more sophisticated functional assays to identify the action of 
compounds at GPCRs (non-radioactive, for HTS, and utilizes readouts such as Ca2+, GTP 
binding, or cAMP).254,255 Contrastingly, ligand binding is classically performed with a 
radioligand in whole tissue or membranes. Differences are expected since in assays 
utilizing cells transfected with human receptors (or membranes), it is possible that the 
receptor protein has been effectively concentrated and available binding sites more 
exposed than those in whole tissue, and this would account for our findings. Despite 
differences in magnitude of selectivity, we were nevertheless encouraged that the general 
trend in degree of selectivity was consistent between our data and the literature reports.  
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iv. Summary and Compound Selection 
 
From literature reports and our own studies, the most promising compounds are 
159c and 155c, owing to their high affinity for the D3 receptor and good selectivity over 
the D2 receptors. The remainder of this work focuses on the synthesis and evaluation of 
[11C]155c. Moving this project forward, 159c would be a promising candidate for 18F-
fluorination. Competition curves against [3H]R-(+)-7-OH-DPAT and [3H]Spiperone for 
both compounds can be found from page 274. 
 
v. Synthesis of [11C]155c  
 
The general approach to labeling this scaffold was to utilize a naphthyl Grignard, 
to undergo [11C]CO2 insertion, followed by formation of the acyl chloride with thionyl 
chloride and catalytic DMF. The acyl chloride would then be combined with the amine 
precursor 155b, in base, to form the amide, 155c (Scheme 4- 27). This utilized an in-
house Grignard prepared same-day, or commercially available naphthyl Grignard, 161. 
In each case, the Grignard reagent was titrated with salicylaldehyde phenylhydrazone as 
described previously.256 
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Scheme 4- 26 Synthesis of standard and precursor for [11C]155c 
 
 
Scheme 4- 27 Synthetic strategy for C-11 labeling 
 
Carbon-11 was produced via the 14N(p,D)11C nuclear reaction, and ~40 min beam 
to produce roughly 3 Ci of carbon-11 as [11C]CO2. The preparation of [11C]155c began by 
bubbling [11C]CO2 into a solution of the Grignard (in THF) for 5.5 min at 7 mL/min. This 
was followed by addition of thionyl chloride with cat. DMF in THF for 1.5-2 min. The 
precursor was then added and the reaction was stirred for 5 min. The stirring was turned 
off and the reaction mixture let settle for 1 min, before being passed through a Gelman 
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Acrodisc 13 CR PTFE 0.2 micron filter, and injected onto a semi-preparative C18 HPLC 
column (60% MeCN, 20mM NH4OAc, 2 mL HOAc) at 2.5 mL/min. The desired peak was 
collected (RT 10 – 11.5 min, Figure 4- 29). Chemistry optimization demonstrated good 
yield with carrier-added (1 mL CO2), with radiochemical conversions (non-reformulated 
doses) of 23-26% (n=3), while non-carrier was 8-10% (n=2). 
 
 
Figure 4- 29 Semi-preparative HPLC trace for [11C]155c 
 
Reformulation for preparation of an injectable dose for microPET imaging 
consisted of the following: compound [11C]155c was diluted into 45 mL water containing 
1mL 1% NH4OH. This solution was passed through a C18 sep-pak (Waters), the cartridge 
was rinsed with another 2 mL water to remove residual HPLC mobile phase. Product 
[11C]155c was eluted with ethanol (x mL – varied as a result of the desired final volume 
desired) and diluted with 0.9% saline to provide the final formulated product as a sterile 
isotonic product in 10% ethanolic saline solution (pH 5.5).  
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Non-carrier added synthesis were performed, and [11C]155c was obtained in 
0.8±0.2% decay-corrected radiochemical yield (RCY) (0.025 ±0.005% non-decay 
corrected) in 82±1% radiochemical purity (RCP), n=2. Carrier added syntheses were also 
attempted in which 1 mL of CO2 was included in the synthesis of [11C]155c. Product 
[11C]155c was obtained in slightly higher RCYs (4.9±0.6% decay corrected RCY (0.11±-
.01% non-decay corrected RCY)), in 100±0% RCP, n=2. Carrier-added synthesis gave 
modest specific activity of 133 Ci/mmol, while non-carrier specific activities were higher 
1941 Ci/mmol. The imaging properties of both the carrier added and no-carrier added 
products were evaluated in female Sprague Dawley rats. 
 
vi. MicroPET imaging: General Considerations 
 
MicroPET imaging studies were conducted using a Concorde Microsystems P4 
PET scanner (Figure 4- 30). Anesthesia was induced in healthy, female Sprague-Dawley 
rats (293-346 g) using isoflurane/O2, and anesthesia was maintained with 2-4% 
isoflurane/O2 throughout the experiment. Body temperature was maintained by a heating 
pad. A transmission scan for attenuation correction was acquired prior to administration 
of the radiolabeled compound of interest via tail vein injection (378-494 μCi). 
 
255 
 
 
Figure 4- 30 Concorde Microsystems P4 PET scanner 
 
Emission data were collected over 60 minutes. The emission data were corrected 
for attenuation, decay, dead time and random coincidences before reconstruction using 
an iterative ordered subset expectation maximization–maximum a posteriori (MAP) 
method to generate reconstructed images. The frames were summed, smoothed, and a 
region-of-interest was defined on several planes for the whole brain. The volumetric ROI 
was then applied to the full dynamic data set to obtain the brain tissue time-radioactivity 
data. Standardized uptake values (SUVs) were calculated for time-radioactivity data. 
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vii. MicroPET Imaging [11C]155c: First Impressions 
 
 
Figure 4- 31 Summed sagittal rodent image (0–60 min post-injection of [11C]155c) and time-radioactivity curves for 
[11C]155c (Cbm: cerebellum, CPu: caudate putamen,  OLFTU: olfactory tubercle) 
 
We were encouraged to see good CNS penetration of the radiotracer, as well as 
increased retention in identifiable brain regions. Notably, highest uptake was in the 
olfactory tubercle (peak SUV ~1.5), caudate putamen (including nuclear accumbens) 
region (peak SUV ~1.2) and hypothalamus (peak SUV ~0.9), known D3-rich areas of the 
brain251,257 that are consistent with the highest distribution of D3 receptors identified in the 
[3H]R-(+)-7-OH-DPAT autoradiography experiments described above. There was also 
uptake in the cerebellum (Cbm) that was lower (peak SUV ~1.0), and is also consistent 
with the known distribution of D3 receptors in the rat brain. D3 receptors are found in the 
cerebellum, but at lower areas than, for example, the caudate putamen and olfactory 
tubercle.257 There was also uptake of [11C]155c in both the thyroid (Thy) and pituitary (Pit) 
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glands (Figure 4- 31), consistent with other radiotracers based upon the BP897 
scaffold21,216,258 and possibly indicative of non-specific binding.  
Future experiments aimed at understanding the extent of non-specific binding, in 
vivo selectivity for D3 over D2 receptors, and sensitivity of the radiotracer to endogenous 
dopamine will occur following scale up and optimization of the radiosynthesis and 
translation of the radiotracer into nonhuman primates, where small D3-rich areas of the 
brain are more accurately identifiable and quantifiable. 
 
viii. MicroPET imaging with Carrier-Added [11C]155c 
 
 Initial imaging was conducted using carrier added [11C]155c. (raw data: Figure 4- 
32; adjusted to SUV: Figure 4- 33, PET:Figure 4- 34). While the imaging shows initial 
good uptake in the brain, clearance was not traditional and accumulation of a labeled 
entity was seen throughout the brain and the rest of the body of the rat. Whether this 
entity was the original (desired) compound, [11C]155c, or a metabolite was of interest.  
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Whole Brain TAC 1094 Whole Brain Tac 1095 
  
Figure 4- 32 Raw Whole Brain TACs for Carrier-Added Syntheses 
 
 
Figure 4- 33 CA Adjusted to SUV 
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MicroPET imaging, Carrier-Added Rat 1094 
 
Figure 4- 34 MicroPET Rat 1094, Carrier-Added 
 
ix. MicroPET imaging with No Carrier-Added [11C]155c 
 
We also conducted microPET imaging with no-carrier added [11C]155c to not only 
produce a dose of higher specific activity, but to explore the role of cold mass in the final 
product and in vivo kinetics compared to the carrier-added synthesis. as well as blood 
stability of the carrier-added prepared compound. It should be noted that RCYs with 
carrier are traditionally higher than without carrier, and was apparent in this synthesis as 
well. Carrier-added synthesis produced activities around 3 mCi, while non-carrier 
products were regularly under 1 mCi.  
 Synthesis of [11C]155c was performed as previously described, ROI’s drawn for 
whole brain, and TACs generated. The in vivo behavior of the non-carrier added 
radiolabeled compound was as expected for a brain tracer with good uptake and washout 
in the whole brain (raw TAC: Figure 4- 35, adjusted to SUV: Figure 4- 36, PET: Figure 4- 
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37). While this behavior is desired, the non-carrier synthesis suffered with poor yields, 
regularly under 1 mCi.  
 
Whole Brain TAC 1093 Whole Brain TAC 1101 
  
Figure 4- 35 Raw Whole Brain TACs for Non-Carrier Added Syntheses 
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Figure 4- 36 NCA Adjusted to SUV 
 
microPET imaging, Non-Carrier-Added, Rat 1093 
 
Figure 4- 37 microPET, NCA Rat 1101 
 
 Given the restricted expression of the dopamine D3 receptors in the brain, and 
resolution of PET, these regions cannot readily be identified in rodents. In order to 
thoroughly explore this potential radiotracer, target engagement and binding with 
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pharmacological agents and amphetamine challenge to stimulate endogenous dopamine 
release, non-human primate imaging in necessary. However, the low yields of the 
radiochemical syntheses are such that further in vivo studies in non-human primates are 
not currently feasible. Since >1 mCi of the dose is required for non-human primate 
imaging, it is necessary to further improved the radiosyntheses prior to imaging in higher 
species. This work extends beyond the scope of this thesis. 
Given the clear discrepancy of in vivo behavior of these two compounds prepared 
with and without carrier, we sought to understand this by exploring the stability of 
[11C]155c in human and rat blood. 
 
x. [11C]155c Stability Studies 
 
1. General Methods 
 
The stability of [11C]155c was examined in female rat and female human plasma. 
Blood was collected up to three days prior to radiosynthesis; heparin was added and the 
blood stored at 8oC, in the refrigerator, if it was not used same-day. Carrier-added 
[11C]155c was synthesized as described above, and delivered in 10% ethanol/saline. 
Whole human blood (with heparin) was centrifuged at 1000xg (later experiments at 
7500rpm) for 5 min, and the plasma/supernatant was transferred to a separate tube. 
[11C]155c (100 μL) was added to 50 μL of plasma. stirred and incubated at RT for 5, 15 
and 30min. After incubation, 50 μL samples were removed, diluted with 50 μL of EtOH 
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and mixed. This mixture was centrifuged for an additional 2 min and the supernatant was 
analyzed by radioTLC (silica TLC plates eluted with 10% MeOH/EtOAc). 
 
2. Results & Discussion 
 
RadioTLC was the chosen method for most of these stability studies, given the 
short half life of carbon-11 (20 minutes) and multiple incubation/extraction steps in the 
blood plasma. Several TLC plates could be run and analyzed back-to-back in a shorter 
time frame compared to a single HPLC run of 15 min (nearly 1 half life). The TLC plate 
could then be exposed on film for phosphorimaging. In this way, we wanted to be able to 
visualize the initial dose, co-spot, and product after incubation in blood at the same time. 
To that end, [11C]155c was prepared as before, but kept in semi-preparative HPLC 
buffer due to low activity (60% MeCN, 20 mM ammonium acetate, 2 mL HOAc). Roughly 
1 mL of human and 1 mL rat blood was processed separately as follows: 172 μCi was 
delivered and 400-500 μl added to each blood sample (66.3 μCi and 24.7 μCi decay 
corrected to human and rat) and incubated for 10 minutes. These were centrifuged 7500 
RPM for 5 minutes. The pellet (P) and supernatant (S) were isolated. Shuman 21.2 μCi and 
Phuman 15.7 μCi; and Srat 17.5 μCi and Prat 9.5 μCi (decay corrected). To the supernatant 
was added 500 μl absolute ethanol, sample was mixed thoroughly, then centrifuged 
14,000 RPM for 5 min. The supernatant (S) and pellet (P) were isolated again and the 
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supernatant used for radioTLC analysis. Shuman 27.2 μCi and Phuman 6.7 μCi; and similarly 
for rat: Srat 21.6 μCi and Prat 6.7 μCi (decay corrected).  
 
Phosphorimaging, of [11C]155c 
stability in human or rat blood 
 
10% MeOH/EtOAc 
S = dose 
C = co-spot 
P = product after incubation in blood 
Figure 4- 38 Phosphorimaging of [11C]X stability in Human and Rat blood 
 
 While there appears to be a new product, across human and rat, the co-spot 
indicates a mere shift in the retention factor, and no actual breakdown in product (Figure 
4- 38). We sought to explore the stability further with HPLC. A breakdown product was 
never obtained, as low activity in initial synthesis, and following blood incubation or after 
circulating in vivo, extraction, and injection on HPLC severely limited our detection. 
Isolation and identification of the breakdown product was not identified.  
 Further exploration and final investigation of dose stability in solution was explored 
on HPLC. [11C]155c was prepared as before, aliquots taken in (1) semi-preparative HPLC 
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buffer, (2) 100% EtOH, (3) ethanolic saline and analyzed via analytical HPLC. 
Degradation of the parent compound under these conditions was not seen on HPLC  
In conclusion, NCA [11C]155c deserves further exploration as its possible utility a 
a D3 radiotracer. There is a clear difference in uptake between NCA and CA syntheses, 
as there appears to be increased uptake in the thyroid or lymphatic glands, but good brain 
penetrance. While the TAC of the CA tracer provides what we initially suspected was 
evidence of metabolism, we were unable to isolate a metabolite for HPLC (during plasma 
stability studies) and, in contrast to initial radioTLC data, later radioTLC plasma stability 
studies reproducibly confirms that [11C]155c is stable in plasma (also confirmed in HPLC: 
in semi-preparative HPLC buffer, ethanol, ethanolic/saline; please see methods from 
page 266). Therefore future efforts will optimize the radiosynthesis of [11C]155c so that 
additional in vivo evaluation in non-human primates can be undertaken. 
 
xi. Nucleophilic F-18 Fluorination of other Prospective D3 selective 
compounds 
 
 Other prospective dopamine D3 receptor compounds were pursued and a selection 
of these will be discussed here. In the naphthylamide class, 157  and 158, was designed 
to explore the SAR at this receptor. Indeed, while selectivity at the receptor was later 
found to be poor (Table 4- 13), initial labeling by nucleophilic F-18 fluorination was 
explored with standard F-18 preparation in K222/K2CO3, as well as TEA-HCO3 (Table 4- 
14Scheme 4- 28).  
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Scheme 4- 28 F-18 Fluorination of 157c 
 
 A brief screen of conditions, from F-18 fluoride prep, to precursor amount, 
temperature, and time was performed manually. Initial attempts utilized standard F-18 
fluorination conditions for halex exchange at the pyridine ring, utilizing DMF, Kryptofix-
222, and potassium carbonate at 100oC and 120oC for 20 min. While Entry 2 appeared 
promising (Table 4- 14) via HPLC, it was not easily reproduced. A different fluoride 
preparation with TEA-HCO3 was pursued as it has good success in our lab with halex and 
isotopic exchange. With that, modest yields were obtained at 4 and 5% RCC manually 
(Entry 8-9) which surpassed the modest <2% RCC in the standard F-18 preparation 
(Entry 4-5). While this compound can be labeled, given the preliminary in vitro studies 
and more selective compounds identified, this potential tracer will not be pursued further. 
  
Table 4- 14 Preliminary F-18 Fluorination of 157c to give [18F]158c 
Entry RCC (%) Precursor Solvent Prep T (
o
C) Time Notes Analysis  
(crude rxn mix) 
1 X* 2 mg 1 mL DMF K
222
, K
2
CO
3
 100 20 min Manual HPLC 
2 74** 2 mg 1 mL DMF K
222
, K
2
CO
3
 120 20 min Manual, broad peak HPLC 
3 1 2 mg 1 mL DMF K
222
, K
2
CO
3
 120 20 min Manual radioTLC 
4 1.4 2 mg 1 mL DMF K
222
, K
2
CO
3
 120 20 min Manual radioTLC 
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5 1.6 2 mg 1 mL DMF K
222
, K
2
CO
3
 120 20 min Manual radioTLC 
6 x 1 mg 1 mL DMSO TEA-HCO
3
 170 20 min Manual radioTLC 
7 x 1 mg 1 mL DMSO TEA-HCO
3
 140 20 min Manual radioTLC 
8 4.11 1 mg 1 mL DMF TEA-HCO
3
 120 20 min Manual radioTLC 
9 5 1 mg 1 mL DMF TEA-HCO
3
 120 40 min Manual radioTLC 
*malfunctioning hotplate, unlikely to be at 100oC 
**Non-reproducible 
1 mL solvent volume 
 
xii. Conclusions and Future Considerations 
 
 The original goals of this project were to synthesize and evaluate potential PET 
radioligands selective for the dopamine D3 receptor. The original set of pramipexole-
containing compounds proved to be difficult to not only synthesize, but stability issues in 
radiolabeling caused other scaffolds to be explored. The BP897 derived naphthylamide 
compounds, including preliminary microPET and evaluation of NCA [11C]155c show 
promise as potential PET radioligands at the D3 receptor. The CA TAC could be the result 
of a miss injection such that, instead of a bolus injection (such as the NCA TAC), the dose 
could have been injected subcutaneously and not intravenously, which would cause 
activity to slowly acquire (resembling an infusion, instead of a bolus injection), as we see 
in the TAC. Even so, stability of [11C]155c was explored in blood plasma using 
phosphorescence imaging and HPLC, which also suggest the compound to be stable 
(please see methods for HPLC traces of stability studies). Predicted metabolism of 
[11C]155c does not suggest a brain penetrant metabolite, At this time, the differences in 
the CA and NCA images are unexplainable and require further investigation. With that, 
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the NCA [11C]155c would be better pursued as a [18F]CF3-substituted tracer (163, Figure 
4- 39). This would benefit from longer half life and prospective improved yields by 
negating the need for a water-sensitive organometallic reagent. 
 With regard to in vivo behavior, these radiolabeled compounds would be best 
evaluated in non-human primates through microPET imaging. Due to resolution 
limitations of imaging techniques, non-human primates as opposed to rodents will allow 
for identification of specific brain regions specific to D3 receptors: this includes the globus 
pallidus, substantia nigra/ventral tegmental areas and the thalamus. In addition, it is 
known that differences among species regarding the distribution of D3 receptors, brain 
permeability and subsequent radioligand metabolism varies and may result in misleading 
conclusions and for this reason, young mature female rhesus monkeys would be ideal. 
Baseline imaging studies will provide tissue time-radioactivity data for brain uptake/efflux 
determination and concurrent blood samples will be drawn at various time points during 
scan to determine radioligand metabolism. 
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Figure 4- 39 Prospective D3 PET Radioligands that require further evaluation 
 
 Target engagement through the use of pharmacological blocking studies would be 
possible through the use of previously reported selective for the dopamine D2 or D3 
receptor. Specific binding and non-specific binding of the radioligands will be assessed 
through procedures previously reported.212 More specifically, microPET imaging will be 
utilized alongside chemical blockade via SB-277011, a selective D3 antagonist, as well 
as SV-156, a compound with no intrinsic activity but with 40-fold selectivity at the D2 
receptor, alongside the fluorine-18 radioligands (Figure 4- 39). 
 Furthermore, microPET imaging in non-human primates to determine radioligand 
sensitivity to endogenous dopamine would provide further information on the in vivo 
behavior of these compounds. Behavioral manipulations95,188,259–261 and pharmacological 
treatment31,174,260,262,263 have been shown to produce a reduction in radioligand binding to 
dopamine D2/3 receptors when measured with PET (or SPECT). Interestingly, 
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amphetamine administration to patients with schizophrenia results in even greater 
reductions in D2 preferring antagonist [11C]raclopride binding.165,264–267  
As a result, fluctuations or changes in synaptic dopamine as a way to deduce 
changes in dopamine levels in the human brain can understood by measuring changes 
in radioligand binding. However, since these studies have proceeded with D2 or mixed 
D2/3 radioligands, a D3-selective radioligand is desirable. If shown to be sensitive to 
endogenous dopamine level fluctuations, the functional status or the D3 receptor may be 
better understood. MicroPET imaging following administration of amphetamine will be 
performed as previously described267 with the expectation of reduced radioligand binding 
due to competition from endogenous dopamine at the receptor. 
 
 
271 
 
xiii. Experimental Methods, Considerations, and Supporting Data 
 
1. Methods: Ligand Binding 
 
 D3 Receptor Saturation 
 Tissue sections were preincubated for five minutes in PBS, pH 7.4 at 25° C or 
50mM Tris-HCl, pH 8.0, 50mM NaCl, 30mM EDTA at room temperature.  The slides for 
total binding were then incubated in 5 - 60nM [3H]R-(+)-7-OH-DPAT (American 
Radiochemical, Inc) in the above buffer for 15 minutes at room temperature. 10µM 
Pramipexole was added and an adjacent slide was incubated to define non-specific 
binding. Sections were washed twice for a total of two minutes in ice cold buffer then 
rinsed briefly in distilled water. Sections were air-dried before opposing to tritium sensitive 
phosphoimaging screen for three to five days.   
 
 D3 Receptor Displacement 
 Tissue sections were preincubated for five minutes in PBS, pH 7.4 at 25° C or 
50mM Tris-HCl, pH 8.0 (± 150mM NaCl) at room temperature. Slides were then incubated 
in 35nM [3H]R-(+)-7-OH-DPAT (American Radiochemical, Inc) with no addition (total 
binding) or various concentrations (300nM to 1mM, f.c.) of competing compound in the 
above buffer for 15 minutes at room temperature.  10µM Pramipexole was added and an 
adjacent slide was incubated to define non-specific binding. Sections were washed twice 
for a total of two minutes in ice cold buffer then rinsed briefly in distilled water.  Sections 
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were air-dried before opposing to tritium sensitive phosphoimaging screen for three to 
five days.   
 
D2 Receptor Saturation 
 Tissue sections were preincubated for five minutes in PBS, pH 7.4 at 25° C or 
50mM Tris-HCl, pH 8.0, 50mM NaCl, 30mM EDTA at room temperature.  The slides for 
total binding were then incubated in 0.5 - 50nM [3H]Spiperone (American Radiochemical, 
Inc) in the above buffer for 30 minutes at room temperature.  10µM (+)Butaclamol was 
added and an adjacent slide was incubated to define non-specific binding.  Sections were 
washed twice for a total of four minutes in ice cold buffer then rinsed briefly in distilled 
water. Sections were air-dried before opposing to tritium sensitive phosphoimaging 
screen for three to five days.   
 
 D2 Receptor Displacement 
 Tissue sections were preincubated for five minutes in PBS, pH 7.4 at 25° C or 
50mM Tris-HCl, pH 8.0 (± 150mM NaCl) at room temperature. Slides were then incubated 
in 5nM [3H]Spiperone (American Radiochemical, Inc) with no addition (total binding) or 
various concentrations (300nM to 1mM, f.c.) of competing compound in the above buffer 
for 30 minutes at room temperature. 10µM (+)Butaclamol was added and an adjacent 
slide was incubated to define non-specific binding.  Sections were washed twice for a 
total of four minutes in ice cold buffer then rinsed briefly in distilled water.  Sections were 
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air-dried before opposing to tritium sensitive phosphoimaging screen for three to five 
days.   
 
2. Densitometry 
 Calibrated plastic radioactive standards were included with tissue sections to 
correct for variations in exposure. After development (Fuji Typhoon FLA 7000), images 
were analyzed with ImageQuant software (Fuji).  Phosphoimager units were converted to 
femtomoles on the basis of image densities overlying the radioactive standards and the 
specific activity of the radioligand.  
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3. Competition Curves 
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4. Additional Methods: Human/Rat Plasma Stability Studies 
RadioTLC was performed in 20% MeOH/EtOAc with 0.5 μl of dose, 0.5 μl dose in 
human/rat blood, or 0.5 μl dose and 1.0 μl dose/blood co spot. These were spotted and 
LC performed as described, then exposed on film for 5-10 min before phosphorimaging. 
 
158c 
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5. Chemistry 
a.  Experimental Procedures 
 
 
tert-butyl 4-(4-iodophenyl)piperazine-1-carboxylate (131). This product was prepared 
as previously described.231 The product was purified on SiO2 in EtOAc/hexanes to give 
11.76 g (70%) over two steps. Rf 0.5 (20% EtOAc/hexanes). The 1H NMR was the same 
as previously described.231 
 
tert-butyl 4-(3'-methoxy-[1,1'-biphenyl]-4-yl)piperazine-1-carboxylate (132). This 
product was prepared as previously described The product was purified on SiO2 by 
column chromatography in EtOAc/hexanes in 1.1 g (47%). Rf 0.36 (20% EtOAc/hexanes). 
The 1H NMR was the same as previously described.231 
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1-(3'-methoxy-[1,1'-biphenyl]-4-yl)piperazine (164). This product was prepared as 
previously described. The product was obtained 0.413 g (90%). The 1H NMR was the 
same as previously described.231 
 
 
 
1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-(3'-methoxy-[1,1'-biphenyl]-4-
yl)piperazine (133).231 This product was prepared as previously described. The product 
was purified on SiO2 by column chromatography in EtOAc/hexanes to afford the final 
product, 0.617 g (72%). Rf 0.18 in (20% EtOAc/hexanes). The 1H NMR was the same as 
previously described.231 
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2-(4-(3′-Methoxybiphenyl-4-yl)piperazin-1-yl)ethanol (134).This product was prepared 
as previously described. The product was purified on SiO2  by column chromatography in 
EtOAc/hexanes in 0.431 g (64%). Rf 0.67 (20% MeOH/DCM). The 1H NMR was the same 
as previously described.231 
 
2-(4-(3′-Methoxybiphenyl-4-yl)piperazin-1-yl)- acetaldehyde (165). This product was 
prepared as previously described.231 It was used without further purification to the next 
step. It was monitored via IR for peak appearance at ~2900 C=O, and peak 
disappearance at ~3250-3300 O-H to suggest aldehyde formation. The product was 
obtained 0.236 g (95%). Rf 0.83 ((20% MeOH/DCM). 
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 (S)-N6-(2-(4-(3'-methoxy-[1,1'-biphenyl]-4-yl)piperazin-1-yl)ethyl)-N6-propyl-
4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (135). This product was prepared as 
previously described.231 The product was purified on SiO2 by column chromatography in 
EtOAc/hexanes to afford the final product, 0.195 g (35%). Rf 0.24 (20% MeOH/EtOAc). 
The 1H NMR was the same as previously described.231 HPLC: Waters-Spherisorb 5μ-C8, 
4.6x150mm, 35% 20mM NH4OAc: 65% MeCN, 2mL HOAc, 1.5 mL/min, 30oC: Rt  8.3 min. 
Beckman Coulter – Ultrasphere 5μ-RP-C18, 10mm x 25 cm, 35% 20mM NH4OAc: 65% 
MeCN, 2mL HOAc, 3 mL/min, 30oC: Rt  8.02 min. 
 
1-(4-iodophenyl)piperazine (166). This product was prepared as previously 
described.231 The product was obtained in 17.6 g (46%). Rf 0.04 (1:1 EtOAc/hexanes). It 
was used without further purification to the next step. 
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1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-(4-iodophenyl)piperazine (136). A mixture 
of compound (166) (0.2 g, 0.7 mmol), (2-bromo-ethyl)-tert-butyldimethylsilane (0.411 g, 
1.4 mmol), K2CO3 (0.3 g, 2.1 mmol) in CH3CN (2.3 mL) was refluxed for 14 h. Acetonitrile 
was evaporated under vacuo and the crude material was purified on silica by column 
chromatography (hexanes/EtOAc) to afford the solid product 0.135 g (43%). Rf 0.54 (1:1 
EtOAc/hexanes). 1H NMR (400 MHz, Chloroform-d) δ 7.53 – 7.46 (m, 1H), 7.29 – 7.23 
(m, 0H), 6.96 – 6.81 (m, 1H), 6.70 – 6.63 (m, 1H), 3.84 – 3.74 (m, 2H), 3.23 – 3.12 (m, 
3H), 2.73 – 2.63 (m, 3H), 2.63 – 2.53 (m, 2H), 0.90 (d, J = 1.6 Hz, 10H), 0.11 – 0.04 (m, 
7H); 13C NMR (101 MHz, Chloroform-d) δ 150.89, 137.95, 137.45, 118.05, 117.81, 81.21, 
61.36, 60.49, 53.87, 53.62, 48.89 (d, J = 45.0 Hz), 26.06, 25.71 (d, J = 24.1 Hz), -5.21. 
HRMS (ESI) m/z: [M+H]+ calc for C18H31IN2OSi, 447.1323; found 447.1323. 
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1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-(3'-(methoxymethoxy)-[1,1'-biphenyl]-4-
yl)piperazine (137). A suspension of (136) 2.23 g (5 mmol) and commercially avilable [3-
(methoxymethoxy)phenyl]-boronic acid (1 g 5.5 mmol), Na2CO3 (5 mL, 10mmol,  of 2M 
aqueous solution), Pd(PPh3)4 (0.433 mg, 0.375 mmol), in dimethoxy ethane/ethanol (7 
mL: 7 mL) was refluxed 3-4 hours. The solvents were removed in vacuo, the palladium 
removed via fritted funnel filtration with SiO2, and the crude product was concentrated. 
The product was purified on SiO2 by column chromatography in hexanes/EtOAc. The 
product was obtained 1.28 g (45%). Rf 0.67 (20% EtOAc/hexanes). 1H NMR was taken 
in Chloroform and K2CO3 to ensure intact MOM protecting group. 1H NMR (400 MHz, 
Chloroform-d) δ 7.54 – 7.48 (m, 2H), 7.32 (t, J = 7.9 Hz, 1H), 7.27 – 7.18 (m, 3H), 7.01 – 
6.93 (m, 3H), 5.22 (s, 2H), 3.82 (t, J = 6.3 Hz, 2H), 3.51 (s, 3H), 3.29 – 3.23 (m, 4H), 2.75 
– 2.69 (m, 4H), 2.61 (t, J = 6.3 Hz, 2H), 0.91 (s, 9H), 0.08 (s, 6H). HRMS (ESI) m/z: 
[M+H]+ calc for C26H40N2O3Si, 457.2881; found 457.2884.  
 
2-(4-(3'-(methoxymethoxy)-[1,1'-biphenyl]-4-yl)piperazin-1-yl)ethan-1-ol (138). In to 
a stirring solution of (137) (0.5 g, 1mmol) in anhydrous THF (8 mL), n-
tetrabutylammonium fluoride (1.1 mL, 1 M solution in THF) was added at 0oC. The 
reaction mixture stirred for 1.5 hours at room temperature. THF was removed in vauo and 
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the crude reaction mixture was washed with water (15 mL) and extracted with methylene 
chloride (3 x 50 mL). The organic layer was washed with brine and dried over Na2SO4. 
The product was purified 2x on SiO2 in EtOAc, then MeOH/DCM. TBAF proved 
challenging to remove, 0.519 g was recovered as a dark amber oil, and part was carried 
forward to the next step. Rf 0.18 (1:1 EtOAc/DCM). 1H NMR (400 MHz, Chloroform-d) δ 
7.52 – 7.42 (m, 3H), 7.34 – 7.16 (m, 4H), 7.05 (d, J = 8.4 Hz, 1H), 6.98 – 6.91 (m, 2H), 
5.21 (s, 1H), 5.19 – 5.14 (m, 2H), 3.49 (s, 1H), 3.45 (s, 3H), 3.35 (t, J = 5.0 Hz, 3H), 3.18 
– 3.09 (m, 4H), 2.99 – 2.74 (m, 3H). 
 
2-(4-(3'-(methoxymethoxy)-[1,1'-biphenyl]-4-yl)piperazin-1-yl)ethyl 4-
methylbenzenesulfonate (167). At 0oC, a solution of (138) (0.2 g, 0.58 mmol), DCM 
(1mL) and triethyl amine (0.147 g, 1.45 mmol) was added p-toluene sulfonyl chloride 
(0.166 g, 0.87 mmol) and stirred 12 h. The crude mixture was washed with water (20 mL) 
and extracted with methylene chloride (3 x 75 mL). To remove TBAF from the previous 
reaction, it was washed with Et2O/H2O 1:1 and NH4Cl 5 times and dried over Na2SO4. 
The product was purified on silica plug, 0.19 g (66%). This was used directly in the next 
step. Rf 0.48 (1:1 EtOAc/hexanes), Rf 0.72 (DCM).  
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(S)-N6-(2-(4-(3'-(methoxymethoxy)-[1,1'-biphenyl]-4-yl)piperazin-1-yl)ethyl)-N6-
propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (139). In a stirring solution of 
tosylate (167) (0.190 g, 0.38 mmol) in methylene chloride (0.8 mL) was slowly added a 
solution of (S)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (0.161 g, 0.76 
mmol) and N,N-Diisopropylethylamine (0.246 g, 1.9 mmol). This was stirred at room temp 
for 14 h. The reaction mixture was extracted with methylene chloride (3 x 75 mL), washed 
with brine, dried over Na2SO4 and concentrated. The product was purified on SiO2 by 
column chromatography in Methanol/DCM to provide the product in 70% yield. 1H NMR 
(400 MHz, Chloroform-d) δ 7.52 (dd, J = 13.0, 7.8 Hz, 2H), 7.32 (dd, J = 15.5, 7.5 Hz, 
2H), 7.24 – 7.17 (m, 2H), 7.12 (t, J = 8.1 Hz, 1H), 6.98 (d, J = 6.0 Hz, 1H), 6.62 – 6.56 
(m, 1H), 6.50 (d, J = 8.4 Hz, 1H), 5.14 (s, 2H), 3.49 (d, J = 5.6 Hz, 3H), 3.47 (d, J = 0.9 
Hz, 4H), 3.38 – 3.09 (m, 8H), 2.70 (d, J = 6.6 Hz, 3H), 2.42 (d, J = 8.8 Hz, 2H), 1.25 (s, 
4H), 1.02 (t, J = 7.3 Hz, 2H), 0.89 (s, 3H).HRMS (ESI) m/z: [M+H]+ calc for 
C30H41N5O2S, 536.3054; found 536.3044. Rf 0.16 (20% MeOH/DCM).   
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(S)-4'-(4-(2-((2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-
yl)(propyl)amino)ethyl)piperazin-1-yl)-[1,1'-biphenyl]-3-ol (128). Compound (139) 
(0.05 g, 0.09 mmol) in Methanol (250 μl) was added a trace amount of concentrated HCl 
(3 drops), sealed and refluxed overnight. Reaction was neutralized with 1M KOH (1 mL), 
and extracted with methylene chloride (3 x 10 mL), and dried over Na2SO4. The product 
was purified on SiO2 by column chromatography in Methanol/DCM. Product was obtained 
in 0.032 g (77%). Rf 0.03 (20% MeOH/DCM). HRMS (ESI) m/z: [M+H]+ calc for 
C28H37N5OS, 492.2792; found 492.2786. HPLC: Waters-Spherisorb 5μ-C8, 
4.6x150mm, 35% 20mM NH4OAc: 65% MeCN, 2mL HOAc, 1.5 mL/min, 30oC: Rt  2.24 
min. Beckman Coulter – Ultrasphere 5μ-RP-C18, 10mm x 25 cm, 35% 20mM NH4OAc: 
65% MeCN, 2mL HOAc, 3 mL/min, 30oC: Rt  3.67 min. 1H NMR (400 MHz, Chloroform-d) 
δ 7.78 (d, J = 8.0 Hz, 2H), δ 7.52 (dd, J = 13.0, 7.8 Hz, 2H), 7.32 (dd, J = 15.5, 7.5 Hz, 
2H), 7.12 (t, J = 8.1 Hz, 2H), 3.33 – 3.25 (m, 2H), 2.98 (dtd, J = 10.0, 5.2, 2.5 Hz, 4H), 
2.85 (ddt, J = 15.4, 5.3, 1.4 Hz, 4H), 2.60 – 2.49 (m, 5H), 2.39 (dddd, J = 15.4, 8.4, 2.8, 
1.8 Hz, 5H), 2.31 (s, 1H), 2.00 (q, J = 3.4, 2.5 Hz, 2H), 1.71 – 1.62 (m, 5H), 0.98 (t, J = 
7.3 Hz, 3H).  
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tert-butyl 4-(3'-fluoro-[1,1'-biphenyl]-4-yl)piperazine-1-carboxylate (142). A 
suspension of commercially available (3-fluorophenyl)boronic acid (1 eq), iodo compound 
(131) (1 eq), Na2CO3 (2 eq, 2M solution in water), and Pd(PPh3)4 (0.05 -0.075 eq) in 
dimethoxy ethane/ethanol (1:1) was refluxed for 1-4 hr. The solvents were removed in 
vacuo. The product was purified on SiO2 by column chromatography in hexanes/ethyl 
acetate and the crude product was purified by flash chromatography using 
hexanes/EtOAC. to yield compound (X) (30%).1H NMR (500 MHz, Chloroform-d) δ 7.51 
(d, J = 8.8 Hz, 2H), 7.36 (dt, J = 13.9, 7.9 Hz, 2H), 7.30 – 7.23 (m, 2H), 7.02 – 6.97 (m, 
2H), 3.64 – 3.58 (m, 4H), 3.25 – 3.17 (m, 4H), 1.50 (s, 9H). 19F NMR (470 MHz, 
Chloroform-d) δ -113.38 (td, J = 9.3, 5.3 Hz). HRMS (ESI) m/z: [M+H]+ calc for 
C21H25FN2O2, 357.1973; found 357.1973.  
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1-(3'-fluoro-[1,1'-biphenyl]-4-yl)piperazine (168) 1-(3′-fluoro-biphenyl-4-yl)piperazine 
(10). Into a stirring solution of compound 142 (1eq) in CH2Cl2 (0.4mmol/mL) and 
triethylsilane (1eq), TFA (28eq) was added slowly at room temperature, and the reaction 
mixture was stirred for 4 h. Unreacted TFA and solvent CH2Cl2 were removed in vacuo, 
and the salt formed was washed with diethyl ether. Saturated solution of sodium 
bicarbonate was added to the salt, and it was extracted with dichloromethane (3x). The 
combined organic layer was dried over Na2SO4, filtered, and evaporated in vacuo to 
provide the compound 10 (%). Rf 0.2 (1:1 EtOAc/hexanes). HRMS (ESI) m/z: [M+H]+ calc 
for C16H17FN2, 257.1449; found 257.1449. 1H NMR (500 MHz, Chloroform-d) δ 7.51 (d, 
J = 8.7 Hz, 1H), 7.39 – 7.22 (m, 3H), 6.99 (d, J = 8.9 Hz, 2H), 6.94 (d, J = 8.3 Hz, 2H), 
3.29 (dd, J = 6.6, 3.5 Hz, 4H), 3.20 (dd, J = 6.4, 3.8 Hz, 4H).13C NMR (126 MHz, 
Chloroform-d) δ 150.90, 129.26, 127.81, 120.79, 116.74, 116.52, 113.37, 48.75, 44.93, 
44.76. 13C NMR (101 MHz, Chloroform-d) δ 164.45, 162.01, 151.40, 143.20, 130.74, 
130.08 (d, J = 8.6 Hz), 127.68, 122.00, 115.97, 49.94, 46.05. 19F NMR (376 MHz, 
Chloroform-d) δ -113.41. 
 
1-(2-chloroethyl)-4-(3'-fluoro-[1,1'-biphenyl]-4-yl)piperazine (143). At 0oC, (168) (0.07 
mg, 0.27 mmol), K2CO3 (0.075 g, 0.54 mmol), in acetonitrile (0.75 mL) was added 1-
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bromo-2-chloroethane (0.043 g, 0.3 mmol). Reaction was monitored hourly via TLC for 
consumption of starting material and stirred at room temperature for 2 hours. Rf 0.7 (1:1 
EtOAc/hexanes). This product was not isolated and used directly in next step.  
 
(S)-N6-(2-(4-(3'-fluoro-[1,1'-biphenyl]-4-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-
tetrahydrobenzo[d]thiazole-2,6-diamine (144). To reaction mixture (143) was added 
(S)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (0.085 mg, 0.4 mmol) at 
room temperature and stirred 48 hours. Product was washed with water and extracted 
with methylene chloride (3 x 20 mL) and dried over sodium sulfate. It was purified over 
silica by column chromatography in methanol/EtOAc to afford the final product in 31% 
over two steps. Rf 0.2 (10% MeOH/EtOAc). HRMS (ESI) m/z: [M+H]+ calc for 
C28H36FN5S, 494.2748; found 494.2751 and 494.2745. 1H NMR (400 MHz, Chloroform-
d) δ 7.49 (d, J = 8.8 Hz, 2H), 7.38 – 7.30 (m, 2H), 7.26 (t, J = 1.7 Hz, 1H), 7.22 (d, J = 1.9 
Hz, 1H), 6.97 (dt, J = 7.4, 2.6 Hz, 4H), 3.26 (t, J = 5.1 Hz, 5H), 3.05 (d, J = 4.7 Hz, 1H), 
2.69 (dt, J = 14.0, 5.8 Hz, 9H), 2.61 – 2.44 (m, 6H), 2.07 – 1.96 (m, 2H), 1.77 – 1.65 (m, 
1H), 1.48 (h, J = 7.3 Hz, 2H), 1.26 (t, J = 7.1 Hz, 1H), 0.89 (t, J = 7.3 Hz, 3H). 13C NMR 
(101 MHz, Chloroform-d) δ 165.49, 150.90, 145.00, 130.08, 130.00, 127.67, 121.98, 
117.41, 115.86, 113.27, 113.05, 74.80, 58.68, 58.09, 53.66, 53.56, 48.67, 48.40, 41.55, 
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26.52, 25.84, 25.15, 22.36, 11.82. 19F NMR (376 MHz, Chloroform-d) δ -113.30 – -
113.54 (m). 
 
 
tert-butyl 4-(3'-bromo-[1,1'-biphenyl]-4-yl)piperazine-1-carboxylate (148). A 
suspension of commercially available (3-bromophenyl)boronic acid (0.142 g, 0.71 mmol), 
iodo compound (131) (0.25 g, 0.64 mmol), Na2CO3 (0.64 mL of 2M solution in water, 
0.032 mmol), and Pd(PPh3)4 (0.05 -0.075 eq, 0.037 g, 0.032 mmol) in dimethoxy 
ethane/ethanol (1:1, 2mL) was refluxed for 1-4 hr. The solvents were removed in vacuo. 
the palladium removed via fritted funnel filtration with SiO2, and the crude product was 
concentrated. The product was purified on SiO2 by column chromatography in 
hexanes/EtOAc to yield compound (X) (50%). Rf 0.46 (20% EtOAc/hexanes). HRMS 
(ESI) m/z: [M+H]+ calc for C21H25BrN2O2, 417.1172; found 417.1156. 1H NMR (400 
MHz, Chloroform-d) δ 7.69 (t, J = 1.8 Hz, 2H), 7.48 (dd, J = 8.2, 6.3 Hz, 3H), 7.42 – 7.38 
(m, 1H), 6.98 (d, J = 8.7 Hz, 2H), 3.60 (t, J = 5.2 Hz, 4H), 3.20 (d, J = 5.4 Hz, 4H), 1.49 
(s, 9H).  
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1-(4-(3'-bromo-[1,1'-biphenyl]-4-yl)piperazin-1-yl)-2-chloroethan-1-one (149). Into a 
stirring solution of compound  (148) (0.13 g, 0.31 mmol)) in CH2Cl2 (1 mL) and 
triethylsilane (0.31 mmol), TFA (0.66 mL, 8.7 mmol) was added slowly at room 
temperature, and the reaction mixture was stirred for 4 h. Unreacted TFA and solvent 
CH2Cl2 were removed in vacuo, and the salt formed was washed with diethyl ether. 
Saturated solution of sodium bicarbonate was added to the salt, and it was extracted with 
dichloromethane (3 x 75 mL). The combined organic layer was dried over Na2SO4, 
filtered, and evaporated in vacuo to provide the compound X (0.103 g, 99%). HRMS (ESI) 
m/z: [M+H]+ calc for C18H18BrClN2O, 314.0648; found 317.0653. 1H NMR (400 MHz, 
Chloroform-d) δ 7.70 (t, J = 1.9 Hz, 1H), 7.50 – 7.45 (m, 3H), 7.40 (ddd, J = 8.0, 2.0, 1.1 
Hz, 1H), 7.27 (d, J = 7.8 Hz, 1H), 7.01 – 6.95 (m, 2H), 3.26 – 3.17 (m, 4H), 3.10 – 2.99 
(m, 4H). 13C NMR (101 MHz, Chloroform-d) δ 151.36, 143.00, 130.19, 129.34 (d, J = 
18.1 Hz), 127.72, 125.01, 122.85, 116.01, 49.87, 45.95. 
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1-(4-(3'-bromo-[1,1'-biphenyl]-4-yl)piperazin-1-yl)-2-chloroethan-1-one (150). Into a 
solution of (149) (0.2 g, 0.63 mmol) at 0oC, triethylamine (0.170 mL), methylene chloride 
(1 mL) was slowly added chloroacetyl chloride (0. 78 mg, 0.69 mmol). Reaction stirred 
and come to room temperature over 1 hour, then extracted with DCM (3 x 10 mL) and 
dried over Na2SO4. It was purified over SiO2 by column chromatography in 
EtOAc/hexanes to afford the final product in 0.197 g (80%). Rf 0.18 (20% 
EtOAc/hexanes). 1H NMR (400 MHz, Chloroform-d) δ 7.69 (t, J = 1.9 Hz, 1H), 7.48 (td, J 
= 8.1, 7.4, 1.7 Hz, 2H), 7.41 (ddd, J = 8.0, 2.0, 1.0 Hz, 1H), 7.33 – 7.23 (m, 1H), 7.00 – 
6.95 (m, 2H), 6.95 – 6.90 (m, 1H), 4.12 (d, J = 4.2 Hz, 2H), 3.79 (q, J = 5.5 Hz, 2H), 3.69 
(dd, J = 6.3, 4.3 Hz, 2H), 3.28 (t, J = 5.2 Hz, 2H), 3.23 (dd, J = 6.4, 3.9 Hz, 2H). 13C NMR 
(101 MHz, Chloroform-d) δ 165.14, 150.32, 142.73, 131.63, 130.26 (d, J = 2.7 Hz), 129.52 
(d, J = 4.9 Hz), 127.90, 125.10, 122.89, 116.70, 49.27, 48.87, 46.11, 41.97, 40.81. 6p59 
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(S)-N-(2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-2-(4-(3'-bromo-[1,1'-
biphenyl]-4-yl)piperazin-1-yl)-N-propylacetamide (151). In a suspension of (S)-N6-
propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (0.053 g, 0.25 mmol), K2CO3 
(0.069 g, 0.5 mmol) and catalytic potassium iodide in acetonitrile (6 mL) was added (149) 
(0.15 g, 0.38 mmol) and refluxed for 3 h. The crude reaction mixture was filtered, washed 
with EtOAc and concentrated in vacuo. The product was purified on SiO2 by column 
chromatography (EtOAc/MeOH) to give 0.053 g (70%). Rf 0.23 (95:5 EtOAc/MeOH). 
HRMS (ESI) m/z: [M+H]+ calc for C28H34BrN5OS, 568.1740; found 568.1739.  
1H NMR (400 MHz, Chloroform-d) δ 7.68 (t, J = 1.8 Hz, 1H), 7.47 (dd, J = 9.0, 7.0 Hz, 
3H), 7.42 – 7.38 (m, 1H), 7.26 (s, 2H), 6.98 (dd, J = 9.0, 2.4 Hz, 2H), 3.94 – 3.62 (m, 5H), 
3.55 (s, 2H), 3.34 – 3.10 (m, 5H), 2.70 (d, J = 20.7 Hz, 3H), 2.60 (s, 4H), 2.03 (d, J = 5.9 
Hz, 1H), 1.73-1.70 (m, 2H), 0.90 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, Chloroform-d) 
δ 169.28, 165.89, 150.52, 142.78, 137.75, 131.30, 130.22, 129.48 (d, J = 6.8 Hz), 127.81, 
125.07, 122.87, 116.40 (d, J = 16.8 Hz), 112.65, 58.26, 55.23, 52.95, 49.43, 48.90, 45.19, 
41.79, 26.12, 25.54, 24.65, 21.38, 11.85. 
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(S)-N6-(2-(4-(3'-bromo-[1,1'-biphenyl]-4-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-
tetrahydrobenzo[d]thiazole-2,6-diamine (146). In a solution of (151) (0.053 g, 0.09 
mmol) in anhydrous THF (0.7 mL) at 0oC, under argon, was slowly added borane-THF 
(0.545 mL, 1M solution). Reaction was then stirred at room temperature for 36 hours, 
then quenched with MeOH, and solvents removed in vacuo. The resultant solid was 
suspended in 6N HCl/MeOH (2 mL) and stirred for 2 h at room temperature. Methanol 
was removed in vacuo, and the pH was adjusted to alkaline with Na2CO3/NaHCO3 and 
extracted with EtOAc, then methylene chloride. The product was dried over sodium 
sulfate and purified on SiO2 by column chromatography. The desired product was isolated 
0.043 mg (68%) in MeOH/EtOAc. Rf 0.12 (10% MeOH/EtOAc). HRMS (ESI) m/z: [M+H]+ 
calc for C28H36BrN5S, 554.1948; found 554.1936. 1H NMR (400 MHz, Chloroform-d) δ 
7.68 (q, J = 1.8 Hz, 1H), 7.49 – 7.42 (m, 3H), 7.39 (ddd, J = 8.2, 2.3, 1.2 Hz, 1H), 7.25 (d, 
J = 4.6 Hz, 2H), 6.96 (dd, J = 8.9, 1.9 Hz, 2H), 3.77 – 3.58 (m, 2H), 3.28 (q, J = 7.2, 5.1 
Hz, 5H), 2.87 (s, 3H), 2.70 (t, J = 13.4 Hz, 11H), 2.04 (s, 1H), 1.89 – 1.65 (m, 2H), 0.91 
(td, J = 6.6, 5.8, 2.5 Hz, 3H). 13C NMR (101 MHz, Chloroform-d) δ 165.88, 150.71, 
144.68, 142.94, 132.30, 130.57, 130.28, 129.34, 127.71 (d, J = 16.9 Hz), 125.00 (d, J = 
16.8 Hz), 122.84, 116.18, 115.94, 58.71, 57.05, 53.45, 48.51, 47.61, 46.78, 26.32, 24.98 
(d, J = 18.0 Hz), 21.40, 11.71.  
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4-(4-phenylpiperazin-1-yl)butanenitrile (156a). 1-pheynl piperazine (0.3 g, 1.85 mmol) 
in K2CO3 (0.28 g, 2.03 mmol), cat. KI, and anhydrous acetonitrile (9.25 mL) were stirred 
for 5 min at room temperature. Then 4-bromobutyronitrie (0.3 mg, 2.03 mmol) was added, 
the flask was sealed and the reaction refluxed for 14 h. Reaction was cooled, water 
added, and the product was extracted with methylene chloride and dried over Na2SO4The 
product was characterized and used directly in next step, 0.42 g, (99%). Rf 0.72 (20% 
MeOH/EtOAc). HRMS (ESI) m/z [M+H]+ calcd for C14H19N3, 230.1652, Found, 
230.1652. 1H NMR (400 MHz, Chloroform-d) δ 7.27 (dd, J = 8.7, 7.2 Hz, 2H), 6.95 – 6.90 
(m, 2H), 6.90 – 6.84 (m, 1H), 3.21 – 3.15 (m, 4H), 2.60 – 2.54 (m, 4H), 2.48 (t, J = 6.8 Hz, 
2H), 2.40 (t, J = 7.1 Hz, 2H), 1.83 (q, J = 6.9 Hz, 2H). 13C NMR (101 MHz, Chloroform-
d) δ 151.27, 129.33, 128.94, 119.90, 116.12, 56.27, 53.09, 49.07, 22.72, 14.90.  
 
 
4-(4-phenylpiperazin-1-yl)butan-1-amine (156b). To a mixture of nitrile (156a) (0.424 
g, 1.85 mmol) in anhydrous THF (14 mL) at 0OC, under argon, was slowly added borane-
THF (11.1 mmol, 1M in THF) over 5 minutes. Reaction was let to come to room 
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temperature overnight and stirred for a total of 48 h. Mixture was cooled to 0OC and 
quenched with methanol. The product was suspended in 6 HCl/MeOH and stirred for 2 
hours at room temp, then concentrated. The pH was adjusted to alkaline with 
Na2CO3/NaHCO3, extracted with ethyl acetate and dried over Na2SO4. The product was 
purified on silica by column chromatography with 20% methanol/ethyl acetate to give 0.25 
g (58%). Rf 0.04 (20% MeOH/EtOAc). HRMS (ESI) m/z [M+H]+ calcd for C14H23N3, 
234.1965, Found, 234.1968. 1H NMR (400 MHz, Chloroform-d) δ 7.21 (t, J = 7.8 Hz, 2H), 
6.88 (d, J = 8.1 Hz, 2H), 6.80 (t, J = 7.3 Hz, 1H), 3.15 (t, J = 5.0 Hz, 4H), 2.90 – 2.75 (m, 
2H), 2.69 (t, J = 6.6 Hz, 2H), 2.55 (t, J = 5.0 Hz, 4H), 2.36 (q, J = 7.6, 6.5 Hz, 2H), 1.59 – 
1.41 (m, 4H). 13C NMR (101 MHz, Chloroform-d) δ 151.26, 129.14, 119.57, 115.91, 
58.39, 53.22, 49.05, 41.72, 31.00, 24.27.  
 
N-(4-(4-phenylpiperazin-1-yl)butyl)-2-naphthamide (156c). In dry round bottom flask 
was added amine starting material (156b) (0.15 g, 0.64 mmol), anhydrous methylene 
chloride (1.5 mL) triethylamine (0.324 g, 3.2 mmol) for 5 min. To this was added 2-
naphthoyl chloride (0.147 g, 0.77 mmol). Reaction was stirred at room temp for 1-2 hours, 
then extracted with methylene chloride (3 x 15 mL), dried over Na2SO4 and purified on 
SiO2 by column chromatography. The product was obtained 0.154 g (62%). Rf 0.3 (20% 
MeOH/EtOAc). HRMS (ESI) m/z [M+H]+ calcd for C25H29N3O, 388.2383, Found, 
388.2386. 1H NMR (400 MHz, Chloroform-d) δ 8.26 (d, J = 1.6 Hz, 1H), 7.85 (qd, J = 8.3, 
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1.9 Hz, 4H), 7.53 (dddd, J = 18.0, 8.2, 6.9, 1.4 Hz, 2H), 7.25 (dd, J = 8.7, 7.1 Hz, 2H), 
6.92 (t, J = 5.5 Hz, 1H), 6.90 – 6.82 (m, 3H), 3.54 (q, J = 6.3 Hz, 2H), 3.18 – 3.11 (m, 4H), 
2.58 (t, J = 5.0 Hz, 4H), 2.44 (t, J = 6.9 Hz, 2H), 1.77 – 1.63 (m, 4H). 13C NMR (101 MHz, 
Chloroform-d) δ 167.79, 151.21, 134.63, 132.57, 132.21, 129.12, 129.03, 128.87, 128.81, 
128.41, 127.78, 127.72, 127.52, 127.24, 126.74, 126.66, 123.73, 119.70, 116.01, 57.96, 
53.34, 53.23, 49.03, 40.09, 39.97, 27.45, 24.52.  
 
4-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)butanenitrile (155a). 1-(3-
trifluoromethyl)phenylpiperazine (0.3 g, 1.3 mmol) in K2CO3 (0.198 g, 1.43 mmol), cat. KI, 
and anhydrous acetonitrile (6.5 mL) were stirred for 5 min at room temperature. Then 4-
bromobutyronitrie (0.215 mg, 1.43 mmol) was added, the flask was sealed and the 
reaction refluxed for 14 h. Reaction was cooled, water added, and the product was 
extracted with methylene chloride and dried over Na2SO4. Rf 0.76 (20% MeOH/EtOAc). 
The product was characterized and used directly in next step, 0.42 g, (99%). HRMS (ESI) 
m/z [M+H]+ calcd for C15H18F3N3, 297.1526, Found, 298.1531. 1H NMR (400 MHz, 
Chloroform-d) δ 7.32 (t, J = 8.0 Hz, 1H), 7.09 (d, J = 2.0 Hz, 1H), 7.07 – 7.01 (m, 2H), 
3.23 – 3.17 (m, 4H), 2.59 – 2.53 (m, 4H), 2.48 (t, J = 6.7 Hz, 2H), 2.42 (t, J = 7.1 Hz, 2H), 
1.83 (q, J = 6.9 Hz, 2H). 13C NMR (101 MHz, Chloroform-d) δ 151.31, 131.41, 129.76, 
119.80, 118.83, 115.88, 112.18, 56.12, 52.80, 48.54, 22.64, 14.83. 19F NMR (376 MHz, 
Chloroform-d) δ -62.59.  
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4-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)butan-1-amine (155b). To a mixture of 
nitrile (155a) (0.386 g, 1.3 mmol) in anhydrous THF (10 mL) at 0OC, under argon, was 
slowly added borane-THF (7.8 mmol, 1M in THF) over 5 minutes. Reaction was let to 
come to room temperature overnight and stirred for a total of 48 h. Mixture was cooled to 
0OC and quenched with methanol. The product was suspended in 6 HCl/MeOH and 
stirred for 2 hours at room temp, then concentrated. The pH was adjusted to alkaline with 
Na2CO3/NaHCO3, extracted with ethyl acetate and dried over Na2SO4. The product was 
purified on silica by column chromatography with 20% methanol/ethyl acetate to give 
0.355g (72%). Rf 0.07 (20% MeOH/EtOAc). HRMS (ESI) m/z [M+H]+ calcd for 
C15H22F3N3, 301.1841, Found, 302.1841. 1H NMR (400 MHz, Chloroform-d) δ 7.24 (d, 
J = 15.7 Hz, 1H), 7.03 (s, 1H), 6.97 (t, J = 7.2 Hz, 2H), 3.44 (s, 2H), 3.14 (q, J = 8.5, 6.7 
Hz, 4H), 2.67 (t, J = 6.5 Hz, 2H), 2.50 (q, J = 7.0, 6.0 Hz, 4H), 2.31 (q, J = 6.0, 5.4 Hz, 
2H), 1.47 (th, J = 6.7, 3.4 Hz, 4H). 13C NMR (101 MHz, Chloroform-d) δ 151.28, 131.07, 
129.55, 125.65, 118.52, 115.51, 111.97, 58.20, 52.91, 48.47, 41.66, 30.50, 24.07. 19F 
NMR (376 MHz, Chloroform-d) δ -62.68.  
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N-(4-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)butyl)-2-naphthamide (155c). In dry 
round bottom flask was added amine starting material (155b) (0.15 g, 0.5 mmol), 
anhydrous methylene chloride (1 mL) triethylamine (0.253 g, 2.5 mmol) for 5 min. To this 
was added 2-naphthoyl chloride (0.0.114 g, 0.6 mmol). Reaction was stirred at room temp 
for 1-2 hours, then extracted with methylene chloride (3 x 15 mL), dried over Na2SO4 
and purified on SiO2 by column chromatography. The product was obtained 0.197 g 
(87%). Rf 0.4 (20% MeOH/EtOAc). HRMS (ESI) m/z [M+H]+ calcd for C26H28F3N3O, 
456.2257, Found, 456.2261. 1H NMR (400 MHz, Chloroform-d) δ 8.27 (d, J = 1.6 Hz, 
1H), 7.85 – 7.79 (m, 4H), 7.52 (ddd, J = 8.1, 6.8, 1.4 Hz, 1H), 7.46 (ddd, J = 8.2, 6.9, 1.3 
Hz, 1H), 7.32 (t, J = 7.9 Hz, 1H), 7.09 – 6.96 (m, 4H), 3.54 (q, J = 6.1 Hz, 2H), 3.21 (dd, 
J = 6.4, 3.8 Hz, 4H), 2.64 (dd, J = 6.2, 3.9 Hz, 4H), 2.51 (t, J = 6.8 Hz, 2H), 1.72 (dd, J = 
6.3, 3.3 Hz, 4H). 13C NMR (101 MHz, Chloroform-d) δ 167.84, 151.10, 134.60, 132.54, 
132.12, 129.63, 128.84, 128.37, 127.65, 127.28, 126.59, 123.72, 118.71, 116.02, 112.21, 
57.64, 52.72, 48.19, 39.82, 27.29, 23.93. 19F NMR (376 MHz, Chloroform-d) δ -62.68.  
 
4-(4-(3-bromophenyl)piperazin-1-yl)butanenitrile (160a). 1-(3-
bromophenyl)piperazine (0.3 g, 1.25 mmol) in K2CO3 (0.19 g, 1.38 mmol), cat. KI, and 
anhydrous acetonitrile (6.25 mL) were stirred for 5 min at room temperature. Then 4-
bromobutyronitrie (0.203 mg, 1.38 mmol) was added, the flask was sealed and the 
reaction refluxed for 14 h. Reaction was cooled, water added, and the product was 
extracted with methylene chloride and dried over Na2SO4. Rf 0.8 (20% MeOH/EtOAc). 
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The product was characterized and used directly in next step, 0.38 g (99%). HRMS (ESI) 
m/z [M+H]+ calcd for C14H18BrN3, 308.0757, Found, 308.0761, 310.0740. 1H NMR (400 
MHz, Chloroform-d) δ 7.10 (t, J = 8.1 Hz, 1H), 7.03 (t, J = 2.1 Hz, 1H), 6.95 (ddd, J = 7.8, 
1.8, 0.9 Hz, 1H), 6.82 (ddd, J = 8.4, 2.5, 0.9 Hz, 1H), 3.21 – 3.16 (m, 4H), 2.60 – 2.55 (m, 
4H), 2.51 (t, J = 6.7 Hz, 2H), 2.46 (t, J = 7.1 Hz, 2H), 1.86 (p, J = 6.9 Hz, 2H). 13C NMR 
(101 MHz, Chloroform-d) δ 152.39, 130.31, 123.21, 122.25, 119.72, 118.67, 114.34, 
56.18, 52.88, 48.64, 22.69, 14.93.  
 
4-(4-(3-bromophenyl)piperazin-1-yl)butan-1-amine (160b). To a mixture of nitrile 
(160a) (0.385 g, 1.25 mmol) in anhydrous THF (9.6 mL) at 0OC, under argon, was slowly 
added borane-THF (7.5 mmol, 1M in THF) over 5 minutes. Reaction was let to come to 
room temperature overnight and stirred for a total of 48 h. Mixture was cooled to 0OC and 
quenched with methanol. The product was suspended in 6 HCl/MeOH and stirred for 2 
hours at room temp, then concentrated. The pH was adjusted to alkaline with 
Na2CO3/NaHCO3, extracted with ethyl acetate and dried over Na2SO4. The product was 
purified on silica by column chromatography with 20% methanol/ethyl acetate to give 0.1g 
(26%). Rf 0.02 (20% MeOH/EtOAc). HRMS (ESI) m/z [M+H]+ calcd for C14H22BrN3, 
312.107, Found, 312.107, 314.1054. 1H NMR (400 MHz, Chloroform-d) δ 6.99 (d, J = 8.1 
Hz, 1H), 6.94 (t, J = 2.1 Hz, 1H), 6.85 (dd, J = 7.7, 1.8 Hz, 1H), 6.73 (dd, J = 8.3, 2.4 Hz, 
1H), 3.38 (s, 2H), 3.10 (t, J = 5.1 Hz, 4H), 2.66 (t, J = 6.5 Hz, 1H), 2.58 (h, J = 4.9, 4.2 
Hz, 1H), 2.49 (t, J = 5.2 Hz, 4H), 2.32 (dt, J = 11.7, 4.3 Hz, 2H), 1.55 – 1.41 (m, 4H), . 
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13C NMR (101 MHz, Chloroform-d) δ 152.33, 130.27, 123.12, 122.04, 118.47, 114.23, 
58.16, 52.87, 48.41, 24.13, 22.23, 18.98, 13.94.  
 
N-(4-(4-(3-bromophenyl)piperazin-1-yl)butyl)-2-naphthamide (160c). In dry round 
bottom flask was added amine starting material (160b) (0.380 g, 1.23 mmol), anhydrous 
methylene chloride (2.5 mL) triethylamine (6.15 mmol) for 5 min. To this was added 2-
naphthoyl chloride (0.0.191 g, 1.5 mmol). Reaction was stirred at room temp for 1-2 hours, 
then extracted with methylene chloride (3 x 15 mL), dried over Na2SO4 and purified on 
SiO2 by column chromatography. The product was obtained 0.28 g (49%). Rf 0.33 (10% 
MeOH/EtOAc). HRMS (ESI) m/z [M+H]+ calcd for C25H28BrN3O, 466.1489, Found, 
466.1488, 468.1470. 1H NMR (400 MHz, Chloroform-d) δ 8.26 (d, J = 1.6 Hz, 1H), 7.89 
– 7.78 (m, 4H), 7.52 (dddd, J = 17.5, 8.1, 6.8, 1.4 Hz, 2H), 6.99 – 6.88 (m, 3H), 6.79 – 
6.72 (m, 1H), 3.54 (q, J = 6.2 Hz, 2H), 3.19 – 3.09 (m, 4H), 2.60 – 2.53 (m, 4H), 2.45 (t, J 
= 6.9 Hz, 2H), 1.79 – 1.60 (m, 4H). 13C NMR (101 MHz, Chloroform-d) δ 167.82, 152.32, 
134.62, 132.54, 132.17, 130.29, 128.80, 128.42, 127.75, 127.55, 127.23, 126.75, 123.71, 
123.19, 122.23, 118.58, 114.30, 57.84, 52.93, 48.42, 40.01, 27.39, 24.33.  
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4-(4-(3-fluorophenyl)piperazin-1-yl)butanenitrile (159a). 1-(3-bromophenyl)piperazine 
(0.3 g, 1.67 mmol) in K2CO3 (0.254 g, 1.84 mmol), cat. KI, and anhydrous acetonitrile (8.4 
mL) were stirred for 5 min at room temperature. Then 4-bromobutyronitrie (0.272 mg, 
1.84 mmol) was added, the flask was sealed and the reaction refluxed for 14 h. Reaction 
was cooled, water added, and the product was extracted with methylene chloride and 
dried over Na2SO4. Rf 0.8 (20% MeOH/EtOAc). The product was characterized and used 
directly in the next step, 0.413 g (99%). HRMS (ESI) m/z [M+H]+ calcd for C14H18FN3, 
248.1588, Found, 248.1559. 1H NMR (400 MHz, Chloroform-d) δ 7.18 (td, J = 8.2, 7.0 
Hz, 1H), 6.67 (ddd, J = 8.4, 2.4, 0.9 Hz, 1H), 6.58 (dt, J = 12.4, 2.4 Hz, 1H), 6.53 (tdd, J 
= 8.2, 2.4, 0.9 Hz, 1H), 3.22 – 3.17 (m, 4H), 2.58 (dq, J = 5.4, 2.7, 2.3 Hz, 4H), 2.52 (t, J 
= 6.8 Hz, 2H), 2.46 (t, J = 7.1 Hz, 2H), 1.87 (q, J = 6.9 Hz, 2H). 13C NMR (101 MHz, 
Chloroform-d) δ 165.02, 130.06, 119.71, 111.12, 105.98, 102.77, 56.18, 52.87, 48.58, 
22.68, 14.93. 19F NMR (376 MHz, Chloroform-d) δ -112.37. 
 
4-(4-(3-fluorophenyl)piperazin-1-yl)butan-1-amine (159b) To a mixture of nitrile (159a) 
(0.413 g, 1.67 mmol) in anhydrous THF (12.8 mL) at 0OC, under argon, was slowly added 
borane-THF (10 mmol, 1M in THF) over 5 minutes. Reaction was let to come to room 
temperature overnight and stirred for a total of 48 h. Mixture was cooled to 0OC and 
quenched with methanol. The product was suspended in 6 HCl/MeOH and stirred for 2 
hours at room temp, then concentrated. The pH was adjusted to alkaline with 
Na2CO3/NaHCO3, extracted with ethyl acetate and dried over Na2SO4. The crude product 
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0.566 g (94%) was used directly in the next step. HRMS (ESI) m/z [M+H]+ calcd for 
C14H22FN3, 252.1871, Found, 252.1874. 1H NMR (400 MHz, Chloroform-d) δ 7.07 (q, 
J = 7.9 Hz, 1H), 6.56 (dd, J = 8.4, 2.3 Hz, 1H), 6.47 (dt, J = 12.4, 2.4 Hz, 1H), 6.40 (td, J 
= 8.2, 2.3 Hz, 1H), 3.39 (s, 2H), 3.09 (t, J = 5.1 Hz, 4H), 2.63 (t, J = 6.5 Hz, 2H), 2.33 – 
2.25 (m, 2H), 1.50 – 1.38 (m, 4H). 13C NMR (101 MHz, Chloroform-d) δ 164.90, 162.49, 
152.73, 129.94, 110.98, 105.72, 52.86, 48.35, 24.08, 22.24, 18.95, 13.87. 19F NMR (376 
MHz, Chloroform-d) δ -112.38.  
 
N-(4-(4-(3-fluorophenyl)piperazin-1-yl)butyl)-2-naphthamide (159c) In dry round 
bottom flask was added amine starting material (159b) (0.42 g, 1.67 mmol), anhydrous 
methylene chloride (3.3 mL) triethylamine (8.35 mmol) for 5 min. To this was added 2-
naphthoyl chloride (0.0.381 g, 2 mmol). Reaction was stirred at room temp for 1-2 hours, 
then extracted with methylene chloride (3 x 15 mL), dried over Na2SO4 and purified on 
SiO2 by column chromatography. The product was obtained 0.3 g (42%). Rf 0.33 (10% 
MeOH/EtOAc). HRMS (ESI) m/z [M+H]+ calcd for C25H28FN3O, 406.2289, Found, 
406.2292. 1H NMR (400 MHz, Chloroform-d) δ 8.26 (s, 1H), 7.88 – 7.79 (m, 4H), 7.51 
(dddd, J = 20.8, 8.1, 6.9, 1.4 Hz, 3H), 7.16 (td, J = 8.5, 6.9 Hz, 1H), 6.96 (t, J = 5.6 Hz, 
1H), 6.64 – 6.58 (m, 1H), 6.53 (dd, J = 5.9, 2.5 Hz, 1H), 6.50 (t, J = 1.8 Hz, 1H), 3.54 (q, 
J = 6.2 Hz, 2H), 3.15 (dd, J = 6.3, 3.8 Hz, 4H), 2.59 (dd, J = 6.3, 3.9 Hz, 4H), 2.47 (t, J = 
6.9 Hz, 2H), 1.77 – 1.63 (m, 4H). 13C NMR (101 MHz, Chloroform-d) δ 167.82, 164.99, 
152.79, 134.61, 132.54, 132.15, 130.08, 128.85, 128.40, 127.76, 127.26, 123.71, 57.78, 
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52.87, 48.32, 39.95, 27.37, 24.21. 19F NMR (376 MHz, Chloroform-d) δ -112.31 (d, J = 
13.3 Hz).  
 
4-(4-(2-chloropyridin-4-yl)piperazin-1-yl)butanenitrile (157a). 1-(2-chloropyridin-4-
yl)piperazine (0.3 g, 1.52 mmol) in K2CO3 (0.23 g, 1.67 mmol), cat. KI, and anhydrous 
acetonitrile (7.6 mL) were stirred for 5 min at room temperature. Then 4-bromobutyronitrie 
(0.247 mg, 1.67 mmol) was added, the flask was sealed and the reaction refluxed for 14 
h. Reaction was cooled, water added, and the product was extracted with methylene 
chloride and dried over Na2SO4. Rf 0.5 (20% MeOH/EtOAc). The product was 
characterized and used directly in the next step, 0.327 g (81%). HRMS (ESI) m/z [M+H]+ 
calcd for C13H17ClN4, 265.1215, [M+Na]+ 287.1034, Found, 265.1214. 1H NMR (400 
MHz, Chloroform-d) δ 8.02 (d, J = 6.1 Hz, 1H), 6.65 (d, J = 2.4 Hz, 1H), 6.57 (dd, J = 6.1, 
2.4 Hz, 1H), 3.36 – 3.31 (m, 4H), 2.58 – 2.53 (m, 4H), 2.51 (d, J = 6.7 Hz, 2H), 2.46 t, J = 
7.0 Hz, 2H), 1.86 (p, J = 6.8 Hz, 2H). 13C NMR (101 MHz, Chloroform-d) δ 156.64, 
152.72, 149.57, 119.60, 107.36, 107.34, 56.08, 52.36, 45.94, 22.58, 14.93.  
 
4-(4-(2-chloropyridin-4-yl)piperazin-1-yl)butan-1-amine (157b). To a mixture of nitrile 
(157a) (0.325 g, 1.23 mmol) in anhydrous THF (9.5 mL) at 0OC, under argon, was slowly 
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added borane-THF (7.36 mmol, 1M in THF) over 5 minutes. Reaction was let to come to 
room temperature overnight and stirred for a total of 48 h. Mixture was cooled to 0OC and 
quenched with methanol. The product was suspended in 6 HCl/MeOH and stirred for 2 
hours at room temp, then concentrated. The pH was adjusted to alkaline with 
Na2CO3/NaHCO3, extracted with ethyl acetate and dried over Na2SO4. The crude product 
0.33 g (99%) was used directly in the next step. HRMS (ESI) m/z [M+H]+ calcd for 
C13H21ClN4, 269.1528, Found, 269.1523. 1H NMR (400 MHz, Chloroform-d) δ 7.88 (d, 
J = 6.1 Hz, 1H), 6.52 (t, J = 2.1 Hz, 1H), 6.47 (dt, J = 6.1, 2.0 Hz, 1H), 3.50 (t, J = 6.7 Hz, 
2H), 3.26 (dt, J = 18.6, 5.2 Hz, 4H), 2.63 (q, J = 6.8 Hz, 2H), 2.44 (q, J = 5.2 Hz, 4H), 2.30 
(dt, J = 11.6, 6.6 Hz, 2H), 1.62 (p, J = 6.4 Hz, 2H), 1.52 (q, J = 6.2 Hz, 2H). 13C NMR 
(101 MHz, Chloroform-d) δ 156.59, 152.28, 149.27, 107.31, 107.11, 52.31, 45.71, 34.80, 
27.59, 18.91, 13.87.  
 
 
N-(4-(4-(2-chloropyridin-4-yl)piperazin-1-yl)butyl)-2-naphthamide (157c). In dry 
round bottom flask was added amine starting material (157b) (0.33 g, 1.23 mmol), 
anhydrous methylene chloride (2.5 mL) triethylamine (6.15 mmol) for 5 min. To this was 
added 2-naphthoyl chloride (0.191 g, 1.5 mmol). Reaction was stirred at room temp for 1-
2 hours, then extracted with methylene chloride (3 x 15 mL), dried over Na2SO4 and 
purified on SiO2 by column chromatography. The product was obtained 0.282 g (54%). Rf 
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0.12 (10% MeOH/EtOAc). HRMS (ESI) m/z [M+H]+ calcd for C24H27ClN4O, 423.1946, 
[M+Na]+ 445.1766, Found, 423.1950, 445.1764. 1H NMR (400 MHz, Chloroform-d) δ 
8.25 (d, J = 1.7 Hz, 1H), 7.99 (d, J = 6.1 Hz, 1H), 7.86 (t, J = 8.4 Hz, 4H), 7.81 (dd, J = 
8.6, 1.8 Hz, 1H), 7.58 – 7.49 (m, 2H), 6.58 (d, J = 2.4 Hz, 1H), 6.51 (dd, J = 6.1, 2.4 Hz, 
1H), 3.55 (q, J = 6.4 Hz, 2H), 3.30 – 3.24 (m, 4H), 2.58 – 2.51 (m, 4H), 2.46 (t, J = 7.0 
Hz, 2H), 1.75 – 1.60 (m, 4H).  
 
4-(4-(2-fluoropyridin-4-yl)piperazin-1-yl)butanenitrile (158a). 1-(2-fluoropyridin-4-
yl)piperazine (0.3 g, 1.66 mmol) in K2CO3 (0.253 g, 1.83 mmol), cat. KI, and anhydrous 
acetonitrile (8.3 mL) were stirred for 5 min at room temperature. Then 4-bromobutyronitrie 
(0.271 mg, 1.83 mmol) was added, the flask was sealed and the reaction refluxed for 14 
h. Reaction was cooled, water added, and the product was extracted with methylene 
chloride and dried over Na2SO4. Rf 0.47 (10% MeOH/EtOAc). The product was purified 
on SiO2 by column chromatography, to give 0.282 g (68%). HRMS (ESI) m/z [M+H]+ 
calcd for C13H17FN4, 249.151, [M+Na]+ 271.1329, Found, 249.1513, 271.1335. 1H 
NMR (400 MHz, Chloroform-d) δ 7.88 (d, J = 6.1 Hz, 1H), 6.54 (dt, J = 6.1, 1.9 Hz, 1H), 
6.18 (dd, J = 2.3, 1.2 Hz, 1H), 3.37 – 3.32 (m, 4H), 2.56 (dd, J = 6.1, 4.2 Hz, 4H), 2.52 (t, 
J = 6.7 Hz, 2H), 2.46 (t, J = 7.0 Hz, 2H), 1.87 (q, J = 6.8 Hz, 2H). 13C NMR (101 MHz, 
Chloroform-d) δ 147.67, 147.48, 119.61, 106.57, 56.09, 52.37, 46.13, 22.59, 14.93. 19F 
NMR (376 MHz, Chloroform-d) δ -69.33.  
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4-(4-(2-fluoropyridin-4-yl)piperazin-1-yl)butan-1-amine (158b). To a mixture of nitrile 
(158a) (0.27 g, 1.1 mmol) in anhydrous THF (8.4 mL) at 0OC, under argon, was slowly 
added borane-THF (6.53 mmol, 1M in THF) over 5 minutes. Reaction was let to come to 
room temperature overnight and stirred for a total of 48 h. Mixture was cooled to 0OC and 
quenched with methanol. The product was suspended in 6 HCl/MeOH and stirred for 2 
hours at room temp, then concentrated. The pH was adjusted to alkaline with 
Na2CO3/NaHCO3, extracted with ethyl acetate and dried over Na2SO4. The crude product 
0.28 g (99%) was used directly in the next step. HRMS (ESI) m/z [M+H]+ calcd for 
C13H21FN4, 353.1823, Found, 253.1828. 1H NMR (400 MHz, Chloroform-d) δ 7.83 (dd, 
J = 6.1, 2.2 Hz, 1H), 6.51 (dt, J = 6.0, 1.9 Hz, 1H), 6.14 (t, J = 1.7 Hz, 1H), 3.38 (t, J = 5.2 
Hz, 2H), 3.31 (t, J = 5.3 Hz, 2H), 2.71 (dt, J = 13.5, 6.7 Hz, 2H), 2.53 (dt, J = 13.5, 5.1 Hz, 
4H), 2.41 (t, J = 5.9 Hz, 2H), 1.70 (q, J = 6.2 Hz, 2H), 1.63 (q, J = 6.2 Hz, 2H), 1.56 – 1.45 
(m, 2H).13C NMR (101 MHz, Chloroform-d) δ 106.64, 57.91, 52.35, 48.55, 45.86, 28.00, 
24.71. 19F NMR (376 MHz, Chloroform-d) δ -69.59.  
 
N-(4-(4-(2-fluoropyridin-4-yl)piperazin-1-yl)butyl)-2-naphthamide (158c). In dry 
round bottom flask was added amine starting material (158b) (0.28 g, 1.1 mmol), 
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anhydrous methylene chloride (2.2 mL) triethylamine (5.5 mmol) for 5 min. To this was 
added 2-naphthoyl chloride (0.252 g, 1.32 mmol). Reaction was stirred at room temp for 
1-2 hours, then extracted with methylene chloride (3 x 15 mL), dried over Na2SO4 and 
purified on SiO2 by column chromatography. The product was obtained 0.239 g (53%). Rf 
0.12 (10% MeOH/EtOAc). HRMS (ESI) m/z [M+H]+ calcd for C24H27FN4O, 407.2242, 
[M+Na]+ 429.2061, Found, 407.2248, 429.2067. 1H NMR (400 MHz, Chloroform-d) δ 
8.26 (d, J = 1.4 Hz, 1H), 7.91 – 7.83 (m, 4H), 7.59 – 7.49 (m, 2H), 6.70 (s, 1H), 6.51 – 
6.46 (m, 1H), 6.11 (d, J = 2.2 Hz, 1H), 3.56 (q, J = 6.3 Hz, 2H), 3.30 (t, J = 5.2 Hz, 4H), 
2.56 (t, J = 5.2 Hz, 4H), 2.47 (t, J = 7.0 Hz, 2H), 1.71 (dq, J = 22.0, 7.3 Hz, 4H). 19F NMR 
(376 MHz, Chloroform-d) δ -69.42.  
 
 
 
 
b. Spectral and Other Characterization Data 
 
NMR spectra were recorded with a Varian 400 MHz or 500 MHz instrument at 
room temperature with tetramethylsilane (TMS) as an internal standard. Mass spectra 
were performed on an Agilent Q-TOF HPLC-MS or VG (Micromass) 70-250-S Magnetic 
sector mass spectrometer employing the electrospray ionization (ESI) method. 
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6. Radiochemistry Supporting Information for [11C]155c 
 
a. HPLC Conditions: 
HPLC was performed using a Shimadzu LC-2010A HT system. 
• Quality Control: 40% MeCN, 20mM NH4OAc, 2 mL HOAc, 40oC. Luna C18 100A, 
150x4.6mm Phenomenex S/N H16-384835  
• Semipreparative HPLC: 60% MeCN, 20mM NH4OAc, 2 mL HOAc, 40oC, 2.5 mL/min. Luna 
C18(2) 10 micron, 250x150mm, S/No 486505-1; 00G-4253-N0 
HPLC Traces  
• NCA Rat 1093 
• NCA Rat 1101 
• CA Rat 1094 
• CA Rat 1095 
 
PET scans, summed images, 3 views (coronal, sagittal, tranverse) 
• NCA Rat 1093 
• NCA Rat 1101 
• CA Rat 1094 
• CA Rat 1095 
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NCA Rat 1093 
Cut Peak 
 
QC (93% RCP RCP) 
 
Coinjection (>80% RCP) 
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NCA Rac 1101 
Cut Peak 
 
QC (82% RCP) 
 
Coinjection (83% RCP )
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CA Rat 1094 
Cut Peak 
 
QC (>99% RCP) 
 
Coinjection (>99% RCP) 
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CA Rat 1095 
Cut Peak 
 
QC (>99% RCP) 
 
Coinjection (>99% RCP) 
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b. microPET scans for [11C]155c 
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c. Stability Studies for [11C]155c (Carrier Added) 
40% MeCN, 20mM NH4OAc, 2 mL HOAc, 40oC. Luna C18 100A, 150x4.6mm 
Phenomenex S/N H16-384835  
 
Standard; 96% RCP 
 
 
 
Reformulated Dose in semi-preparative HPLC Buffer; 96% RCP 
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In 100% ethanol; Initial >99% RCP 
 
In 100% ethanol; After 1.5 hours, >99% RCP 
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In 10% ethanolic saline; Initial >99% RCP 
 
 
In 10% ethanolic saline; After 15 min from initial, 80% RCP 
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In 10% ethanolic saline; 1.5 hours from initial, 78% RCP 
 
In 10% ethanolic saline; 2 hours from initial, 77% RCP 
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In 10% ethanolic saline; coinjection 2.5 hours after start; >99% RCP 
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